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Abstract 
Major mental illness is now recognised as one of the leading causes of adult 
morbidity. Of the adult onset psychiatric disorders, the functional psychoses 
(schizophrenia, bipolar disorder and recurrent major depression) are the most severe 
and most common in the general population. Evidence suggests that certain genetic 
factors influence an individual’s susceptibility todeveloping these disorders when 
combined with appropriate social and environmental conditions. Several good 
candidate genes have been identified. Of relevance to this study is Disrupted in 
Schizophrenia 1 (DISC1) which was identified in a large Scottish family that carried a 
balanced translocation (t1:11) and had a history of major mental illness. In 2008, two 
ENU mutant mouse models with missense mutations in exon 2 of Disc1 were 
characterised and found to have behavioural and neuroanatomical phenotypes 
consistent with schizophrenia and major depression. The primary aim of this thesis is 
to further analyse these mouse models by performing whole genome gene expression 
studies and secondary protein analysis to identify genes involved in the aetiology of 
schizophrenia and major depression. 
 
My initial analysis used Illumina BeadChip microarray technology to identify 368 
genes that were differentially expressed in ENU mutant animals under different 
biological conditions, compared to appropriate contr l animals. Nine biological 
groups were compared including one embryonic group at E13, and three groups 
treated with appropriate anti-psychotic or anti-depressant drugs. Of the 368 genes 
identified as differentially expressed, 46 were chosen for validation by qRT-PCR 
based on fold-change, p-value, functional significance, overenrichment of GO terms, 
pathway analysis and previous implications in major mental illness. NRXN1, NRXN3 
and CDH11 were found to be significantly up-regulated in the schizophrenia mouse 
model with EGR4 significantly down-regulated compared to C57BL/6J wild-type 
controls. These findings were also replicated in an independent sample using wild-
type littermates. The mental retardation gene PAK3 was up-regulated in the 
schizophrenia mouse model and expression levels were co rected to a level not 
significantly different to wild-type, when treated with the PDE4 inhibitor Rolipram. 
Semi-quantitative western blotting also confirmed the disregulation of EGR4 and 
PAK3 at the protein level in these animals. RNA expr ssion profiles were also 
characterised for each of the genes above, and DISC1, through development. 
 v 
 
In summary this thesis describes the striking disregulation of four prominent genetic 
candidates of major mental illness in an independent animal model. A first functional 
link between DISC1 and NRXN1 is described suggesting, for the first time, a DISC1-
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Chapter 1 2 
1.1 Major Mental Illness Overview 
Major mental illness is now recognised as one of the leading causes of adult morbidity, 
affecting populations throughout the world [1] with little demographic variability. Of the 
adult onset psychiatric disorders, the functional psychoses (schizophrenia, bipolar 
disorder and recurrent major depression) are the most severe and the most common in the 
general population. Functional psychoses are serious disorders with, as yet, no known 
organic cause [2] often rendering the sufferer unable to maintain normal day to day 
activities. They encompass disorders of thought, perception, often leading to delusion and 
hallucination, mood and behaviour. Evidence suggests that genetic factors influence an 
individual’s susceptibility to developing these disorders [3] when combined with 
appropriate social or environmental conditions. Over the last century the functional 
psychoses have classically been divided into two diagnostic groups; schizophrenia and 
affective disorders (recurrent major depression and bipolar disorder). More recently, it 
has been suggested that the disorders may not be as distinct as was once thought but form 
a continuum with recurrent major depression at one e d and schizophrenia at the other 
[4]. This view is supported by epidemiological evidence that shows genetic sharing of 
risk between schizophrenia and bipolar disorder [5], increased risk of both schizophrenia 
and bipolar disorder in first degree probands with sc izophrenia or bipolar disorder [6], 
recent genome wide association studies [7] and indeed arlier work from our own 
laboratory [8]. 
 
Schizophrenia is the most common form of psychotic illness with a lifetime morbid risk 
of around 1% (more if the many schizophrenia spectrum disorders are also considered) 
and roughly equal proportions of males and females ffected. The illness is characterised 
by behavioural and cognitive symptoms, which can be cat gorised as either positive or 
negative (referring to an increase or absence in normal functioning). Positive symptoms 
include heightened sensory perception, often leading to delusion and hallucination, 
disorganisation, rapidity of speech, uncoordinated gait and altered cognitive functioning. 
Negative symptoms include social withdrawal, lack of care over personal appearance or 
wellbeing and the inability to act to achieve simple goals [9]. Diagnosis of schizophrenia 
is based on patient interview with presentation of at least two symptoms over a period of 
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2-6 months affecting ability to work, socialise or p ovide basic self care. Many 
schizophrenia patients are permanently or temporarily hospitalised as they may pose a 
danger to themselves, and current statistics show 10% of schizophrenia patients commit 
suicide and many more attempt to [10]. The need for long term social and medical care of 
schizophrenia patients costs the health service around £1 billion per year in England and 
Wales alone [11]. Onset of psychosis is normally in adolescence to mid-twenties after the 
end of puberty, with male patients being admitted on average 4-5 years earlier than 
female patients [12]. Some studies have concluded that the symptomology of 
schizophrenia differs between the sexes, with femals often displaying less extreme 
symptoms than males [13] (also reviewed in [14] [15] ). As well as presenting around 4 
years after males, females have a second peak of onset around the age of 50. Animal 
studies suggest this is due to the protective effects of oestrogen until menopause [16] and 
treatment with combined oestrogen and antipsychotics has been shown to accelerate 
symptom remission, when compared to antipsychotic treatment alone, in both males and 
females. 
Brain morphology of affected individuals is often abnormal with increased ventricle size 
and reduction in anterior hippocampal volume commonly shown by MRI scanning [17]. 
Patients on continual medication had less reductions n hippocampal volume over time, 
and those with a longer duration of psychosis prior to first treatment had greater 
reductions in temporal lobe volume, suggesting thateither the reduced volume is due to 
developmental effects or breakdown during the initial onset of psychosis. It is proposed 
that the increases in ventricle size are not due to confounding treatment effects [18] as 
patients with better disease outcome and drug response had less changes in ventricular 
size. Recent meta-analysis studies of brain morphology in schizophrenia have found 
reductions in grey matter volume in frontal, temporal, insular and cingulate cortex and 
thalamus [19]. Overall cerebral volume is reduced in schizophrenia with an increase in 
lateral ventrical volume and bilateral reduction in amygdala and hippocamal volume 
relative to the overall decrease in brain size [20]. Further meta-analysis has also shown 
bilateral reductions in thalamic volume in both fist-episode and chronic schizophrenia 
patients compared to control subjects [21]. In addition, reductions in frontal white matter 
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have been observed through voxel based morphometry and have also been confirmed by 
meta-analysis [22]. MRI studies of high risk children and non-psychotic relatives of 
individuals with a schizophrenia diagnosis reveal volumetric abnormalities of the 
prefrontal and temporal regions to a lesser extent han affected individuals, but still 
significantly different to controls. Further high risk studies indicate reductions in 
amygdala and hippocampal volumes and in superior temporal gyrus suggesting these 
volumetric changes may be indicative of disease susceptibility (reviewed in [23]).  
  
 The main treatment for patients with schizophrenia is anti-psychotic drugs. Classic 
treatments involve the use of Thorazine plus chlorpromazine and Haloperidol which are 
effective in treating the positive symptoms while nwer ‘atypical’ (second generation) 
treatments such as Risperidone and Clozapine are also p rtially effective in reducing the 
negative symptoms [24]. Clozapine acts by blocking receptors for some key 
neurotransmitters in the brain, including dopamine type 4 receptors, serotonin type 2 
receptors, norepinephrine receptors, acetylcholine receptors, and histamine receptors 
[25]. It is also a partial blocker of the dopamine type 2 receptor. Typical (first generation) 
antipsychotics such as Haloperidol act primarily on the dopamine type 2 receptor and can 
have sedative effects. Approximately one third of patients do not respond to treatment 
with first generation antipsychotics. Clozapine was the first second generation 
antipsychotic to be licenced by the FDA for treatment of treatment resistant 
schizophrenia [26] and is currently the only effective treatment for refractory 
schizophrenia. The main side effect of Clozapine use i  the development of 
agranulocytosis, a reduction in the white blood cell ount, which can be fatal due to the 
high risk of infection resulting from a suppressed immune system [27]. Risk can be 
dramatically reduced through monitoring of white blood cell counts. Side effects of 
treatment with first generation antipsychotics include dysphoria, dystonia, akathisia, 
dyskinesia, and Parkinsonian motor symptoms. There may also be an increase in the 
depressive/demoralization aspects of illness course, impaired learning, and slow 
information processing, and increased hostility, aggression, and suicide [28-30]. While 
the majority of side effects seen in the first generation antipsychotics are not present in 
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the second generation antipsychotics, they do carry their own risks. These include 
metabolic syndrome, hyperlipidemia and reduced insuli  sensitivity with an increased 
incidence of diabetes. A reduced lifespan due to exposure to adverse drug effects is also 
observed [31-33]. Current work is concentrating on the discovery of drug targets outwith 
the dopamine system, that may reduce the negative and cognitive symptoms not helped 
by the current anti-psychotics used [34] and may have more favourable side effects than 
current treatments. The use of multiple antipsychoti s and/or augmentation strategies 
(such as combined treatment with estrogen in males [35]) are also currently being studied 
[36]. Gender differences in presentation of schizophrenia have been observed for a long 
time, and it is proposed that estrogen and other femal  sex hormones may have a 
neuroprotective effect [37], delaying presentation of symptoms in females til later in life 
when hormonal changes occur due to menopause [38]. Psychotherapy is occassionally 
used along-side a programme of drug treatment in schizophrenia patients but, however 
effective these treatments may be in controlling symptoms, there is currently no cure for 
schizophrenia and treatment is lifelong.  
 
Like schizophrenia, bipolar disorder has a lifetime pr valence of approximately 1% and 
affects an equal proportion of males and females [39]. Bipolar disorder is a severe mood 
disorder characterised by mood disturbances ranging from severe depression to extreme 
elation and is often accompanied by psychotic featur s and cognitive changes. 
Pathological mood swings may occur spontaneously or be cyclic in nature while some 
individuals will have predominant manic or depressive episodes with few mood swings. 
In some cases states can be mixed, with characteristics of mania intruding upon the 
depressive episode or vice versa. When in the depressive phase sufferers will, for 
example, display social withdrawal, anhedonia, difficulty with concentration and decision 
making, fatigue and loss of self esteem. The prevalence of suicide in bipolar individuals 
is high when in the depressive phase and many require constant monitoring and care to 
prevent self injury [40]. As an almost a direct result of this, 35% of the £200 million a 
year spent on bipolar disorder by the NHS is the result of hospital admissions alone [41]. 
In contrast, while in the manic phase sufferers will display elevated mood, delusions, 
hallucinations, extreme restlessness and inflated self e teem. Males and females do not 
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display sex differences in age of onset (mean age ~ 25) but show differences in type of 
episode at first presentation. Males are more likely to present with mania prior to initial 
diagnosis while females more commonly present with major depression [42]. Bipolar 
patients normally receive treatment in the form of lithium and other mood stabilisers. 
Lithium is the most favoured of the mood stabilisers as it does not have a sedative effect 
while still being effective, and is effective for both manic and depressive phases [43]. The 
exact mechanism by which lithium works is still unknown but studies of animal models 
suggests a neuroprotective role against glutamate induced excitotoxicity [44]. 
Psychotherapy is also widely used as treatment for bipolar disorder.  
 
Recurrent major depression carries a lifetime risk of 16.2% [45] and often associates with 
schizophrenia or bipolar disorder in high risk families [5, 8]. Recurrent major depression 
is unipolar and characterised by phases of severe dpression without mania. Symptoms 
are similar to those of bipolar individuals in the d pressed phase. Treatment of recurrent 
major depression with anti-depressant drugs is somewhat effective (around 53% 
improvement rate) [46], however, residual symptoms including insomnia, fatigue and 
anhedonia persist in many patients [47], increasing the risk of full relapse [48]. Overall 
one third of patients will make a full recovery, one third will have persistent reduced 




1.2 A Genetic Basis for Major Mental Illness 
The definitive causes of schizophrenia and severe mood disorders are as yet unknown, 
but it has been shown that genetic control is involved [49]. Familial studies have shown 
that an individual’s risk of developing schizophrenia increases relative to how closely 
related they are to a sufferer [50]. Adoption studies have shown that children with one 
schizophrenic parent have around a 13% chance of developing the illness later in life 
(compared to 1% in the general population) even when raised by mentally healthy 
adoptive parents [51]. It has been claimed that the heritability estimates are incompatible 
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with transmission through a single major locus in the majority of cases, but become 
plausible when modelled with multiple loci [52].  
Bipolar disorder is also heritable; concordance rates in monozygotic twins are ~43% 
while in dizygotic twins this drops to ~6% [53]. Around half of patients with bipolar 
disorder have a parent with a major mood disorder [54]. Family studies have shown that 
families with probands of schizophrenia have a higher prevalence of unipolar depression, 
and aggregation of psychotic affective disorders occurs in families of probands with 
either schizophrenia or bipolar disorder [55].  
 
In 2009, Lichtenstein et al [5] carried out a large scale study of the Swedish population to 
asses environmental and genetic factors involved in the predisposition to schizophrenia 
and bipolar disorder. Using multivariate generalised linear mixed model analysis of 
information from the multi-generation register and the hospital discharge register, they 
could investigate these risk factors for schizophrenia and bipolar disorder and the 
comorbidity of the disorders.  They found an increased risk of schizophrenia or bipolar 
disorder in individuals with a first degree relative who suffered from the same disorder. 
The risk was higher in full siblings than half siblings with heritability estimates of 64% 
for schizophrenia and 59% for bipolar disorder. There was also an increased risk of 
schizophrenia in relatives of probands with bipolar disorder, including in children 
adopted and raised by healthy parents. Common additive genetic effects contributed 
highly to the comorbidity between the disorders (63%). Patterns of inheritance of major 
mental illness are not simple and it is likely many i teracting factors are involved. Large 
families that display quasi-Mendelian segregation d exist [56], which highlight potential 
genetic risk factors of major effect conferring susceptibility to major mental illness in 
some cases. Both genetic and allelic heterogeneity occur in major mental illness. Genetic 
heterogeneity accounts for the large number of genes that give rise to the same 
classification of mental illness. Allelic heterogeneity occurs when multiple different 
single mutations affecting the same gene give rise to the same disorder, such as the case 
of DISC1, described in section 1.3.  
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1.2.1 Linkage Analysis 
Linkage analysis involves the study of closely related, high risk families (ie families with 
multiply affected members where genetic factor(s) show high penetrance), to identify a 
region of the chromosome that co-segregates with the disease. This information can then 
be used to study genetic mutations within the linkage regions to identify potential 
candidate genes. Linkage analysis tends to identify large regions of the genome due to the 
sharing of large sections of the chromosome between subjects, hence the subsequent 
identification of sucseptibility genes can be difficult. 
 
None the less, several linkage regions identified for schizophrenia and bipolar disorder 
have been replicated in multiple studies. 1p13-q23, 1q42, 2p12-q22, 5q21-q33, 6p24-p22, 
6q16-q25, 8p22-p11, 8p22-p21, 10p15-p11, 13q32-q34 and 22q11-q12 [57, 58] are now 
well established linkage regions for schizophrenia, while 5p15, 6q21, 8q24, 10q26, 
11p15, 12q24, 17q25, 18p11, 18q22, 20q13, 22q12 and Xq26 [59] have been established 
as strong linkage regions for bipolar disorder. What is most evident from linkage studies 
to date, is the large number of putative susceptibility regions that have been identified, 
scattered throughout the entire genome, which supports the theory of multiple genes of 
small effect [60]. 
 
 
1.2.2 Association Studies 
Classical association analysis differs from linkage analysis as it involves the study of 
unrelated individuals in a population for the frequncy of alleles (particularly SNPs – 
single nucleotide polymorphisms). Up until recently, individual functional candidate 
genes or in positional candidate genes within identifi d linkage peaks were studied. The 
completion of the human genome sequence has greatly faci itated the identification and 
study of genes for complex human diseases. In addition, he International HapMap 
project (www.hapmap.org), which characterises SNP frequency and correlation in 
samples from four geographically diverse populations, has allowed the identification of 
patterns of linkage disequilibrium within and between populations (The International 
HapMap Consortium 2003). The basis of the HapMap project is that within populations, 
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the human genome is divided into linkage disequilibrium regions (LD) between hotspots 
of recombination [61] and that the extent of LD will determine the tendancy of alleles at 
two or more loci to be inherited together at a higher degree than that expected by chance 
[62]. In numerical terms, this is the difference betw en observed and expected allelic 
frequencies. LD is influenced by rate of mutation, rate of recombination, genetic drift, 
population structure and genetic linkage. The use of LD to define tagging SNPs can, 
therefore, cover more of the variation within the region of interest than the genotyping of 
randomly spread SNPs [63]. Association studies for schizophrenia have identified 
neuregulin 1 (NRG1) and disrupted in schizophrenia 1 (DISC1) as strong candidate genes 
([64-66] and others). Originally identified by linkage studies they have been supported by 
findings from classic association studies and copy number variants, suggesting particular 
polymorphisms confer risk population wide and are not confined to distinct family 
groups. mRNA analysis confirms the expression of these genes in distinct brain regions 
involved in the pathology of schizophrenia, including the prefrontal cortex and 
hippocampus, and functional data links many of these genes to processes which are 
thought to be involved in major mental illness[67].   
 
The combination of commercial high throughput genotyping and knowledge of linkage 
disequilibrium means that association studies can now be carried out in a genome wide 
fashion, and are no longer restricted to distinct genes or chromosomal regions. GWAS 
(Genome Wide Association Study) combines classical association analysis with the 
positional cloning flexibility of genome-wide linkage scans to provide a powerful tool for 
the identification of candidate genes, with genome wide significance that requires no 
prior hypothesis about the role or function of the candidate genes in disease pathology 
[68]. While some possible susceptibility genes for bipolar disorder have been identified 
by classical association studies, the GWAS method has generally been more successful 
for schizophrenia. To date, the largest schizophrenia GWAS tested approximately one 
million SNPs in 3322 schizophrenia and 3587 controls [7]. They found association with 
MYO18B and 450 SNPs in the major histocombatibility complex in schizophrenia cases. 
The major histocompatability complex had also been implicated by Steffanson et al 
(2009) [69] using combined SNP data from several large scale genome wide scans. Kirov 
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et al (2008) [70] carried out a GWAS study using parent-offspring trios, to minimise the 
risk of population stratification, with 574 schizophrenia patients, their parents and 605 
unaffected individuals and identified RBP1 and CCDC60 as susceptibility genes for 
schizophrenia. RBP1 inhibits PI3K/Akt signalling which has previously been implicated 
in schizophrenia pathology [71]. In addition, IL3RA, CSF2RA and RELN have also been 
associated with schizophrenia [72-74]. In 2010, one GWAS study tested 572888 markers 
for association with schizophrenia and found no genome wide significance in the sample 
set from a Norwegian population [75] but found significance when expanded to a large 
European cohort. What is apparent from these studies is that there are multiple genes 
involved and little overlap of genes identified betw en sample sets. This apparent lack of 
reproducibility could be due to a number of factors, including the use of different SNP 
sets, genotyping platforms, sample size and genetic or phenotypic heterogeneity between 
samples. This second factor was addressed in part by the Wellcome Trust Case Control 
Consortium in 2007. They examined seven common diseases, including bipolar disorder, 
and demonstrated the use of a carefully selected and co sistant control group was crucial 
in the reproducibility of results [76].  
 
The Psychiatric GWAS Consortium (PGC) was set up in 2007 with the aim of 
consolidating the data from GWAS studies by statistically robust meta-analysis. To date 
there are five disease working groups (schizophrenia, bipolar disorder, major depressive 
disorder, autism and ADHD), a statistical analysis group and a cross disease working 
group. Early studies proved that small sample sizes (<1000 cases and 1000 controls) were 
often not large enough to reach genome wide significance and that larger samples (around 
3000 cases and 3000 controls) were required for greater power. The formation of the 
PGC has allowed researchers access to far more sample sets and enabled them to increase 
the power of their analysis. The four main aims were to harmonize data, carry out within 
disorder meta-analysis, increase availablitiy of shared data and to identify convincing 
associations common to two or more of the five disease groups [77]. A number of genes 
have been associated with schizophrenia and bipolar disorder through GWAS meta-
analysis. Zinc-finger protein 804A (ZNF804A) was originally associated with 
schizophrenia and bipolar disorder through genome wide association. Further meta-
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analysis has replicated this association with high statistical significance (p=2.5x10-11 
schizophrenia, p=4.1x10-13 schizophrenia and bipolar disorder combined) supporting the 
theory of genetic overlap between disorders [78]. Additional meta-analysis (n=5142 
cases/6561 controls) have identified a SNP mapping 85kDa from fibroblast growth factor 
receptor 2 (FGFR2) with high association with schizophrenia (p=0.0009) [79]. The 
accumulation of data from multiple studies has led to the emergence of some interesting 
and consistent patterns. It is proposed that certain isk haplotypes in these genes may 
have a detrimental effect on brain function which is modulated by poorly understood 
environmental variables and social factors [80], and the spectrum of clinical features are 
suggestive of risk through overlapping sets of genes [81]. 
 
 
1.2.3 Copy Number Variation 
Much recent work has investigated the role of copy number variants (CNVs) in 
neurodevelopmental disorders (reviewed in Kirov 2010) [82]. As the aetiology of 
schizophrenia and other major mental illness is so varied, with multiple genetic 
components identified, the general consensus is that multiple small components are likely 
to be responsible, and as CNVs account for a substantial proportion of human genetic 
variation, they are likely to play an important role.  
 
A study of 418 individuals, including 150 individuals affected with schizophrenia or 
schizoaffective disorder and 268 healthy controls, identified 24 previously unreported 
copy number variants in schizophrenia cases [83]. These included deletions in NRXN1, 
ERBB4, GRM7 and SLC1A, all known synaptic genes. Additionally, Xu et al (2008) [84] 
identified de novo and inherited copy number variations in schizophrenia cases associated 
with neural development, small GTPase activity and RNA binding/processing. In a study 
of 724 patients with psychiatric disorders and 314 healthy controls, Saus et al (2010) [85] 
studied the dosage effects of 68 known candidate genes for psychiatric conditions 
overlapping with CNVs. Contrary to revious reports, no statistically significant difference 
was found in the overall burden of gains or losses in psychiatric patients compared to 
control individuals. However, 47% of rare structural v riants identified were found only 
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in psychiatric disorder patients and not in control individuals. These included variants in 
GRM7, and COMT, both previously implicated in schizophrenia. Need t al (2009) were 
also unable to confirm the ‘load burden’ previously reported but did identify a number of 
large deletions in cases but not controls. Using samples from 1013 cases and 1084 
controls from schizophrenia cohorts in Aberdeen, Munich and America, Need et al found 
that deletions >2Mb were not present in control subjects but were in many schizophrenia 
cases. They propose that large deletions confer risk to psychiatric illness. In the Aberdeen 
cohort, deletions affecting NDE1, MPV17L, ABCC1, KIAA0430, KIAA0866, MRP6 and 
SPRY2 were found to be significantly associated with schizophrenia, and in the Munich 
cohort deletions affecting TUSC3, PCM1, NAT1, NAT2 and ASAH1 were significantly 
associated [86]. Many of these genes have been implicated in schizophrenia previously. 
 
 
1.2.4 Genome wide gene expression analysis 
From current research it is clear that schizophrenia and related synaptopathies are 
complex trait disorders, attributable to multiple gnes and epigenetic factors [87]. 
Microarray technology allows relatively rapid, large scale screening of genes with the 
potential to identify candidate genes and pathways involved in complex trait disorders. 
 
Recent microarray studies of human schizophrenia patients have identified multiple 
presynaptic and myelin related genes dysregulated in the prefrontal cortex [88, 89]. 
Mirnics et al (2000) identified a group of genes involved in presynaptic secretory 
function whose RNA expression was decreased in schizop renia patients. Genes involved 
in GABA and glutamate neurotransmission were also reduced. These findings were 
consistent with previous targeted gene expression studies in hippocampus, which found 
GABA and glutamate receptor function was decreased in schizophrenia patients [90, 91]. 
Vawter et al (2002) [89] carried out a targeted microarray for 1127 brain related genes in 
the dorsolateral prefrontal cortex of post mortem schizophrenia brains and matched 
controls and reported an overlap in 5 of the presynaptic secretory genes, GABA and 
glutamate receptor genes identified by Mirnics et al. In a similar study, Sugai et al (2004) 
identified oligodendrocyte and astrocyte related genes, and growth/neurotrophic factors 
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and their receptors, as being altered in the prefrontal cortex of schizophrenia patients 
[92]. In the superior temporal gyrus, which has connections to the thalamus, the limbic 
system and the prefrontal cortex, altered expression of genes involved in 
neurotransmission, neurodevelopment and presynaptic function were identified in post 
mortem brain tissue of schizophrenia patients [93]. Two studies have also identified 
genes involved in mitochondrial function and oxidatve stress as being differentially 
expressed in schizophrenia patients [94, 95]. 
 
While it is clear that microarray studies are somewhat useful in identifying candidate 
genes for the complex psychiatric disorders, there are a number of drawbacks to the 
method. Bunney et al (2003) [96] highlight the possible pitfalls of using microarray 
technology for studying psychiatric disorders. One major limiting factor is the availability 
of post mortem brain tissue from psychiatric patients. Post mortem interval and 
heterogeneity of human samples will effect gene expression and are difficult to control 
for. Brain tissue from subjects who had previously been medicated will display altered 
expression in some genes relative to unmedicated, otherwise matched, individuals. It is 
therefore important to note the medical history of the subject prior to making conclusions 
about gene expression patterns [96]. An alternative approach using samples from live 
patients, such as lymphoblastoid cell lines derived from blood samples, can increase the 
availability of subjects and allow ongoing assessment. Lymphoblastoid cell lines 
overcome the problems associated with drug treatments a d post mortem interval, 
however, many genes that have been identified by studies using brain tissue are not 
expressed in blood [97] and studies comparing gene expression in brain and that in blood 
suggest the different tissue types will yield very different results. It is therefore suggested 
that while brain tissue can provide candidate genes, blood samples will provide possible 
biomarkers for disease. 
 
It is of most interest that the same genes appear to ecur in genetic studies of 
schizophrenia and mood disorders suggesting a causative link between the two illnesses 
[98]. The genetic overlaps between schizophrenia, recur ent major depression and bipolar 
disorder are becoming increasingly more convincing through the results of high 
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throughput microarray studies [99] and some research rs have suggested they may not be 




Cytogenetics is the study of chromosomal abnormalities that cause disease. This can be 
the addition of an entire chromosome (as in Down’s syndrome), the absence of a 
chromosome (Turner’s syndrome) or the translocation of one part of a chromosome to 
another. Diseases resulting from chromosomal abnormalities tend to be Mendelian in 
nature, however a number of genes for major mental illness have been discovered 
through the use of cytogenetics [100] suggesting that single genes of large effect do exist 
for these disorders, and that the polygenic theory of psychiatric illness may not be the 
whole story. This project focuses on the DISC1 gene, which was first identified in a 





1.3 Identification of Disrupted in Schizophrenia-1  
A Scottish family was first reported by Jacobs (1970) [101] who noted a balanced 
translocation – (t1:11) (q42;q14.3) – in an individual with an adolescent conduct disorder 
and subsequently in members of four generations of the extended family. A 20 year 
follow up study [102] observed increased occurrence of major psychiatric disorders 
including schizophrenia, bipolar disorder and major depression in translocation carriers, 
but not in non-carrier relatives (LOD=7.1)[8]. Of interest was one individual diagnosed 
with bipolar disorder whose child went on to develop schizophrenia, adding to the 
evidence that the functional psychoses have overlapping genetic predispositions. Further 
studies determined that the translocation breakpoint d rectly disrupts two genes on 
chromosome 1 (DISC1 and DISC2) [56] making them ideal candidates for further 
research. This translocation breakpoint occurs in intron 8 of DISC1 leading to the transfer 
of the coding sequence for 257 C-terminal amino acids (exons 9-13) from chromosome 1 
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to chromosome 11 in translocation carriers[103]. There is, however, no evidence of a C-
terminal truncated protein in translocation carriers [104]. Instead the expression of DISC1 
in the brains of affected individuals is reduced by half compared to karyotypically normal 
controls, suggesting haploinsufficiency is the most likely mechanism of susceptibility to 
schizophrenia and other major mental illness in (t1:11) (q42;q14.3) translocation carriers. 
Zhou et al [105] later identified a novel gene that was disrupted by the translocation on 
chromosome 11. This gene (termed Boymaw) was suggested to form fusion proteins with 
DISC1 in translocation carriers. While these fusion proteins have been generated and 
their function studied in cell cultures [105], work to determine whether fusion proteins 
are transcribed in translocation carriers is still ongoing. 
 
Translocation carriers (as well as unrelated patients with schizophrenia without the 
translocation) show prolonged latency and reduced amplitude of P300 event related 
potential (a measure of attention dependant information processing which has been 
shown to be impaired in schizophrenia patients) compared with controls, and 
karyotypically normal relatives[8, 103, 106]. This f nding led to the proposal that the 
balanced (t1;11)(q42.1;q14.3) translocation conferred predisposition to slower and more 
inefficient processing of stimuli in short term memory. Thus DISC1 is likely to 
participate in pathways important for cognitive function. DISC2 is antisense to DISC1, 
and it is also disrupted by the translocation. Sequence analysis of DISC2 suggests it is 
transcribed in the opposite direction to DISC1 and has no protein coding potential. It 
appears to be an anti-sense RNA gene, which may regulat  activity of DISC1 [103]. So 
far DISC2 has only been detected in humans, suggesting relatively recent evolutionary 
origins. 
 
While the translocation is confined to one family, many association and linkage studies of 
other populations have discovered other variants within the DISC1 locus that also 
associate with schizophrenia, bipolar disorder and recurrent major depression [8, 107-
110]. Three independent studies have, however, failed to find association between DISC1 
locus variations and schizophrenia [111-113] although it is proposed that this can be 
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explained by small sample size, too few SNPs being studied and ethnic differences in 
susceptibility [113].  
 
Replication of linkage in a Finish sample has shown under-transmission of three common 
DISC1 haplotypes and major mental illness (HEP2, HEP3 and HEP4), and the over-
transmission of one haplotype (HEP1). The under-transmitted haplotypes represent 
regions spanning intron 1 to exon 2, exon 4 and exon 13 respectively. HEP3 occurred in 
the control group at a frequency of 1% and a frequency of 8.8% in the schizophrenia 
patients group [114]. HEP3 is also associated with poor visual working memory and 
attention [115] and HEP1 has been associated with impaired long-term verbal memory 
and total hippocampal volume reduction [116]. In addition, the HEP3 haplotype is 
strongly associated with schizophrenia in a Scottish case-control group [117] and also 
shows overlap with a three-SNP haplotype associated with Aspergers syndrome in cohort 
of families with infantile autism and Aspergers syndrome [118]. This study also found 
association with an intragenic single nucleotide polym rphism (SNP) of DISC1 
(rs1322784) and Aspergers syndrome. They also established association between autism 
and a DISC1 intragenic microsatellite (D1S2709) suggesting a strong role for DISC1 in 
early onset neuropsychiatric conditions and neurodevelopment. In a genome wide linkage 
scan of schizoaffective disorder, Hamshere t al (2005) [119] reported the highest linkage 
peak (LOD 3.54) occurring at 1q42, close to the DISC1 locus. Furthermore, a missense 
allele in exon 9 of DISC1 was reported to be overrepresented in patients with 
schizoaffective disorder [120] suggesting DISC1 may confer risk to this disorder. 
 
DISC1 has been associated with neurocognitive functioning [121] in measures of verbal 
working memory and rapid visual searching. The associati n of variations in DISC1 with 
cognitive function was investigated in a large birth cohort tested using a general mental 
ability test at ages 11 and 79 [122]. Cognitive ability was compared with genotype within 
age groups, and between ages 11 and 79 to test for effects on cognitive ageing. After 
adjustment for cognitive ability at age 11, it was found that females homozygous for the 
DISC1 Cys (Ser704Cys SNP) allele had significantly lower cognitive ability score than 
males, suggesting a sex specific role of DISC1 genotypes on cognitive ageing [122]. 
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Callicott et al (2005) also report that a nonsynonymous SNP in exon 11 (Ser704Cys) of 
DISC1 is associated with schizophrenia. Using fMRI they observed abnormal 
engagement of the hippocampus during cognitive tasks, and a reduction in hippocampal 
grey matter volume [123]. Further to this, Di Giorgi  et al (2008) [124] investigated the 
effects of the polymorphism on grey matter volume and formation, hippocampal 
formation and functional coupling during memory recognition tasks. Using fMRI they 
showed that individuals with two Ser alleles had greater engagement of the hippocampus 
and greater functional coupling to the frontal cortex during memory recognition tasks, but 
in contrast with Callicott et al, observed higher grey matter volume than heterozygus 
individuals. While these results are in part contradictory, they both support a role for 
DISC1 in hippocampal formation and function. The authors suggest this inconsistency is 
due to the ‘flip-flop’ effect, where the direction of the allele association may be 
dependent on interaction with another allele at a different locus, thus the same allele 
could exert different effects in different populations depending on their genetic pressures. 
The Cys allele has also been shown to reduce activation of the left medial and superior 
frontal gyrus during a verbal fluency task, relative to Ser homozygotes [125]. No brain 
regions were found to be significantly more activated in Cys carriers. These results 
support a strong physiological effect of the DISC1 polymorphism in both the 
hippocampus and the frontal cortex. At the molecular level, sRNAi knockdown of DISC1 
results in suppressed phosphorylation of ERK and Akt. The Ser704 allele phosphorylated 
ERK to a greater extent than the Cys704 allele, implicating reduced biological activation 
of ERK due to polymorphisms in DISC1 in major mental illness pathology [126]. 
 
Current estimates suggest that approximately 2% of individuals with schizophrenia carry 
a DISC1 missense mutation [127]. As discussed in the next s c ion, DISC1 acts as a hub 
protein, with multiple interactors, and as such this estimate may be under representative. 
Interplay between SNP variants [128], common cis-variants [128], and interacting 
proteins [129] has been shown to result in modest reductions of DISC1 gene expression, 
which may exert subtle effects on neurodevelopment, neurophysiology and neural 
circuitry. The DISC1 protein has also been shown to interact with transcriptional 
modulators of cAMP signaling, cytoskeletal, synaptogenic, neurodevelopmental and 
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sensory perception proteins [128]. Current targets of psychiatric drug development are 
highly enriched in this group [128]. With recent evidence suggesting there may be as 
many as 50 DISC1 mRNA isoforms [130], showing dramatic differences in their brain 
expression profiles, it is proposed the combination f common variants of low 
penetrance, and rare variants of high penetrance within the DISC1 pathway may 
contribute a much larger fraction of the genetic variance in schizophrenia and related 




1.4 The Biology of DISC1 and its interactions 
DISC1 acts as a molecular scaffold and has been shown to interact with multiple proteins 
including NUDEL and PDE4B, suggesting roles in neurodevelopmental and signalling 
pathways [131, 132]. The known isoforms of DISC1 are produced by alternate splicing of 
13 major exons, of which exon 2 is the longest (955bp) and present in all isoforms. Exon 
2 encodes most of the protein head domain, and haplotypes spanning this region have 
been shown to associate with schizophrenia and working memory [107, 108].  
 
Recently an interaction network of 127 proteins and 158 interactions has suggested 
DISC1 may also be involved in synapse function and development through these 
complex interactions [132]. The majority of these interactors can be loosely classified as 
cell cycle, signal transduction, cytoskeleton, intracellular transport and central nervous 
system development genes, clearly demonstrating the importance of DISC1 in multiple 
diverse and critical brain functions. A direct role for DISC1 in early brain development i  
vivo was first demonstrated by Kamiya et al (2005) [133] who reported that in utero 
application of short hairpin loop RNA oligonucleotides (shRNA) targeting mouse Disc1 
can repress expression of the gene, resulting in reduced migration of neurons out of the
sub-ventricular zone to the cortical plate. This is accompanied by altered cell polarity and 
reduced dendritic arborisation. This correlates well ith evidence from mouse studies 
where Disc1 is upregulated at crucial developmental time points both embryonically 
(E13), when neurogenesis and cell migration commence, and at the onset of puberty 
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(P35) when synaptogenesis is again occurring [134]. From puberty onwards the 
expression of Disc1 in the mouse remains steady. Interestingly, in adult hippocampal 
neurogenesis, downregulation of Disc1 results in increased acceleration of neuronal 
integration, resulting in mispositioning of dentate granule cells [135]. Newborn Disc1 
knockdown dentate granule cells display increased excitability, dendritic development 
and synapse formation. Frequency of GABAergic and glutamatergic spontaneous 
synaptic currents in the Disc1 knockdown cells was consistently higher, indicative of 
increased synaptic excitability[135]. This would suggest that Disc1 has distinct functions 
during development that differ pre and post-nataly, nd that it is likely to play a role in 
sustained and simultaneous firing of neurons.  
 
While DISC1 has been shown to have multiple interactors, only around 25% of these 
have been confirmed by further study. Of those which have been confirmed however, 
many have been implicated in schizophrenia and related disorders in their own right,  
including NDE1, NDEL1, PDE4B [65] PCM1 [129] and FEZ1 [136], and it has been 
suggested that in some cases where DISC1 is not directly implicated, variants acting on 
its binding partners may act instead to confer riskof major mental illness [65]. In the 
following paragraphs I will discuss the major confirmed interactors of DISC1 with links 
to psychiatric illness; NDE1, NDEL1, LIS1, GRB2, PCM1, GSK3β, FEZ1, ATF4 and 
ATF5.  
 
NDE1, NDEL1 and LIS1 form part of a conserved nuclear distribution pathway involved 
in neurogenesis and neuronal migration [137-140]. Mutations in Lis1 lead to deficits in 
neuronal migration, neuroblast proliferation and corti al layering [141, 142]. Similarly, 
mice with mutations in Nde1 and Ndel1 show defective neurogenesis and neuronal 
migration [139, 140]. DISC1 and NDEL1 have been shown to be selectively upregulated 
during neurite outgrowth in PC12 cells differentiated with neuronal growth factor (NGF) 
(Kamiya 2006) [143]. Inhibition or disturbance of the DISC1-NDEL interaction has been 
shown to inhibit neurite outgrowth in cell culture. This would suggest the resulting 
complex is crucial for successful neurite outgrowth [143].  
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These genes have also been associated with schizophrenia in their own right. mRNA 
studies of post mortem brain implicate both LIS1 and NDEL1 [144] in schizophrenia, 
while NDE1 and NDEL1 have also been associated with schizophrenia in a Finnish 
cohort [145, 146].  
 
GRB2 competes with NDEL1 for binding to DISC1 [147] giving two functionally 
distinct interactions. The DISC1/GRB2 interaction is required for neurotrophin induced 
axonal elongation [147]. GRB2 has been shown to bind several brain proteins including 
PDE4D [148], huntingtin [149], amyloid precursor protein [150] and presenilin 1 [151] as 
well as dopamine receptors 3 and 4 [152]. As such, its involvement in Alzheimers disease 
and molecular pathways involved in other psychiatric syndromes has been suggested 
[153] 
 
PCM1 is a centrosomal protein required for the targetin  of multiple proteins to the 
centrosome for the regulation of microtubular dynamics [154]. Co-immunoprecipitation 
in HEK-293 cells suggests PCM1 and DISC1 may interact to regulate neuronal 
migration. In addition, knockdown of DISC1 expression reduced accumulation of PCM1 
at the centrosome. Further RNAi studies of both DISC1 and PCM1 show delayed radial 
neuronal migration if either protein is knocked down [133, 155]. Gurling et al (2006) 
[156] reported an association between haplotypes of PCM1 and orbitofrontal grey matter 
defects in schizophrenia family and case-control samples although this has as yet failed to 
replicate in other samples. 
 
GSK3ß is a presynaptic protein kinase that is proposed to be involved in the negative 
regulation of synaptic vesicle fusion events [157]. GS3Kß has been shown to suppress 
long-term potentiation and presynaptic release of excitatory glutamate in neurons. Mao et 
al (2009) [158] observed that suppression of Disc1 by shRNA in embryonic mouse brains 
resulted in reduced neural progenitor proliferation, that could be rescued using the 
GSK3ß specific inhibitor SB216763. GSK3ß is inhibited by direct DISC1 interaction 
suggesting that a loss of DISC1 results in increased GSK3β and leads to reduced neural 
progenitor proliferation, leading to premature cell cycle exit and differentiation. 
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Therefore it is suggested that the DISC1-GSK3ß interac ion is required for successful 
neural proliferation.  
 
Many current typical and atypical antipsychotics increase phosphorylation of GSK3ß and 
enhance AKT signalling though GSK3, or by activating AKT directly. AKT1 itself has 
been tentatively associated with schizophrenia [159] although further studies are required.  
The actin binding protein Girdin (KIA1212) was initally identified as a potential DISC1 
interactor by Camargo et al 2007 [132]. Since then, its interaction with DISC1 has been 
confirmed both in vivo and in vitro. Interaction of DISC1 with Girdin in HEK293 cells 
suppresses AKT signaling [160]. When Kim et al [160] knocked down Disc1 in mouse 
hippocampal neurons, Akt activation increased, and increased dendritic growth and 
abnormal migration were observed. Similar observations were made when Girdin was 
selectively overexpressed in these neurons [160]. Interestingly, the effects of Disc1 
suppression could be rescued by rapamycin, which inhibits an AKT activated effector 
pathway. Enomoto et al (2009) [161] showed that Girdin suppression also mimicked the 
effects of Disc1 supression in cultured hippocampal neurons. Girdin appears to be 
anchored at the growth cone by DISC1, and regulates th  migration and positioning of 
dentate gyrus cells from this position. Girdin has also been shown to interact with NDEL, 
another known interactor if DISC1. 
 
Fasciculation and Elongation factor Zeta 1 (FEZ1) is involved in axon outgrowth and has 
been shown to be expressed in a pattern similar to that of DISC1 in the rat brain [162]. In 
addition, protein overexpression leads to robust binding of DISC1 to FEZ1 and co-
localisation to growth cones in rat cultured hippocampal neurons [163]. Expression of 
FEZ1 in post-mortem brain samples is reduced in subjects with schizophrenia [144] 
however genetic/association evidence for FEZ1 as a susceptibility gene for schizophrenia 
is weak [164-166]. 
 
ATF4 and ATF5 have been associated with schizophrenia through the use of yeast two 
hybrid screens of DISC1 [167]. ATF4 has been shown to interact directly with nuclear 
DISC1 and a corepressor, N-Cor, to modulate CRE-mediated gene transcription [168]. 
Chapter 1 22 
There is currently little evidence to suggest ATF4 and ATF5 are involved in psychiatric 
illness in their own right. As they are both cAMP-resposive transcription factors, 
however, and because ATF4 is partially regulated by NRG1, another well characterised 
schizophrenia susceptibility gene [169] they are of interest for further study. Furthermore, 
it has been shown that DISC1 and PDE4B interact dynamically to regulate cAMP 
signalling [131]. Disruption of this interaction, as predicted by some mouse models 
(section 1.7) would, therefore, be predicted to alter modulation of cAMP signalling and 
may result in abnormal gene transcription.  PDE4s are orthologous to the Drosophila 
Dunce, which is involved in learning and memory and know to affect synaptic plasticity, 
which in turn requires alteration of gene expression profiles [170, 171].  DISC1 also 
possibly binds to chromatin remodelling factors, such as SMARCE1 [132]. These 
interactions with transcription factors, together with the fact that DISC1 localises to the 
nucleus [172, 173] is consistent with a role for DISC1 in transcriptional regulation. These 




1.5 Current hypotheses of Major Mental Illness 
1.5.1 The Neurotransmitter Hypotheses 
Selective targeting of individual neurotransmitters has not yet yielded many therapeutic 
results bringing us to the obvious conclusion that no single neurotransmitter hypothesis 
can account for the wide range of symptoms present in schizophrenia. However, the 
combined effect of neurotransmitter dysfunction is likely to account for a large 
proportion of disease pathology. The serotoninergic system has been implicated in both 
schizophrenia and major depression. While no abnormalities in receptor density have 
been found in schizophrenia cases [174], the affinity of successful atypical antipsychotics 
for the serotonin receptor 5-HT2A support a role for the receptor in schizophrenia 
pathology [175]. The formation of the glutamate hypothesis of schizophrenia came from 
the observation that PCP, an NMDA receptor antagonist, could induce schizophrenia-like 
symptoms in healthy subjects [176]. This is also true of other NMDA antagonists [177-
179]. An increase in NMDA receptor binding has been observed in the cortex of post-
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mortem brain samples from schizophrenia patients [180] and a decreased release of 
glutamate has been reported in synaptosomes prepared from frozen brain samples of 
schizophrenia patients [181]. Genes involved in NMDA receptor function have been 
associated with schizophrenia adding further weight to the glutamate hypothesis. One of 
the most established associations, NRG1, regulates the expression of NMDA receptors 
through ErbB4. GRIN2B, the gene coding for the NR2B subunit of the NMDA receptor 
also shows a small but significant association with sc izophrenia [182].  
 
Dysfunction of dopamine neurotransmission has also been implicated in the pathology of 
schizophrenia based on the fact that dopamine-mimetic drugs elicit hallucinations, and 
that neuroleptics caused rigidity [183]. The original hypothesis stated that dopamine 
pathways may be overactive in schizophrenia. Recent studies have suggested an increase 
in dopamine 2 receptors in the striata of schizophrenia patients, which, while not 
statistically significant, indicated a substantial positive trend in dopamine activity [184] 
[185]. In addition, a transgenic mouse with selectively inducible over-expression of 
dopamine 2 receptors displays selective cognitive impairement in working memory tasks, 
but does not exhibit a global cognitive deficit [186]. This working memory deficit is not 
reversed when the transgene is switched off indicating that it is the expression level 
during development and not continued expression that is of key importance. Deficits in 
spacial working memory in individuals with schizophrenia have been well characterized 
([187, 188] and others) 
 
 
1.5.2 The Developmental Hypothesis 
The neurodevelopmental hypothesis states that small neurodevelopmental deficits in key 
circuitry during brain development could lie dormant until puberty, when normal 
molecular changes could facilitate the onset of disease in affected individuals [189]. 
Studies of children from high risk family groups suggest that delays in motor and 
neurological development, deficits in attention and verbal short-term memory and poor 
social skills are evident in children who later go on to develop schizophrenia [190].                                   
Individuals with high genetic liability have been shown to have reductions in grey matter 
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density in the prefrontal and temporal cortex, amygdala, hippocampus and superior 
temporal gyrus (reviewed in [191] ). High risk individuals with subsequent follow up 
scans revealed a significantly greater reduction in temporal lobe size in those who 
developed psychotic symptoms, suggestive that the reduction in grey matter volume may 
be an early indicator of disease. It has also been r ported that early onset human 
schizophrenia patients display a delay in brain development with respect to overall brain 
volume [192]. Evidence from animal models of schizophrenia identifies clear 
neurodevelopmental deficits in migration and proliferation of neurons in the 
hippocampus and cortex [133, 193], two regions implicated in schizophrenia pathology. 
Some very compelling evidence from transient knock-down studies of Disc1 suggests 
that a loss of Disc1, particularly in pyrimidal cells of the prefrontal cortex, results in 
behavioural abnormalities after puberty [194]. There was a reduction in parvalbumin-
positive cells (a marker of fast-spiking GABA intern urons) and reduced dopamine 
expression after puberty but not before. Knock down mice also displayed a marked 
deficit in prepulse inhibition, which was not observ d at earlier ages. The authors suggest 
that a lack of Disc1 during development results in abnormalities in the postnatal 
maturation of dopaminergic neurons which causes dendritic abnormalities and an overall 
disturbance in neural circuitry evident after puberty [194]. 
 
 
1.5.3 The cAMP hypothesis  
PDE4B and PDE4D belong to the family of phosphodiesterase encoding genes whose 
protein products are involved in the inactivation of adenosine 3’,5’-monophosphate 
(cAMP) in the cell. cAMP is part of a second messenger system thought to be critically 
involved in learning and memory, and mood. Induction of cAMP carried out by Millar et 
al[104] resulted in decreased binding of PDE4B to DISC1 suggesting that this interaction 
is cAMP dependent. Immunoprecipitation of PDE4B showed that binding to DISC1 was 
direct and that it required an intact DISC1 N-terminal “head domain”. Therefore it is 
possible that functional or structural variation in DISC1 will modulate the interaction 
with PDE4B, affecting cAMP catabolism and thus altering expression of other 
downstream genes. In addition, a chromosomal rearrangement disrupting PDE4B was 
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identified in a family with schizophrenia and relatd psychoses [131]. PDE4 activity has 
been linked to memory formation in the fly (cognate dunce mutation) and to mood 
disorders in the mouse [195]. It is also the target for rolipram, a potent prototypic 
antipsychotic and antidepressant [196]. Furthermore, Clapcote et al [197] describe two 





1.6 Genome-wide expression and pathway analysis 
Analysis of gene expression datasets using pathway and network analysis is now 
providing insight into the regulatory mechanisms of disease. Porteous and Hennah (2009) 
[128] employed pathway analysis to determine correlations between variants in DISC1 
pathway genes and levels of gene expression in public domain datasets. Data mining of 
the four available HapMap population cohorts (GSE6536 in NCBI GEO) [198] identified 
six cis-acting variants that showed association in at least three of the four cohorts. In all 
cases the minor allele was associated with reduced DISC1 expression. Further analysis 
incorporating the six cis-acting variants, three know  missense mutations, and three 
known genetic interplay SNPs (conferring risk, neutral or protective effects) identified 
100 genes that could be connected in a pathway of interacting molecules. Gene ontology 
analysis of this pathway identified over-enrichment of genes involved in cytoskeletal 
function, transcription factor function, synaptogenesis and sensory perception. While the 
data from Porteous and Hennah’s study pertains to normal genetic variance, its relevance 
to unraveling the function of DISC1 is undeniable, and the identification of regulatory 
networks gives insight into the mechanisms of psychiatric disease. The use of pathway 
analysis to further test the validity of candidate g nes and their likely contribution to 
psychiatric disorders is without doubt a valuable tool for gene expression analysis. 
 
Recently, Torkamani et al (2010) have used co expression network analysis to determine 
gene clusters of functional significance in schizophrenia [199]. Genes were organised 
into functional modules, which were co-regulated an s such likely to be involved in 
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similar cellular processes and pathways. Using standard analysis of differential gene 
expression they found that genes with altered expression in schizophrenia clustered into 
five distinct gene modules, four of which were prefe ntially associated with neuronal 
function. They also found that changes in gene expression between patients with 
schizophrenia and controls differ with age. Harris et al [200] previously reported genes 
related to CNS development, neuron guidance and neurotransmitter secretion were down-
regulated in healthy individuals during post natal development in a sample set from 
individuals from birth to early twenties. Torkamani et al propose that the downregulation 
observed in their control subjects is a continuation of this process in normal individuals. 
These changes were not observed in subjects with schizophrenia however, suggesting a 
progressive neurodevelopmental deficit. It is suggested that the lack of normal down-
regulation of these CNS developmental genes may act as a trigger for the onset of disease 
[199]. As schizophrenia is not normally diagnosed until the late teens, gene expression 
measurements of individuals with schizophrenia during their early post-natal 
development is not possible. The use of animal models may be useful in shedding light 
on normal age-related changes in neuronal gene expression levels.  
 
The use of animal models is becoming increasingly popular in psychiatric research and 
allows further investigation of candidate genes in a system less limited by sample 
availability and tissue type. The effect of alterations in specific candidate genes can also 
be assessed taking investigation into the mechanisms of psychiatric disorders forward 




1.7 The Schizophrenia Mouse 
One question I have been repeated asked is ‘so how do you know if a mouse is 
schizophrenic?’. This is of course a loaded question, mice are not schizophrenic. We can 
however genetically or pharmacologically manipulate mice to display certain behavioural 
phenotypes which model the human condition in an effort to further understand the 
underlying mechanisms, but major psychiatric syndromes are uniquely human conditions 
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and without a defining pathology, and as such, modeling is limited to examination of a 
specific dimension of the disorder [201]. Endophenotypes are heritable, intermediate 
phenotypes between genes and expression of a disorder and are often used as 
‘biomarkers’ for disease. It is generally considered that each complex disorder phenotype 
is made up of a number of endophenotypes, which are und r different genetic control, so 
by studying single endophenotypes the problem of finding genes involved becomes less 
complex [202]. For example, genes influencing liabity to mental disorders such as 
schizophrenia are likely to act on the multiple neural systems that have already been 
associated with this disorder. These could include serotonergic, glutamatergic and 
dopaminergic systems mediating processes such as learning and memory, social 
cognition, emotion and sensorymotor gating. Neurophysiological, neuropsychological 
and biochemical measurements from these systems give quantifiable measures separate 
from disease symptoms that can be used to map multiple genes of small effect [202]. The 
use of endophenotypes also allows researchers to model certain aspects of psychiatric 
disorders in animals, using quantifiable measures that can be related to the human 
condition [203]. While there are no universally accepted risk loci for major psychiatric 
syndromes [204, 205], researchers are concentrating efforts on modeling loci which have 
been identified through cytogenetics, copy number variants, association, linkage or gene 
expression studies as candidate susceptibility genes. Multiple mouse models of 
psychiatric syndromes now exist, though this section will concentrate on examples of 
Disc1 animal models. 
 
Koike et al (2006) [206] reported that a 25bp deletion variant n exon six of Disc1 in the 
129S6/SvEv mouse strain, results in a lack of full length Disc1 protein and impairment of 
working memory in a C57BL6 backcross (>98% C57BL6 genotype). Gross brain 
morphology of these animals was reported to be normal, however in a delayed non-match 
space test (which measures special working memory) there was a clear working memory 
impairment in both heterozygous and homozygous mutant animals, with a dosage 
dependant effect. This same model was used by Kvajo et al [207] when studying 
neuronal architecture and cognition. They confirmed the previous working memory 
impairment and found alterations in the organisation of neurons in the dentate gyrus, and 
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reduction of short term potentiation of the CA3/CA1 hippocampal synapses. The strength 
of synaptic transmission, release probability and long term potentiation were not 
significantly different in the mutant animal. Working memory deficits are considered 
fundamental cognitive symptoms of schizophrenia [208] and impaired dendritic growth 
and misorientation of dendrites have previously been d scribed in human schizophrenia 
subjects [209]. A third study of this mouse strain, which used all available DISC1 
antibodies, found that all isoforms of DISC1 were still expressed, suggesting bypassing 
of the deletion through exon skipping [210]. It is yet to be confirmed whether the original 
working memory deficits reported by Koike et al are indeed a result of the Disc1 deletion 
or what other factors may be in play. 
 
Another mouse model, carrying a dominant-negative Disc1 mutation on a CamKII 
promoter, shows enlargement of the lateral ventricles and a selective reduction in the 
immunoreactivity of parvalbumin in the cortex, indicating a deficit in interneurons, 
leading to cortical asynchrony [193]. Enlargement of he lateral ventricles has long been 
associated with schizophrenia [211] and is usually present at disease diagnosis. In 
addition, this model also displays disturbed sensorym tor gating, increased hyperactivity 
and measures of anhedonia, all behavioural attributes that have previously been reported 
in patients with schizophrenia. It should be noted that these behavioural anomalies are not 
restricted to schizophrenia, and have been associated with multiple psychiatric 
syndromes, but the combination of phenotypes and the known genetic connection 
between DISC1 and schizophrenia indicate that this model may mimic some aspects of 
the human schizophrenia phenotype. 
 
In 2008 Pletnikov et al [212] generated a transgenic mouse model with inducible 
expression of mutant human DISC1. Expression of the transgene was limited to the 
forebrain regions to counteract any effect of the mutation elsewhere. No 
neurodevelopmental abnormalities were observed, but there was mild enlargement of the 
lateral ventricles and primary cortical neurons derived from mutant DISC1 mice produced 
significantly less elaborate neurite outgrowth compared to those from wild-type controls. 
Some gender specific behavioural phenotypes were obs rved which were consistent with 
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other Disc1 mutant mouse models. Inducible Disc1 male mice show increased horizontal 
activity in the open field similar to the dominant-negative Disc1 model [193] and the 
L100P ENU mouse model [197]. Males also display reduc  social interaction consistent 
with the Q31L ENU mouse model [197], and increased aggression. Females display a 
reduction in spacial learning and memory, which has not previously been shown. Further 
studies indicate that prenatal over-expression of N-terminal human DISC1 results in a 
reduction of parvalbumin-positive and dopamine-positive neurons in adult mouse cortex. 
This was indistinguishable to that observed in animals with continuous expression of N-
terminal human DISC1, indicating that there may be a critical period for DISC1 
expression [213]. 
 
In an effort to closely mimic the genetics of the Scottish (t1:11) translocation family, 
Shen et al (2008) developed a transgenic Disc1 mouse that expressed a truncated form of 
Disc1 comprising of exons 1-8 [214]. Truncated Disc1 is expressed in the cerebellum, 
cerebral cortex and hippocampus of these mice. Enlargement of lateral ventricles and a 
reduction in cerebral cortex was observed along with reduced neurite outgrowth in 
culture consistent with observations from Pletnikov et al in the inducible expression 
model [212]. Similar to the phenotype of the dominant-negative mouse model [193] and 
recent work on the inducible expression mouse model [213], these animals also display a 
reduction in parvalbumin neurons in the cortex. This model also displays many novel 
phenotypes not previously reported in a Disc1 mouse model, including reduced 
parvalbumin-positive neurons in the hippocampus, thinning of layer II/III in the cortex 
and selective decrease of neural proliferation in the cortex. Some aspects of the 
behavioural phenotype are consistent with those obsrved in both the dominant-negative 
mouse model [193] and the ENU mouse model (Clapcote et al 2007, discussed next), 
with increased immobility in depression related tests and reduced latent inhibition (table 
1.1). 
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Table 1.1: Phenotypes of DISC1/Disc1 mouse models (adapted from Shen et al 2008). Column 1 shows 
the phenotype and columns 2-7 the mouse models. NS = not significant, - = unknown, ↑ = increased, ↓ = 
reduced, +, ++, +++ = positive effect with p<0.05, 0.01 and 0.001 respectively. 
   
Our collaborators Clapcote and Roder have developed two independent Disc1 mouse 
mutants at the University of Toronto each displaying a different phenotype of psychiatric 
illness [197]. N-ethyl-N-nitrosourea (ENU) is an alkylating agent that when injected into 
male mice, induces mutations at a frequency of one per locus in every 700 gametes 
(Davis et al 1998). Clapcote and Roder screened the RIKEN ENU-based gene-driven 
mutagenesis system (RGDMS) for Disc1 mutants and found to two independent point 
mutations, Q31L and L100P, in exon 2 of the mouse Di c1 gene (figure 1.1) in C57BL6/J 
sperm, which was then used to impregnate DBA female mice. First generation 
individuals carrying either mutation were backcrossed with C57BL6/J mice for 6 
generations until a predominantly C57BL6/J background line (average 98.5% at N6) was 
intercrossed to generate homozygous and heterozygous mutation carriers.  
 
The L100P and Q31L point mutations change the amino acid sequence and are predicted 
to alter the structure and therefore the function of the protein. The evidence suggests that 
in adult mice the gene is expressed at the same level as in wild types but that it may have 
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different functional properties. In the Q31L mutant the mutation from glutamine, a 
hydrophilic amino acid normally expected to be on the outer surface of the protein, to 
leucine, a hydrophobic amino acid expected to be found on the protein inner surface 
would be expected to cause a distinct conformation change. The Q31L mutation also 
disrupts a known pde4b binding site in the disc1 head domain. Cell line studies have 
shown that binding of pde4b is significantly reduced in both the Disc1 mutated lines. In 
Q31L mice, the amount of pde4b protein is not altered from the wild type level, but 
activity is reduced by up to 50% [197]. The change from leucine to proline in the L100P 
line would also be expected to result in distinct structural alterations of the disc1 protein 
due to the ring structure of proline, which is known to cause a sharp transition in 
polypeptide chain direction. It is highly likely both mutations result in altered Disc1 
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Figure 1.1 : The Disc1 Protein. (A) Amino acid changes in Disc1 resulting from ENU mutatgenesis of  
C57B6/J sperm cells (B) Adapted from Clapcote et al 2007. Amino acid sequence of the Disc1 protein with 
the two ENU mutations highlighted. Conserved amino acids between mouse and human are shaded in grey. 
(C) Diagram of the Disc1 protein with known regions of interaction. The area directly affected by the ENU 
mutations is shown by two red lines in the head domain. NLS = nuclear localisation sequence, LZ = leucine 
zipper.  
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Prepulse inhibition and latent inhibition are common methods used to quantify 
information processing (sensory-motor gating) deficits in schizophrenia [107]. Mice 
homozygous for L100P and Q31L had lower prepulse inhib tion (degree to which the 
startle response is reduced when startle eliciting stimulus is preceded by non-startle 
eliciting stimulus) than wild type controls, and latent inhibition (the degree to which 
exposure to a conditioned stimulus decreases the sali nce of a paired unconditioned 
stimulus) was impaired in both lines. Behaviours asociated with depression were 
observed using the forced swim test, social interacion test and reward response test in 
Q31L mice only (Table 1.2). Homozygote Q31L mice displayed high immobility in 
forced swim tests and avoided social interaction and reward responsiveness [197]. 
 
 
Table 1.2: Common behavioural traits and the effects of the ENU missense mutation on phenotype 
when compared to the C57B6/J parent line = no significant change. Adapted from Clapcote et al 2007 
 
Widely used antipsychotic and mood stabilising drugs were shown to reverse these 
behavioural anomalies, almost to the levels of non drug treated wild type controls (Table 
3). Interestingly, treatment with the antipsychotics lozapine and haloperidol was 
effective in correcting the behavioural abnormalities in the L100P mutants, as was the 
PDE4 inhibitor rolipram, while these treatments had no effect on correcting the majority 
of the deficits observed in the Q31L line. Conversely the antidepressant biogenic amine 
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Table 1.3: The effects of drug treatment on behavioural rescue in Q31L and L100P missense mutant 
mouse lines. Adapted from Clapcote t al 2007 
 
From the pharmacological responses and distinct behavioural phenotypes observed 
Clapcote et al [197] categorized the Q31L mutation as depressive-like and the L100P 
mutation as schizophrenia-like. They also observed reductions in brain size coupled with
tissue shrinkage in cortex, thalamus and cerebellum. These areas correspond well to 
known neuroanatomical features of schizophrenia. This could be due to the predicted 
altered function of DISC1 in these mutants during brain development, but prior to this 
time a developmental profile of whole genome gene expression has not been obtained for 
the ENU missense mutant lines.  
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1.8 Thesis Aims 
There were four main aims of this thesis. 
 
1. to determine the effect of the two missense mutations n whole genome gene 
expression through development and into adulthood 
2. to determine the effects of certain drug treatments o  gene expression in adult 
mice ultimately allowing us to determine potential rget genes, or pathways for 
targeting by drug treatment. 
3. to determine gene expression levels throughout embryonic and early post-natal 
development of genes identified in the initial study. 
4. to determine the effects of the disc1 mutations on protein expression in the adult 
mouse and mature neuronal cultures 
.  
 
My hypothesis was that the expression levels of genes i volved in brain function and 
development would be altered in the mutant mouse lines. I proposed that these alterations 
would occur from early embryonic stages, correlating with previous reports of delays in 
neuronal migration and maturation in Disc1 mouse models. My secondary hypothesis 
would suggest that administration of drugs previously shown to correct aberrant patterns 
of behaviour in this mouse model may correct the expr ssion patterns of these genes in 
the tissues tested. This would correlate with the canges in endophenotypes and patterns 
of behaviour observed in previous studies. It would be hypothesized that if this is the case 
it is a secondary effect (due to the action of the drug binding to receptors and preventing 
neurotransmitter release) and not the primary action of the drug, but may give some 
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2.1 Collection of tissue samples 
In order to generate a wild type Disc1 developmental profile, C57BL6 female mice were 
obtained from Harlan, UK and bred to males of the same strain held in-house at the 
Western General Hospital Biomedical Research Unit. Females were taken at key time 
points throughout gestation based on previous results from Shurov et al [134],  and 
sacrificed by cervical dislocation. Pups taken for p st-natal developmental stages were 
sacrificed by decapitation (if under 2weeks) or cervical dislocation. C57BL/6 is an inbred 
laboratory mouse strain widely used in research as a wild type or background strain as it 
has a permissive background for maximal expression of most mutations (www.jax.org). 
They are long lived and breed well.  
 
Missense mutant mice for the microarray study were obtained from Steve Clapcote and 
John Roder at the Samuel Lunenfeld Research Institute, Toronto, Canada. Wild type 
C57BL6J mice were obtained from Jackson Laboratories (www.jax.org). Where possible, 
matings were set up between homozygous individuals to remove the need to genotype all 
animals. Adults of 12 weeks used for the drug treatm nt trial and developmental stages 
were obtained as above.  
 
 
2.1.1 Use of Inbred Strains 
The C57BL/6J inbred strain was created by Dr. CC Little (who went on to found the 
Jackson laboratories) in the 1950’s and all mice in this strain are derived from this 
original mating. All C57BL6 mice carry a mutation Cdh23753A which causes a frame skip 
of exon 7 in Cadherin 23 resulting in age related haring loss at around 10months of age.  
Subsequent splitting of the original C57BL6 line has resulted in the arrival of new 
spontaneous mutations specific to subpopulations. One such mutation results in the 
deletion of the alpha-synuclein locus (which has been implicated in Parkinsons disease) 
in C57BL6 mice from the subpopulation available from Harlen UK (www.harlan.com). 
While this is not thought to affect other genes in this population we wanted to ensure our 
background strain was as close to that of the missense mutants as possible.  
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The L100P and Q31L mutants were backcrossed for several generations with C57BL/6J 
mice from the Jackson Laboratories (which do not carry the alpha-synuclein deletion). 
Due to time restrictions and problems achieving successful matings while in Toronto it 
was deemed necessary to complete the collection of C57BL6 embryonic stages back in 
the UK. The animals immediately available to us were C57BL6 mice from the Harlan 
subpopulation, so to ensure continuity it was necessary to order new breeders from 
Charles River (www.criver.com), the only UK supplier of the Jackson C57BL/6J 
substrain. This done, it meant we could confidently make direct comparison to those 
samples collected in Toronto. It would however be interesting to compare gene 
expression between the Harlan and Jackson subpopulati ns to determine if the 
spontaneous mutation would have had an effect on the experimental outcome. 
 
All necessary measures were taken to ensure minimal stress to animals prior to sacrifice.  
 
 
2.1.2 Extraction of Genomic DNA from adult tissue 
Mice were earmarked for identification and the ear notches used to extract DNA for 
genotyping. 300µl 50mM NaOH was added to the ear notches at room temperature and 
then incubated at 95°C for 15-20minutes on a heat block to break down the tissues. 
Samples were mixed by vortex and pulse spun in a centrifuge to collect any 
condensation. 50µl 1M Tris-HCl was added and samples again mixed by vortex for 15 
seconds. Samples were spun in a centrifuge at 13,000rpm for 6 minutes and the 
supernatant collected for genotyping. Samples were stor d at -20°C until required. 
 
 
2.1.3 Extraction of Genomic DNA from embryonic tiss ue 
Genomic DNA extraction was carried out on embryonic samples from E10 and E13 pups, 
and from those animals for which genotype had to be ascertained. Extractions were 
carried out using the DNeasy blood and tissue kit (Q agen) as per the manufacturer’s 
protocol. Tissue (either a leg for embryonic samples or a tail clipping for post natal 
samples) was cut into small pieces and placed in a 1.5ml eppendorff with 180µl buffer 
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ATL and 20µl proteinase K. The sample was mixed by vortexing and incubated at 56ºC 
for 4 hours to ensure complete lysis of the tissues. Samples were vortexed and 200µl 
buffer AL added. 200µl of 100% ethanol was added immediately and the sample mixed 
by vortexing. The mixture was transferred to a DNeasy mini column in a 2ml collection 
tube and centrifuged at 8000rpm for 1 minute. Flow through was discarded and 500µl of 
wash buffer AW1 added to the column. This was then c trifuged for 1 minute at 
8000rpm and flow through was discarded and 500µl of wash buffer AW2 added to the 
column. This was centrifuged for 3 minutes at 12,000rpm to dry the spin column and 
flow through and collection tube discarded. The spin column was placed in a new 1.5ml 
eppendorff and 200µl buffer AE added directly to the membrane. The column was 
incubated for 1 minute at room temperature and then c trifuged for 1 minute at 
10,000rpm to elute the DNA. DNA was stored at -20ºC until required. 
 
 
2.1.4 Genotyping by sequencing reaction 
2.1.4.1 Polymerase Chain Reaction (PCR) 
A master mix was prepared on ice consisting of 1X Sigma PCR buffer (SIGMA), 0.1mM 
of each forward and reverse primer (Invitrogen), 0.6µM dNTPs and 1U Sigma Taq DNA 
polymerase (SIGMA). Typically 0.5µg gDNA was used for a 20µl reaction volume and 
the master mix aliquoted into the tubes. PCR reactions were run on the Peltier Thermal 
Cycler-225 (MJ Research) and heated lids used to minimise evaporation. The initial PCR 
was run under cycle conditions; 94ºC 10mins, 94ºC 1min, 55ºC 1min, 72ºC 1min (return 
to stage 2 and repeat 30times), 72ºC 5mins, hold at 4ºC. Samples were run on a 1.5% 
agarose gel to check for product. 
 
2.1.4.2 Exosapit Clean-up 
2µl product from the PCR was added to 2µl H2O and 1µl Exosapit for a 5µl reaction 
mix. For each sample there were two reactions, to allow the use of forward and reverse 
primers in the next stage. The plate was run on the Peltier Thermal Cycler-225 (MJ 
Research) at 37ºC 1hour, 80ºC 20mins and held at 4ºC. 
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2.1.4.3 Sequencing reaction 
A master mix was prepared consisting of 0.5µl BD v.3.1, 1.75µl Sequencing buffer, 1µl 
3.2pmol Primer, 2.75µl H2O to a total volume of 6µlper sample. This was added to each 
sample in the plate used for the previous reactions and run on the Peltier Thermal Cycler-
225 (MJ Research) under cycle conditions; 96ºC 1min, 96ºC 10secs, 50ºC 4secs, 60ºC 
4mins (return to stage 2 and repeat 30times), hold at 4ºC. After PCR the samples were 
stored at -20ºC for ethanol/EDTA precipitation the following day. 
 
2.1.4.4 Ethanol/EDTA Precipitation 
Sample plate was allowed to equilibrate to room temp rature and then pulse spun in a 
centrifuge to collect any condensation. 2.5µl 125mM EDTA was added to each well 
along with 30µl 100% EtOH and hybaid sealing mat replaced. Reactions were mixed by 
inversion 4times and incubated at room temperature for 15mins. Plates were spun in a 
Jouan centrifuge at 3000rpm for 30mins and seal remov d before plate was inverted over 
a paper towel to remove most of the EtOH. The paper towel was placed in the bottom of 
a centrifuge bucket and plate spun inverted up to 1000rpm then stopped. 40µl freshly 
diluted 70% EtOH was added to each well and the seal replaced before mixing by 
inversion 4times. The plate was spun in Jouan centrifuge at 3000rpm for 15mins and seal 
removed before plate was inverted over a paper towel to remove most of the EtOH. The 
paper towel was placed in the bottom of a centrifuge bucket and plate spun inverted for 
30secs then stopped. Wells were air dried for 15mins protected from light and the plate 
sealed with adhesive film before being sent to the Medical Research Council sequencing 
service to be sequenced by Agnes Gall. 
 
 
2.1.5 Genotyping using the Transnetyx sequencing se rvice 
Ear notches were collected from mice and placed in the 96-well plate provided by 
Transnetyx services (www.transnetyx.com). Positive and Negative control samples from 
mice with known genotypes were included in the first run. Samples were sent by courier 
to Transnetyx to be analyzed using primers designed from sequence submitted by myself. 
Results were returned within 3 days. 
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2.1.6 Genotyping Q31L het x hom pups 
Genotyping of Q31L pups from het x hom matings was c rried out by Edward Weiss at 
the Toronto Sick Kids Hospital Research laboratories. 
 
 
2.1.7 Dissection of embryos and pups 
Pregnant females were sacrificed by cervical dislocati n and observed until all movement 
had ceased. An incision was made into the females abdominal cavity and the skin pulled 
back to reveal the embryonic sacs. Embryos were remov d and placed in chilled PBS on 
ice. Under a standard dissecting microscope the heads were removed and the top of the 
skull removed to expose the brain. The brain was extracted whole and placed in 
prechilled RNAlater (Ambion) at 4ºC to stabilize the RNA for further analysis, and kept 
at 4ºC for up to 2 weeks before required. For post-natal samples the heads were also 
removed and brains extracted in the same manner as the embryonic stages. 
 
 
2.1.8 Dissection of adult brain samples 
Adults were decapitated post mortem and the skin cut from the back of the head to the 
nose down the midline. The tissue was then peeled back to reveal the top of the skull. 
This was removed by making an incision around the circumference of the skull starting at 
the foramen magnum and proceeding round the top of the skull at the level of the 
occipital openings. The top of the skull was lifted off the brain and the whole brain 
removed intact from the skull and placed dorsal side up on filter paper moistened with 
PBS. The cerebellum was removed by making a coronal cut perpendicular to the paper 
just behind the inferior colliculi, and placed in pre-chilled RNAlater (Ambion). A sagittal 
incision was made down the midline between the two hemispheres to one third from the 
anterior end. Using two paintbrushes the hemispheres w re separated exposing the 
hippocampal groove. One brush was slid into the grove, separating the hippocampus from 
the cortex, and the hippocampus gently rolled out. Once separated from the rest of the 
brain the hippocampus was placed in prechilled RNAlater  prior to further analysis. This 
was repeated for the other hemisphere also. The cort x was gently peeled away and 
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stored in RNAlater. In some cases only the hippocampus was removed in which case the 
cortex and remaining brain tissues were stored in the same eppendorf as the cerebellum. 
Where no further dissection was being carried out the brain was removed from the skull 




2.2 Sample Preparation 
2.2.1 Extraction of total RNA from tissue samples 
Total RNA was isolated from selected tissue in accordance with the protocol supplied 
with the RNeasy mini kit for animal tissues (Qiagen). Tissues were homogenized in 
600µl buffer RLT using a Precellys 24 tissue homogenizer (Bertin Technologies) at 
maximum speed for two 45 second cycles. Lysate was centrifuged for 3 minutes at 
13,000rpm and the supernatant transferred to a fresh micro centrifuge tube. 1 volume of 
70% ethanol was added to the lysate and mixed by pipetting and 700µl of this sample 
transferred to an RNeasy spin column. After centrifugation at 10,000rpm for 15seconds, 
flow through was retained for protein analysis and 700µl buffer RW1 added to the spin 
column. Columns were again centrifuged under the same conditions and flow through 
retained and combined with that from the previous step. The spin column membrane was 
washed by addition of 500µl buffer RPE and spun for 15seconds at 10,000rpm. Flow 
through was again retained and the step repeated with a 2 minute spin time to dry the 
membrane. RNA was eluted by the application of 40 µl sterile H2O directly to the 
membrane and centrifuged for 1 minute at 10,000rpm. Pooled flow through was stored at 
-20°C until required for protein analysis. Concentration and quality of total RNA samples 
(RIN) was determined using a spectrum analyzer (Agilent Bioanalyser ; see section 2.2.5) 
and samples stored at -20°C until required for cDNA synthesis.  
 
The same method was followed for RNA extraction of the samples collected at the 
Samuel Lunenfeld Research Institute however due to lack of access to the Precellys 24 
tissue homogenizer, all tissues were homogenized using a standard mortar and pestle. 
These samples also underwent on column DNA digest (s e section 2.2.3). 
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2.2.2 PARIS procedure  
The PARIS procedure from Qiagen allows simultaneous extraction of RNA and protein 
from the same sample tissue. This enables us to use the same animal and sample section 
for subsequent protein analysis after the initial RNA/DNA analysis is complete. The 
PARIS procedure was used on animals for the second round qRT-PCR Taqman analysis. 
Lysate is prepared by placing tissue in a homogenizer tube with 600µl ice-cold Cell 
disruption buffer (provided with kit) and homogenizi g in a rotor homogenizer for 
30secs. The lysate was split into two eppendorf tubes of equal volume. One tube was 
stored at -80°C for later protein analysis while 300µl 2X lysis/binding solution was added 
to the other tube and mixed by pipetting. One volume 100% EtOH was added and the 
sample was mixed by pipetting to ensure the EtOH reach d the bottom of the tube. The 
sample mix was transferred into a filter cartridge and spun at 10,000rpm for 1min in a 
centrifuge. Flow-through was discarded and 350µl was solution 1 added to the cartridge. 
The sample was spun at 10,000rpm for 30secs and flow-through again discarded. 500µl 
wash solution 2/3 was added to the cartridge and the sample was spun at 10,000 rpm for 
1min. Flow-through was discarded and this step repeated a second time. The empty 
cartridge was spun at 10,000rpm for 15secs to remov any residual wash solution and 
transferred to a fresh collection tube. 40µl pre-heated (to 95ºC) elution solution was 
added to the cartridge membrane and the sample was spun at 10,000rpm for 30secs. This 
was repeated so a total of 80µl RNA was collected. Any genomic contamination was 
removed using the DNA-free kit (Ambion) outlined in section 2.2.3. 
 
 
2.2.3 Post extraction DNase Treatment of RNA 
RNA samples were treated with the DNA-free kit (Ambion) prior to cDNA synthesis to 
remove any traces of genomic contaminant. Treatment was carried out as per the protocol 
supplied with the kit. 0.1 volumes of 10x DNase1 buffer and 1µl rDNase 1 was added to 
the samples and mixed gently before incubation in a 37°C water bath for 30minutes. 0.1 
volume of DNase inactivation reagent was added to the samples and incubated at room 
temperature for 2 minutes ensuring the samples were continually mixed over the 
incubation period to re-disperse the inactivation reagent. After centrifugation at 
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13,000rpm for 2 minutes the supernatant containing the RNA was transferred to a fresh 
tube to be used for cDNA synthesis.  
 
 
2.2.4 On column DNase Treatment of RNA 
On column DNA digest was carried after the preliminary wash stage of RNA extraction 
using the RNase-Free DNase set (Qiagen) by adding 70µl Buffer RDD to 10µl DNase 1 
and applying this mix directly to the spin column me brane. The column was then 
incubated at room temperature for 15-20 minutes to allow complete DNA digest to occur. 
The membrane was washed again with 350µl buffer RW1 and RNA extraction continued. 
 
 
2.2.5 Assessing RNA quality using the Agilent Bioanalyser  
The Agilent 2100 Bioanalyser uses electrophoresis to eparate fragments of the RNA 
sample by size. Quantification of each fragment allows quality control to be carried out at 
the same time as checking quantity. Samples collected at the Samuel Lunenfeld Research 
Institute in Toronto were analyzed by me on my return to Edinburgh. All other samples, 
including those collected in-house at the Molecular Medicine Centre and those which 
required vacuum drying prior to amplification and labeling for the microarray study, were 
analyzed by Alison Condie at the Welcome Trust Clinical Research Facility, Western 
General Hospital, Edinburgh. 
 
The RNA 6000 Nano kit was placed on the bench for 30mins prior to loading the chip to 
allow the dye concentrate to equilibrate to room tep rature. 550µl of RNA 6000Gel 
matrix was pipetted into a spin column and centrifuged for 10 minutes at 1500g. Gel was 
split into 65µl aliquots to be used within 4 weeks. Once at room temperature the RNA 
6000Nano dye concentrate was placed on a 10second pulse spin and 1µl added to a 65µl 
aliquot of filtered gel. The solution was vortexed for 15seconds to mix and centrifuged 
for 10mins at 13000g. RNA samples were denatured for 2minutes at 72ºC and placed on 
ice ready for loading onto the chip. 
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The RNA 6000 Nano chip was placed in the chip priming station and 9µl gel-dye mix 
added to the well marked   and the priming station closed. The plunger was pre sed 
until held in the clip and released after 30 seconds. After 5 seconds the plunger was 
pulled back to the 1ml position and the station opened. 9µl of gel-dye mix was pipetted 
into the wells marked  and the remaining gel mix discarded. The RNA 6000 Nano 
marker was loaded into all 12 sample wells and the ladder well. 1µl of the RNA 6000 
Nano ladder was added to the appropriated well marked  and 1µl of sample into each 
of the 12 sample wells. The chip was placed horizontally in the IKA vortex and vortexed 
for 1 minute at 2400rpm. The chip was placed in the Agilent 2100 Bioanalyser and run 
within 5 minutes of vortexing. The programme selected quantifies total RNA in the 
sample. 
 
After the bioanalyser had completed its programme the chip was discarded and the 
bioanalyser pins cleaned by immersing in 500µl RNA zap for 2mins then 500µl distilled 
H2O for 2 mins before being air dried for 10 seconds. Total RNA results were analyzed 
using the Agilent 2100Expert software. Samples with a RNA Integrity Number (RIN) of 
<5 were deemed unsuitable for use in the microarray study due to problems with 
amplifying low quality RNA (Figure 2.1).  
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Of all samples collected (both in house at the MMC and at the Samuel Lunenfeld 
Research Institute) 96.91% met the RIN number criteria for progressing forward for the 
microarray. Of those groups chosen for the microarray study 95.10% had suitable RNA 
for amplification.  
 
 
2.2.6 Vacuum Drying RNA samples 
While the majority of samples (97%) collected for the microarray study contained enough 
total RNA to go forward for amplification and labeling, a few had very low 
concentrations and would require drying before amplification. This was achieved using a 
vacuum centrifuge.  
 
The centrifuge was cleaned with RNAzap to prevent cross contamination and was set to 
heat to 60ºC for 10minutes prior to loading the samples. Samples were loaded in 1.5ml 
eppendorffs with the lids removed and the vacuum pup and centrifuge set running. 
Progress was checked every 5minutes to ensure the samples were not over-dried and the 
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running time was adjusted according to the volume left in the tubes at any time 
throughout the process. All samples were dried from 45µl down to around 15µl over a 
period of around 35 minutes. An aliquot of the concentrated sample was stored for 
quantification on the Agilent Bioanalyser and the remaining sample stored at -70ºC until 
required for amplification. Some samples returned poor RIN numbers post drying and so 
could not be used for the microarray study. The other samples, with RIN’s above 5, were 
deemed acceptable for amplification and would be checked after this to assess suitability. 
 
 
2.2.7 Synthesis of cDNA 
Single-stranded cDNA was synthesized from DNase treated total RNA using the core 
cDNA synthesis kit (Roche). 2µg total RNA was diluted in sterile H2O to a total volume 
of 16.4µl and denatured at 65°C for 15minutes before being placed on ice for 5minutes. 
This was then incubated at 47°C for 60minutes in the presence of 10x buffer, 25mM 
MgCl2, 5mM dNTPs, OligoT, RNase inhibitor and AMV reverse transcriptase. Controls 
underwent the same conditions in the absence of AMV reverse transcriptase or RNA. The 
reaction was terminated by heat inactivation at 99°C for 5 minutes. Single stranded 
cDNA was stored at -20°C until required for PCR amplification.  
 
 
2.2.8 Synthesis of cDNA from low quantity RNA 
Synthesis of single stranded cDNA from low quantity RNA was carried out using the 
Transcriptor cDNA synthesis kit from Roche. 2µg total RNA was diluted in sterile H2O 
to a total volume of 22µl and added to 4µl random pri ers. The mix was denatured at 
65°C for 15minutes before being placed on ice for 5minutes. This was then run of a cycle 
of 25°C for 10 minutes, 55°C for 30 minutes and 85°C for 10 minutes in the presence of 
5x buffer, 5mM dNTPs, RNase inhibitor and AMV revers  transcriptase. After 
completion of the cycle the samples were held on ice for 5 minutes and transferred to -
20°C until required for further experiments.  
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2.2.9 Determining cDNA concentration using the Quan t-iTTM PicoGreen® 
dsDNA kit   
Concentration of cDNA preparations was determined using the Quant-iTTM PicoGreen® 
dsDNA kit (Invitrogen). The kit contains the Quant-iTTM PicoGreen® dsDNA reagent 
which stains double stranded DNA in solution and fluoresces when excited at 480nm in a 
Cytofluor Fluorimeter (at the Cancer Research Facility, Western General Hospital, 
Edinburgh). Intensity of fluorescence emission of samples and standards was measured at 
520nm.  
 
The 100µg/ml lambda DNA standard supplied with the kit was diluted 50 fold in TE to 
give a 2µg/ml DNA stock for preparing standards. Standards were prepared at 0, 1, 10, 
100 and 1000ng/ml DNA and DNA samples to be measured were diluted in duplicate in 
TE (5µl sample + 95µl TE) in a DynaTech 96 well plate. As the predicted yield of the 
cDNA reaction is 30% all samples should fall within the range of the standard curve.  
The PicoGreen reagent was diluted 200 fold in TE and covered in foil to protect from 
light. The reagent must be used within a few hours to be most reliable so only enough 
working solution for one run was prepared allowing 100µl for each sample and standard. 
The fluorimeter was set to excite at 480nm and measur  emission at 520nm with a gain of 
45 so the highest DNA standard would be close to the fluorimeter’s maximum. The 
Picogreen working solution was added to the samples and readings taken immediately. 
Emission readings of the DNA standards were plotted an  concentration of cDNA 
samples calculated using the regression equation of the standard curve. 
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PicoGreen Standards


























Figure 2.2: Picogreen standard curve for assessing cDNA concentration. 
 
 
2.2.10 Determining cDNA or RNA quantity on the Nano Drop 
The Thermo Scientific NanoDrop 1000 spectrophotometer is a highly accurate full 
spectrum spectrophotometer for measuring concentration nd quality of nucleic acids and 
proteins. As little as 1µl of sample can be used to etermine concentrations, reducing the 
amount of sample required compared to traditional methods. Sample concentration is 
determined using the Beer-Lambert equation (A= e*b*c) where A is the sample 
absorbance measurement (-log[sample intensity/blank intensity]), e is the wavelength-
dependent extinction coefficient (liter/mol-cm), b is the path length in centimeters, and c 
is the analyte molarity (M). On start up the nucleic acid option was chosen and for cDNA 
the ‘ssDNA33’ programme was selected, and for RNA the ‘RNA-40’ programme was 
selected. Selection of the correct programme is essential for accurate calculation of 
concentrations. 
 
The machine was blanked using 1µl dH2O and this is stored as reference for calculating 
the subsequent samples. Each sample was tested on the NanoDrop ensuring the pedestal 
was cleaned after every sample. Concentrations weresav d in the report and absorbance 
ratios and curves checked for quality. The 260/280 ratio gives a comparative value of 
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absorbance at 260 and 280nm and is used to assess quality of RNA and DNA. A 260/280 
ratio of 1.8 is accepted as ‘pure’ for DNA and a ratio of 2.0 ‘pure’ for RNA. Deviations 
from these values would suggest contamination of the sample. Any samples run which 





Polymerase chain reactions (PCR) allow the rapid amplification of a selected region of 
DNA sequence from a complex mixture. Specificity is provided by oligonucleotide 
primers designed to be complimentary to the 5´ region of sequence to be amplified. The 
PCR reaction is a three stage process. First the DNA is denatured at a high temperature, 
and then the temperature is reduced to allowing anne ling of the oligonucleotides to the 
specific DNA sequence. Finally the temperature is adjusted again to allow elongation and 
amplification by a thermo-stable DNA polymerase. Multiple cycling of these stages 
results in exponential amplification of the desired s quence. 
 
 
2.3.1 PCR Reagents 
As only RNA expressed at certain time points was of interest, reverse transcriptase PCR 
(RT-PCR) was used. A master mix was prepared on ice consisting of 1X Sigma PCR 
buffer (SIGMA), 0.1mM of each forward and reverse primer (Invitrogen), 0.6µM dNTPs 
and 1U Sigma Taq DNA polymerase (SIGMA). Typically 0.1µg cDNA was ued for a 
20µl reaction volume and the master mix aliquoted into the tubes. PCR reactions were 




2.3.2 Design and Synthesis of Oligonucleotide Prime r pairs 
Oligonucleotides were designed using the Primer3 software (primer3_www.cgi v 0.2) 
with in-house default features. All oligonucleotides were 18-25bp long with an average 
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50% GC content and a melting temperature (Tm) of 60-65ºC. No primers chosen were 
predicted to dimerise or hairpin when used as a pair. All primer pairs were commercially 
sythesised by Invitrogen at 25nM scale with standard purification.  
 
 
2.3.3 RT-PCR Cycling 
The PCR consisted of an initial denaturing step of 94ºC for 2 mins followed by 30 cycles 
of denaturation, annealing and extension. The denaturation step lasted 30 seconds at 
94ºC. The annealing temperature was determined by the predicted Tm of the 
oligonucleotide primers. Primers were typically designed with a Tm of 64°C so the 
annealing step was carried out 5ºC below this at 59ºC for 30seconds. The extension step 
was carried out at 72ºC, the optimum temperature fo Taq DNA polymerase, and the 
length of stage determined by final predicted product size. Typically 1 minute per 1Kb of 
sequence was used. After the final cycle a further elongation step of 94ºC for 5minutes 
was used to ensure fragments were complete.  
 
The ‘Touch-down’ PCR method was used as standard as it increases specificity of the 
PCR reaction. The initial annealing temperature used i  10 ºC above the final annealing 
temperature required, and drops by 1ºC with every cycle until after ten cycles the final 
annealing temperature is reached. The normal 30cycle reaction at the desired annealing 
temperature can than proceed. This method results in highly specific primer annealing in 
the first few cycles selecting for the correct product in the subsequent cycling sets. 
 
 
2.3.4 Visualisation of PCR Products 
PCR products were separated by electrophoreses on agarose gel of between 1 and 2% 
(w/v) depending on the size of the expected bands (gel used is noted on figure legends). 
Multi-purpose agarose was boiled in 0.5x TBE buffer (45 mM Tris base, 45 mM boric 
acid, 1 mM EDTA pH 8.0) and SYBRsafe (Invitrogen) added 1:50 (v/v). Gel was left to 
set in the dark to prevent any bleaching of the SYBR safe. 2µl loading dye was added to 
the PCR product prior to loading on the gel and 400ng of 1Kb ladder (Invitrogen) run 
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alongside the samples. Products were visualized on a UV transilluminator and 
photographed with a digital camera. 
 
 
2.4 Protein Preparations 
2.4.1 Determining Protein Sample Concentrations 
Concentrations of protein samples obtained during the PARIS procedure were determined 
using the BCA Protein Assay Kit (Pierce Biotechnologies) test tube procedure as per the 
manufacturers’ instructions. This relies on the reduction of copper ions by protein in an 
alkaline medium which is detected by kit reagent A. Protein standards of known 
concentrations from 0-2000µg were initially prepared by dilution of 2mg/ml stock 
Albumin. BCA working reagent was prepared by mixing 50 parts BCA reagent A with 1 
part BCA reagent B. Total volume required was calcul ted as: 
 
(#standards + #unknowns) x (#replicates) x 2 = Total volume working reagent required  
 
0.1ml of each standard and unknown sample replicate w s pipetted into an appropriately 
labeled tube and 2ml working reagent added to each. Tubes were incubated at 37ºC in a 
waterbath for 30 minutes and then allowed to cool t room temperature. As the BCA 
reaction is not an end-point colour change, the colour will continue to develop after 
cooling to room temperature. However, the rate of colour change is so low at room 
temperature that no significant error will be recorded if all samples are measured within 
10 minutes of each other. Sample absorbance was measured at 562nm on a 
spectrophotometer. The absorbance reading for the blank sample was subtracted from 
subsequent standard and unknown sample measurements. These blank correlated BSA 
standards were plotted on a standard curve against their know concentrations and this was 
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2.5 Pre-Pulse Inhibition 
Pre-pulse inhibition is a common method used to quantify information processing deficits 
in schizophrenia with reasonable validity. It can be used with both animal and human 
experiments. PPI measures the degree to which the acoustic startle response is reduced 
when a startle eliciting stimulus is preceded by a brief low-intensity stimulus which does 




Animals from 11.5-14 weeks of age were weighed and the chamber platform of the 
prepulse box was calibrated to take into account the weight of the animal.  
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2.5.2 Drug Administration 
Drugs were administered 30 minutes before the commencement of behavioural testing by 
intra-peritoneal injection in a volume of 10ml/kg by Tatiana Lipina at the Samuel 
Lunenfeld Research Institute. Clozapine (3mg/kg; Tocris) was dissolved in saline (0.9% 
NaCl) containing 0.3% Tween (Biorad). Bupropion (4mg/kg; Sigma) was dissolved in 
distilled water and Rolipram (0.5mg/kg; Sigma) in saline containing 10% DMSO. Saline 
was used as a control for drug naïve animals. All drug doses were selected from previous 
studies carried out at this lab (Clapcote e  al 2007 [197]).  
 
Each genotype was split into groups for drug treatmnt. For the L100P mutant line and 
the C57BL6 line there were 12 mice in each drug treatm nt group of equal numbers male 
and female, including a control group administered with saline. For the Q31L mutant line 
8 mice were used for each drug treatment with equal n mbers of male and females. 
Rolipram was not administered to the Q31L line as it had been deemed unsuccessful at 
behavioural rescue in previous studies [197]. In all c ses animals were sacrificed 1 hour 
after drug administration. 
 
 
2.5.3 Behavioural Testing  
Animals were placed in a pre-pulse chamber 15 minutes after administration of drug 
treatment. The pre-pulse program begins with a 15 minute habituation period so actual 
testing did not begin until 30 minutes post drug administration. Animals are then played a 
series of five ‘startles’, and movement is detected by the platform at the base of the 
chamber. This is followed by 50 trials of startle, startle preceded by pre-pulse or no 
stimulus. The final stage is a further series of 5 pure startle stimuli. 
 
Animals were sacrificed immediately at the end of the pre-pulse testing by cervical 
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2.5.4 Analysis of Behavioural Testing Results 
Analysis of the amplitude of acoustic startle response in the Pre-pulse inhibition trials 
was carried out in Microsoft Excel and Statistica for Windows analysis packages. 
Repeated measures analysis of variance was used to d termine any significant differences 
between groups with appropriate post-hoc tests applied and a standard p-value cut-off or 




2.6 Microarray Analysis of ENU mutant gene expressi on 
This section describes the methods used to carry out the microarray study from 
amplification onward. Preparation and extraction of RNA was as described in section 2.2.  
 
 
2.6.1 cRNA amplification and Biotinylation 
RNA samples were gathered as previously described in sections 2.2.1-2.2.6. Biotinylated, 
amplified cRNA was generated using the Illumina® TotalPrep RNA amplification kit as 
per the manufacturers instructions.  
 
100ng total RNA was used as starting material and master mixes were prepared as 
recommended using the Illumina® TotalPrepTM RNA Amplification Master Mix 
Calculator available online 
(www.ambion.com/techlab/mm_calcs/illumina_rna_totalprep_amp_calc.php). The two 2-
hour incubation cycles (II.C and II.D) were performed in a Peltier Thermal Cycler and 
hybridisation (step II.F) was carried out with overnight incubation for 14 hours at 37ºC in 
a hybridisation chamber. The eppendorf’s were wrapped in parafilm for this step to 
prevent loss of material through condensation. 1.5µl of the final elute, containing 
amplified, biotinylated cRNA, was set aside for quantification and quality control and the 
remainder stored at -70ºC until required. 
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2.6.2 Quantification and Quality control of cRNA 
Samples were loaded onto the Agilent RNA nano chip as described in section 2.2.5. The 
chip was loaded into the bioanalyser and run under the ‘RNA nano-cRNA’ programme, 
designed to measure the quantity of cRNA in the sample. The read-out obtained from the 
bioanalyser gives a measure of concentration and contamination (as a percentage). 
Samples with high levels of contamination would notbe amplified. 
 
 
2.6.3 Preparation of Pooled cRNA 
Due to the number of animals used for the study it was decided samples would be pooled 
before being hybridised to the array. Each pool contained 3 animals of the same sex from 
the same mouse line. In most cases there were 2 pools for each group and sex (table 2.1). 
After determining the concentration of each individual sample using the Agilent 2100 
bioanalyser, equal amounts of each sample were combined to a total concentration of 
150ng/µl. 
 
Table 2.1: BeadChip layout with key. Numbers represent each individual beadchip and letters represent 
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2.6.4 Hybridisation and scanning of Illumina BeadCh ips at the Wellcome 
Trust Clinical Research Facility 
The Illumina MouseWG-6 v2.0 expression beadchip wasused to target 45281genes from 
the RefSeq database release 22 and RIKEN FANTOM across six pooled samples per chip 
(http://www.illumina.com/downloads/GX_Mousev2.0_DataSheet.pdf). Each chip carried 
one identical sample to be used as a between chip control, and one sample set was 
amplified, pooled and hybridised 3 times to control for batch differences. 
 
10 microlitres of each 150ng/µl sample was submitted o Alison Condie at the Genetics 
Core of the WTCRF where the subsequent hybridisation, washing, blocking and 
streptavadin-Cy3 staining was performed in line with manufacturers guidelines. The 
Illumina BeadArrayTM Reader was used to scan the BeadChips and Illumina BeadScan 
software performed specific image processing steps o determine bead intensities from 
raw image data (as described in Kuhn et al 2004 [215]).  Illumina BeadStudio 2.0 Gene 
Expression software was used to read the image data and generate signal data for 
subsequent analysis. Probe information including raw signal intensity, number of beads, 
standard deviation of raw bead intensity and detection P-value were exported to text file 
and returned to myself from the WTCRF. Two sets of data were initially returned, one 
with no normalisation and no grouping, and the other with no normalisation but with 
samples grouped according to line and treatment. This second sample set returned group 
detection P-values which would be used for data filtered later in analysis. 
 
Unfortunately during the hybridisation stage one chip (chip 5) showed signs of drying out 
while in the chamber which resulted in some skewed intensity values of controls. It was 
decided that all samples on this chip should be re-run before further analysis. The chip 5 
repeat gave control intensities comparable with previous runs and intensities from this 
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2.6.5 Data Analysis 
General descriptive statistics and many quality control methods were carried out using 
Microsoft® Office Excel with various add-ins, and Statistica for Windows. Venn 
diagrams were created using a combination of Microsoft® Office Excel and Microsoft 
Office Powerpoint. Most downstream analyses were performed using the free software 
environment R (www.r-project.org) and the R-based open source software for 
bioinformatics, Bioconductor (www.bioconductor.org). 
 
 
2.6.6 Microarray Quality Control Measures 
This section describes the methods used to analyse the inbuilt controls, within the 
Illumina BeadArray Platform, technical replicates and between chip controls outwith the 
standard chip controls. Cluster analysis has also been performed to assess the success for 
the experiment and quality of the data generated. 
 
2.6.6.1 Illumina direct hybridisation assay controls 
The Illumina BeadArrayTM platform has six control categories inbuilt to assess the quality 
and reproducibility of sample intensities obtained as follows: 1) housekeeping controls 
assess the intactness of the biological sample; 2) negative controls provide an estimate of 
background noise; 3) hybridisation controls determine success of hybridisation; 4) biotin 
controls assess the success of biotin labelling and signal generation; 5) high stringency 
and 6) low stringency hybridisation controls assess the stringency of hybridisation. 
Controls 1,2 and 4 are dependant on the quality of he sample, while the others are not. It 
was at this stage the initial failing of the first chip 5 run was noticed and samples re-
submitted. 
 
2.6.6.2 Technical Replicates and Between Chip Controls 
One sample (C57BL6Sal-F2) made up of 3 drug naive female C57BL6 mouse samples 
was loaded onto every chip analysed to assess BeadChip-BeadChip reproducibility. 
Another sample, prepared from the same total RNA but different cRNA preparations 
(C57BL6Sal-F1) was included in triplicate on one BeadChip as a measure of 
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experimental within chip variability. The reproducibility was assessed using the Pearsons 
correlation coefficient (r2). 
 
2.6.6.3 Cluster analysis for detection of experimental artifacts 
Hierarchical cluster analysis was performed to determine whether samples clustered 
together through experimental variables such as batch effect or BeadChip. Various 
methods exist differing in measures of distance betwe n pairs of samples and clusters. As 
this type of analysis had already been carried out by Andrea Christoforou within our 
group, the clustering method she used was followed as this had previously been shown to 
be suitable for similar sample sets. The R package pvclust 
(www.is.titech.ac.jp/~shimo/prog/pvclust/) was used to create a final dendogram and to 
assess the results via multisample bootstrap resampling. One thousand bootstraps were 
performed on each of three bootstrap sample sizes (r=0.5,1.0,1.5 where r is the size of the 
bootstrap sample relative to the actual dataset). 
 
 2.6.6.4 Power Calculations 
Power calculations were performed using the power.multi function for multiple treatment 
designs from the Bioconductor sizepower package. No software package available at this 
time was able to produce power calculations for multiway ANOVA analysis so the 
calculations were carried out on the basis of 33 student t-tests on the smallest group size, 
giving a very conservative estimate of the experimental power. Curves were plotted for a 
range of standard deviations and effect sizes. 
 
2.6.6.5 Pre-processing 
Pre-processing is the steps taken to prepare data for nalysis, and involved 3 stages: 1) 
variance stabilisation and transformation; 2) normalisation and 3) data filtering. The 
Bioconductor package lumi  
(www.bioconductor.org/packages/2.1/bioc/vignettes/lumi/inst/doc/lumi.pdf) which was 
created specifically for use with the Illumina BeadArrayTM platform, was used for pre-
processing. The first stage, variance stabilisation, aims to reduce the heteroskedacity (that 
is, make the variance more constant) across the sample set. This was carried out using the 
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lumi-vst function which is a generalised log transformation determined by direct 
modelling of the mean-variance relationship of bead intensity [216]. The second stage, 
normalisation, aims to remove or reduce systematic non-biological bias incurred by the 




The final stage of pre-processing was to filter the data. Data was filtered in two ways: 
First, any probes not expressed above background in at least one sample group were 
removed from further analysis. This was determined using the Illumina BeadStudio 
detection P-value, which is calculated for every probe in every sample using a non-
parametric method that ranks the probe against that of  negative control. It is interpreted 
as the probability the observed signal is no greate than the background given the amount 
of noise in the data. Secondly, the probes were filt red based on fold change. Pairwise 
comparisons were made between samples grouped by strain and treatment and only 
probes with at least a 1.3 fold change (either above or below that of the reference group) 
were kept. The fold change cut off was chosen as this is the level of sensitivity offered by 
the Illumina platform (www.illumina.com/downloads/GX_Mousev2.0_DataSheet.pdf)  
Fold change was calculated by taking the inverse/anti-log2 of the difference between the 
average nomalised values. Cluster analysis was carried out after both filtering stages to 
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2.7 Testing For Differential Expression 
This section describes the methods used to determin ge es with significant differential 
expression in mutant strains and genes of interest for follow-up studies. 
 
 
2.7.1 Differential expression analysis 
The R package MicroArray Analysis of Variance model (MAANOVA ) was used to test 
the probes for differential expression. The Fs statistic, which makes no assumptions about 
the distribution of variance but borrows information across the probes tested to determine 
the variance, was used as the test statistic, with a nominal P-value threshold of 0.05. The 
false discovery rate (FDR) for each probe was also determined with the MAANOVA  
adjPval function. Probes with a fold change of 1.3 (+/-) p<0.05 compared to the 
appropriate reference set were classed as being differentially expressed. 
 
 
2.7.2 Functional Analysis (Including IPA Pathway an alysis) 
GO terms for each gene were collected from Mouse Genom  Informatics 
(http://www.informatics.jax.org/) and Ensembl Genome Browser 
(http://www.ensembl.org/index.html) where available.  
Pathway analysis was carried out using the Ingenuity Systems pathway analysis 
programme (http://www.ingenuity.com/) held on licence at the University of Edinburgh. 
All probes expressed above background for each strain were initially loaded into the 
system regardless of fold change or p-value. These two factors were then noted as 
observations and appropriate cut-offs (as mentioned i  section 2.8.1) set before running 
the analysis. This resulted in the previously determined differentially expressed genes 
being highlighted and those expressed above background shaded grey indicating there 
presence but not significance. Any genes not expressed above background that appeared 
within the networks were white. 
Ingenuity® works by accessing a database of gene interactions and comparing the input 
gene list with what is known by the database. A significance score is assigned for each 
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network and displayed as the negative log of the networks p-value. This indicates the 
likelihood that the assembly of focus genes within a network could be explained by 
random chance. A score of 3 indicates a 1 in 1000 chan e that the focus genes are 
together by random chance so scores greater than this have at least 99.9% confidence that 
the genes are not grouped by random chance alone. Pathway analysis was carried out for 
both adult mouse mutants, and embryonic stages. 
 
2.7.3 GOTree Analysis of differentially expressed g enes 
GOTreeMachine (GOTM) (http://bioinfo.vanderbilt.edu/gotm) is an online open resource 
for identifying clusters of genes by ontology. By comparing a list of genes of interest 
with a reference gene list it is possible to identify statistically enriched gene ontology 
categories by hypergeometric testing. This gives a list of genes which may have 
functional significance within the dataset and as a result within the disease group. I 
entered the complete list of differentially expressed genes from the microarray study as 
one data set and split by genotype and drug treatment to test if there was an overall over 
enrichment of specific gene sets within the list as a whole or within one group in 
particular.  
 
2.7.4 Testing for overlaps and gene expression corr ections from drug 
treatments 
The resulting differentially expressed genes for each strain were compared using the 
countif function in Microsoft Office Excel. The adults were compared to each other and 
to their drug treated counterparts, and the embryonic stages were compared to each other 
resulting in 5 comparisons in total. Any overlaps in expression changes were noted as 
these may signify genes of interest for follow-up studies. 
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2.7.5 Comparing data with previously published work  
The differential expression data was compared with previously published works on 
schizophrenia genetics to determine if any overlaps were present within our data. Gene 
lists from Walsh et al 2008 [83], Camargo et al 2007 [132] and Kirov et al 2008 [217] 
which have been implicated in schizophrenia were compared to my own lists generated 




2.8 Follow up analysis of the microarray study 
On completion of the microarray study it was necessary to validate the gene list using 
real time PCR. This was carried out over two stages to give a set of robust genes which 
would then be tested further using protein analysis. 
 
2.8.1 Identifying the genes to take forward for val idation 
As previously mentioned the genes which were shown to be differentially expressed by 
the statistical analysis of the microarray data were then subject to functional analysis 
through IPA and GOTree, and were tested for overlap with previous key genetic studies 
of major mental illness. Literary searches were also completed to identify previous 
publications concerning these genes and whether they were significant to the study of 
major mental illness. Each gene was given a score bas d on the evidence available from 
the above analyses and its fold change and p value as noted from the ANOVA of the 
microarray. For each group the top 10-15% of genes aft r scoring were chosen for follow 
up by real time PCR. 
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2.8.2 Preparation of Samples for two phase follow u p 
As the follow up study was two phase there were two sets of samples to be prepared. The 
first phase involved the samples which had been used on the array. RNA from these mice 
was already stored at -80°C and cDNA synthesis carried out as outlined in section 2.2.6.  
The second phase was to be carried out on an indepent sample set of mice bred at the 
Biomedical Research Facility at the Western General Hospital, Edinburgh. These second 
phase mice were descendents of animals that had been shipped over from the Samuel 
Lunenfield Institute after the collection of the first phase samples. This second phase 
collection allowed me to use wild-type littermates, which had not been possible for the 
first round, and determine how useful the C57BL6/J was as a wild-type control in the 
initial study. Samples were processed in the same way as the first phase samples with the 
exception of the RNA extraction method. The PARIS procedure (section 2.2.2) was 
carried out on phase two mice to allow later protein analysis to be carried out on samples 
from the same mice used for the DNA study.  
 
2.8.3 Identification of suitable probes for Taqman real time PCR 
Real time PCR was to be carried out using the ABI taqman bioanalyser at the Wellcome 
Trust Clinical Research Facility. Once genes for follow up had been identified probes 
were ordered from Applied Biosystems. When choosing probes it was important to take 
into account the possible isoforms of any one gene and map the Taqman probe as closely 
to the original array probe as possible. The microarray probe sequences were provided 
with the output data from the CRF and I used these to map to the area of the gene 
targeted by the microarray. I then compared this to the area targeted by the various 
Taqman probes and picked the probe with the best overlap to ensure as much as possible 
the same isoforms of the gene were being detected. It was impossible to have direct 
overlap of both probes as Applied biosystems do not make the probe sequences available 
but identify gene regions targeted. I also tried to have probes with a _m1 product code 
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ending as this signified a probe which spans an exon junction and so would be more 
reliable with cDNA and cut out background from any possible genomic contamination. 
Two control genes were required to allow for accurate comparisons to be made. The most 
commonly used control genes for mouse Taqman studies ar  GAP-DH and Actin. As 
DISC1 is believed to play a role in the Actin cytoskeleton this was considered 
inappropriate as a control gene. Hprt1 was chosen instead. This had previously been used 
successfully by the Cystic Fibrosis group within the centre and was known to be 
expressed in brain tissues.   
 
2.8.4 Verification of genes by ABI Taqman qRT-PCR 
Samples were analysed using the ABI Taqman machine at the Wellcome Trust Clinical 
Research Facility, Western General Hospital, Edinburgh. Samples were transported on 
ice and Taqman master mix was kept at 4°C within the CRF facility for my use.  
The analysis was run on 396 well clear plates with two control genes and x genes of 
interest (x determined by how many samples were being run that day). A standard curve 
from pooled cDNA was run for each gene on each plate as an indicator of how well the 
reaction was working. A 1:200 calibrator was also run on each plate, allowing 
comparison between plates and within plates as this was used in the statistical analysis as 
a correctional value. Each well contained 5µl Taqman mastermix, 0.5µl appropriate 
probe and 4.5µl cDNA. This was sealed with a plastic heet using a heat sealer and 
centrifuged for 30 seconds before being placed on the ABI Taqman platform. After 
completing the plate layout on screen the platform was set to run standard real time PCR 
cycle lasting 1.5 hours. On completion of the cycle th  samples were removed from the 
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2.8.5 Statistical Analysis of ABI Taqman output 
Samples were initially analysed in the ABI taqman screen to determine the efficiency of 
the reaction. For the replicated samples to be effici nt the mean CT value for each 
replicate should be within 1cycle. Data was scanned to determine if this was the case and 
any samples which did not fall within these criteria were omitted. Results were then 
exported as a text file to be opened in excel for further analysis. 
In excel the exported data was summarised to quantity mean and standard deviation of 
each sample. The normalisation factor was calculated by taking the geometric mean of 
the two control genes per sample and dividing by the average of the geometric mean, 
giving a unique normalisation factor for each sample. This was also done for the standard 
deviation using the calculation: 
NF(sd) = NF*((control1 sd/2*(control1 average)) ^2 + (control2 sd/2*(control2 average) 
^2) ^0.5 
For each gene of interest this normalisation factor was used to create a normalised 
quantity mean for each sample by dividing the sample quantity mean by the 
normalisation factor. The normalised standard deviation was then calculated using the 
equation: 
Norm sd = Normalised quantity mean*((NFsd/NF) ^2 + (Gene of Interest sd/Gene of 
Interest quantity mean^2) ^0.5 
This normalised quantity mean and standard deviation was then rescaled to correct for the 
1:200 calibrator by dividing the normalised quantity mean of the sample by the 
normalised quantity mean of the calibrator, and similarly with the standard deviations. It 
was these ‘rescaled’ values that would be used for further analysis. Outliers were detected 
using the inter-quartile range detection method and discarded from further analysis. 
The group average, standard deviation and number were calculated using excel basic 
statistics and these values were transferred into a GraphPad Prism file for further analysis 
(www.graphpad.com). GraphPad Prism is a statistical an ysis and graphing programme 
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on licence within the University. ‘Raw’ rescaled values were also transferred and used to 
create a scatterplot and carry out statistical analysis. For each gene of interest 
comparisons were made between appropriate groups using both unpaired t-tests and 
Mann-Whitney U tests. Which test was most appropriate for which gene was determined 
by drawing normal distribution curves for each gene of interest. Genes with normal 
distribution in samples were analysed by t-test, and non-normal distribution by Mann-
Whitney U test. However, in most cases both tests gave similar results so the need to 
choose between them was arbitrary. Also with such relatively small sample sizes it is 
almost impossible to gain an accurate representatio of normality distribution and this 
was used as more of a guide than a definitive distribution curve. Samples which 
maintained a p-value <0.05 were carried forward for further analysis.  
Analysis of the Disc1 developmental profile was carried out in the same way but graphed 
using rescaled averages with standard error rather than scatterplots. Unpaired t-tests and 
Mann-Whitney U tests were still carried out to determine the difference in Disc1 
expression at key time points between strains. 
 
 
2.9 Protein analysis and Antibody Staining 
Once the microarray validation was complete it was considered logical to look at protein 
expression both from protein lysates and cultured primary neurons.  
 
2.9.1 Identification of suitable antibodies 
Antibodies were ordered from Abcam UK and R and D systems, UK. Suitability for use 
was determined by searching the supplier website for antibodies which were known to 
work in western blotting and immunocytochemistry (ICC), and that had been shown to 
work in mouse samples.  
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2.9.2 Western Blotting 
Composition of all buffers can be found in section 2.10. 
Sample lysate (20µg in 10µl) was added to 10µl protein sample buffer and 1µl DTT and 
boiled for 5 minutes to denature. Due to the small product sizes all westerns were run on 
7% polyacrilamide gels. Samples and marker were added to the gel in the presence of 
running buffer and a positive control of SHSY5Y cell lysate which was used in the initial 
antibody work up. The block was topped up with running buffer and set at a constant 
voltage of 150V for 90 minutes. Sponges were soaked in transfer buffer along with 
PVDF membrane which had previously been dipped in 100% methanol. Once the 
acrilamide gel had run for 90 minutes it was removed from the block and the case 
cracked open to allow access to the gel. The PVDF membrane was applied to the gel and 
filter paper placed either side. A transfer casket was loaded with 2 soaked sponges, then 
the filter paper – gel – membrane – filter paper sandwich, and finally another 2 sponges. 
The casket was loaded into the block and filled with transfer buffer while the surround 
was filled with 650ml cold dH2O to prevent overheating during transfer. Blotter was set 
on constant 30V for 60 minutes. The membrane was remov d and washed twice with 
dH2O and then in Ponceau stain to visualise protein. The membrane was washed again 
with dH2O and put on a shaking plate at low rpm until protein was visible before 
transferring to 40ml blocking buffer for 1hour on a shaking plate.  
Primary antibodies were diluted in 4ml blocking buffer and applied to the membrane. 
Antibodies were diluted as per manufacturers instructions and a full list of conditions can 
be found in Appendix 1. Membranes were incubated at room temperature for 1 hour, or at 
4°C overnight, on a low rpm shaking plate. Membranes w re washed in wash buffer as 
previously described and the appropriate secondary antibody added to the membrane, 
diluted in 4ml wash buffer, for 25 minutes on a shaking plate. Membranes were washed 
in wash buffer as previously described and dabbed dry with tissue paper. ECL PLUS 
mixture (4.8ml reagent A + 120µl reagent B) was applied to the membrane and left to 
incubate for 5 minutes at room temperature. Membranes were dabbed dry and wrapped in 
clingfilm, ensuring there were no air bubbles in the film, before being placed in a cassette 
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to prevent bleaching. Light sensitive film was placed over the membrane in the cassette 
and sealed for the appropriate exposure time before being developed in a BioRad 
developer. 
Films were kept for further analysis and the membranes stripped by placing in 10ml 
stripping buffer for 20 minutes on a shaking plate t room temperature. Membranes were 
then re-blocked and stained for GAP-DH using the same protocol as above. 
 
2.9.3 Quantification of Westerns using Image J 
Films were scanned into a PC in high resolution and imported into Image J for analysis. 
Image J reads the signal intensity of the bands and b ckground within a chosen frame and 
returns a numerical output for each band. The signal intensities were corrected for 
loading differences by dividing the numerical output from the gene of interest by the 
signal intensity of GAPDH on the same membrane. Themean signal intensity and 
standard error for each group was calculated in Microsoft Excel and imported into 
GraphPad prism for further statistical analysis andgraph production.  
 
2.9.4 Culture of Primary Neurons 
Coverslips were prepared by incubating overnight in 100% ethanol before washing with 
distilled water, heat-dry sterilisation and incubating in Poly-D-Lysine solution.  
Adult female mice were sacrificed 18 days post conception and embryos removed for 
neuron culture. The E18 embryo brains were removed and placed in dissection buffer 
containing HBSS (+CaCl2 +MgCl2), L-glutamate and HEPES (1M, pH 7.3-7.5) and kept 
on ice through the dissection process. The hippocampus was removed and placed in fresh 
dissecting buffer under a standard dissection microscope. Once all hippocampi had been 
collected, the dissection buffer was removed and the tissue chopped up using a scalpel. 
Trypsin was added at 0.1% to aid protein digestion and incubated at 37°C for 45mins. 
The suspension was passed through a wide Pasteur pipette 5x to remove clumps and 
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centrifuged at 1500rpm for 5mins. Trypsin was removed and the pellet resuspended in 
10ml DMEM with foetal bovine serum to deactivate the trypsin. The process was 
repeated to ensure all traces of trypsin were removd and then the suspension was passed 
through a wide necked Pasteur pipette 20x and a narrow necked Pasteur pipette 10x. 
Suspension was centrifuged at 1500rpm for 5 mins, supernatant removed and pellet 
resuspended in 10mls DMEM (no FBS). The suspension was passed through a 40µM cell 
filter and cells counted before being centrifuged and resuspended in Neurobasal +++ 
medium (Neurobasal medium, B-27 supplement, GlutaMAX-1 supplement, Pen/Strep 
solution) at a concentration of 2x105 in a 12 well dish previously prepared with Poly-D-
Lysine coverslips. 
Cells were incubated at 37°C for 21days before being used for ICC. The neurobasal +++ 
medium was changed every 7days and cells checked to nsure health and growth. 
 
2.9.5 ICC of Primary Neurons 
The neurobasal medium was removed from the plate wells with an aspirator and 
coverslips washed twice with PBS at 4°C. Ice cold methanol was added to the coverslips 
and left to incubate at room temperature for 10minutes to fix the cells. Methanol was 
removed by aspiration and coverslips washed a further two times in PBS. Cells were 
blocked in 3% BSA for 20 minutes on a shaking plate at low rpm. Cells were then given 
two quick washes in PBS followed by 3 5 minute washes in PBS to remove all of the 
BSA. Primary antibodies were diluted in 3% BSA to a total volume of 200µl. After 
numerous trials a dilution of 1:50 was deemed the most appropriate for all primary 
antibodies of the genes of interest. Cells were also co-stained for alpha-tubilin and PSD-
95. The antibodies were added to the coverslips and left on a shaking plate at room 
temperature for 1 hour to incubate. The primary antibody was removed by aspiration and 
coverslips washed as after the blocking treatment. Appropriate fluorescently labelled 
secondary antibodies were chosen and diluted in 3% BSA to a total volume of 200 µl. 
The colour of the fluorescent probe determined the dilutions. Red was diluted 1:800, 
green 1:500 and blue 1:1000. Secondary antibodies were added to the coverslips and left 
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to incubate on a shaking plate at room temperature for 1 hour. To prevent bleaching of 
the secondary antibodies the plate was wrapped in tinfoil to protect from light. The 
coverslips were washed as after the primary antibody treatment. A drop of mounting 
medium containing a Dapi stain was placed onto fresh slides and the coverslips mounted 
onto these with the cells facing downwards. Air bubles were removed and slides stored 
away from light at 4°C until viewed with the confocal microscope. 
 
2.10 Buffers 
2.10.1 Western Blotting 
Protein Sample Buffer (PSB)  
• 6.25ml 1M Tris pH 6.8 
• 10ml glycerol 
• 10ml 20% SDS 
• 13.75ml dH2O 
• 0.5mg Bromophenol Blue 
Ponceau Stain 
• 0.5g ponceau S 
• 2ml Acetic acid 
• 98ml dH2O 
Wash Buffer 
• 100ml 10x PBS 
• 900ml dH2O 
• 2ml tween 
Running Buffer 
• 20ml 20x NuPage Tris Acetate SDS running buffer 
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• 380ml dH2O 
Transfer Buffer 
• 25nl NuPage transfer buffer 
• 50ml methanol 
• 425ml dH2O 
Blocking Buffer 
• 2.5g Marvel 
• 50ml PBS 
• 100µl tween 
 
2.10.2 Primary Neuron Production 
500 µg/ml Stock Poly-D-Lysine Solution 
• 5mg Poly-D-Lysine 
• 10ml distilled water 
• Filter sterilised and stored at -20°C 
20 µg/ml Poly-D-Lysine Solution 
• 25ml Borate buffer pH 8.5 
• 22.5ml Distilled H2O 
• 2.5ml Stock Poly-D-Lysine 
Dissection Buffer 
• 500ml HBSS (+CaCl2 + MgCl2) 
• 5ml L-glutamate 
• 3.5ml HEPES (1M, pH7.3-7.5) 
PBS 
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• PBS – (no CaCl2 + MgCl2) 
0.1% Trypsin 
• 20ml Trypsin/EDTA 0.25% 
• 30ml dissection buffer 
Neurobasal Medium 
• 500ml Neurobasal medium 
• 10ml B-27 supplement 
• 5ml GlutaMAX-1 supplement 
• 2.5ml Pen/Strep solution 
DMEM 
• 500ml DMEM 
• 50ml foetal bovine serum 
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3. Sample collection and processing of a genome wid e microarray analysis 
of the Disc1 ENU mouse mutants  
 
3.1 Introduction 
DNA microarrays are widely considered the gold standard in genome wide expression 
studies of psychiatric genomics [99]. The complex multistep process allows extensive 
analysis of genome wide gene expression levels fromrelatively small sample numbers. 
This chapter describes the experimental preparation and preliminary analysis of a 
genome-wide microarray study comparing the Disc1 ENU mutant mouse lines described 
by Clapcote et al (2007)[197], with C57BL/6J control animals. 
 
 
3.1.1 Background and motivation 
Recently studies of ENU mutant mice have shown deficits in prepulse inhibition 
connected to genetic mutations, which can be partially reversed by antipsychotic 
medications[197]. Clapcote t al (2007) identified two missense mutant mouse lines with
mutations within exon 2 of the Disc1 gene, in which they showed PPI deficits that were 
partially reversible with antipsychotic and antidepressant medication. These two mouse 
strains, L100P and Q31L, were described as ‘schizoprenic-like’ and ‘depressive-like’ by 
virtue of their behavioural profile and physiological observations and pharmacological 
responses that were considered comparable to human disease [218] (Table 3.1).  
The two exon-2 mutants display two slightly different phenotypes corresponding to a 
schizophrenic-like and a depressive-like phenotype. The more severe schizophrenic-like 
phenotype occurs in the L100P mouse mutant. Here a point mutation has altered amino 
acid 100 from a leucine to a proline residue in the mouse Disc1. These mice have a 
marked reduction in PPI and overall startle response. The pronounced PPI deficit is 
partially rescued by administration of the typical antipsychotic haloperidol and the 
atypical antipsychotic clozapine. Interestingly, the anti-depressant and PDE4B inhibitor, 
rolipram also had a significant effect in rescuing PPI in the L100P mutant mice. Disc1 is 
known to bind to particular PDE4 isoforms at specific binding sites in the protein’s head 
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domain[104]. Two of these binding sites are disrupted by the mutations in both mouse 
lines suggesting that binding to PDE4B is likely to be impaired. The Q31L mutant mouse 
also displayed a reduction in PPI, although not to the extent of the L100P mutant. 
Interestingly, the deficit displayed by the Q31L “depressive-like” mice was not reversible 
by treatment with antipsychotic medications or with rolipram. Consistent with the lack of 
response to rolipram treatment the Q31L mice also exhibit decreased PDE4B activity 
compared to wild-type littermates and L100P “schizophrenic-like” mutant mice [197]. 
The antidepressant bupropion abolished the PPI deficit in these animals.  
Both mouse lines displayed a disruption in Latent Inhibition (LI), which is a phenomenon 
by which prior exposure to a stimulus that holds no reward decreases the response to that 
stimulus when it is paired with an unconditioned stimulus. Again, administration of 
clozapine abolished this effect in the L100P mouse mutant, but not in the Q31L line. The 
Q31L mouse mutant, but not the L100P mouse mutant, displayed increased immobility 
during a forced swim test, a measure of behavioural despair, and reduced social 
interaction and reward responsiveness (measures of withdrawl and anhedonia 
respectively). The Q31L and L100P mouse models had overall reductions in brain size of 
6 and 13% respectively, with tissue contraction mainly of the cortex, entorhinal cortex, 
thalamus and cerebellum. 
 
The aim of the work described in this and the following chapter was to partially replicate 
the study by Clapcote and Roder to confirm the presence of PPI deficits in the Q31L and 
L100P mouse lines when compared to my control group f C57BL/6J mice bought in 
from Jackson laboratories that were to be used in my microarray study, and to identify 
genes whose expression was altered as a result of these mutations. In the original 
behavioural study, administration of selected antipsychotic and antidepressant drugs 
partially rescued the behavioural phenotype of the two lines.  
 
In this chapter I will describe an attempt to replicate the behavioural study and describe 
the sample collection and primary analysis of a genome wide gene expression study in 
the ENU mutant mouse lines. By identifying other genes dysregulated by these mutations 
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it may be possible to identify pathways involved in major mental illness and possible new 
targets for treatment. Millar et al previously described a dynamic interaction between 
DISC1 and PDE4B that served to regulate cAMP signalling (Millar 2005)[131].  
Disruption of this interaction is predicted to alter modulation of cAMP signalling and 
may result in abnormal transcription of genes with cAMP response elements in regulatory 
regions. DISC1 also interacts with the cAMP response element-dependent transcription 
factor ATF4, and possibly binds to chromatin remodelling factors such as SMARCE1 
[132]. These interactions with transcription factors, together with the fact that DISC1 
localises to the nucleus [172, 173] is consistent with a role for DISC1 in transcriptional 
regulation. Thus the view was that examination of the gene expression profile, by whole-
genome microarray analysis, in the developing and adult brain of the two Disc1 mutant 
mouse lines was a key step towards understanding the factors underlying the behavioural 




3.2 Partial Replication of Clapcote et al’s  Behavioural Analysis of the Disc1 
ENU mouse mutants 
Prepulse inhibition (PPI) is a neurological phenomenon in which the reaction to a startle 
stimulus (pulse) is reduced when it is preceded by a weaker prestimulus (prepulse) within 
a short time frame of under 500ms (figure 3.1). Thereduction in startle response reflects 
the ability of the nervous system to adapt temporarily to a strong stimulus when a 
warning stimulus is present. It is generally accepted that this reflects the ability to filter 
out unnecessary information and so is a good measur of sensorimotor gating, a 
neurological function known to be deficient in schizophrenia[219].  
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Figure 3.1: Image depicting the effective reduction in an animals startle response when a strong 
stimulus is preceded by a weaker prestimulus.  
 
In some healthy individuals prepulse inhibition is as great as 70%. Individuals with major 
mental disorders such as Alzheimer’s, schizophrenia, and bipolar depression however 
have significantly reduced prepulse inhibition compared to healthy controls[220]. As PPI 
deficits are observed in many mental disorders theyar  not diagnostic, but may indicate 
deficits in mental pathways common to these disorders. In particular, the inability to filter 
out unnecessary information could explain the sympto s of hallucinations and delusions 
associated with these disorders. In human patients there is also a noted gender difference 
in prepulse inhibition with males having higher PPI than females under all 
conditions[221]. Atypical antipsychotic medications such as risperidone and olanzapine 
are particularly effective in increasing PPI in indivi uals where a deficit is present[218]. 
 
Prepulse inhibition is not a purely human characteristic and has been widely observed in 
other mammals including rodents [219]. These animals are tested in a startle chamber 
(figure 2.4) with sensors detecting whole body movement as a measure of startle 
response. Pulse and pre-pulse are tones fed into the chamber via speakers mounted in the 
wall and controlled by computer programme. Pulse-alone results are compared to 
prepulse-plus-pulse, and the percentage of the reduction in the startle reflex represents 
prepulse inhibition. The baseline activity of each animal is also measured and subtracted 
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from the startle response measurements. Baseline activity does not appear to affect the 
prepulse inhibition of an individual[222]. 
 
Table 3.1: Behavioural Phenotypes of the L100P and Q31L Disc1 mutant mice. Table displays result 
from multiple behavioural tests carried out by Clapcote et al (2007) on the L100P and Q31L mutant mice. 
Reduction in social interaction, reward responsiveness and increased immobility during a forced swim test
indicated a ‘depressive-like’phenotype in the Q31L mutant mouse. Greatly reduced PPI and LI in the 
L100P mutant mouse indicate a ‘schizophrenic-like’ phenotype.  
 
Groups of mutant and control mice were also treated with drugs that had previously been 
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3.2.1 Effect of Gender on PPI in non-drug treated a nimals 
Mice were tested as outlined in section 2.4.1. Twelve mice per group (8 Q31L adult) 
were tested on consecutive days. Analysis was carried out on startle response (120dB) 
and prepulse inhibition at 3 decibel levels (69, 73 and 81dB) and combined. The effects 
of gender, drugs and genotype were investigated. 
There was no gender effect on total PPI (F=1.393, p=0.226) or acoustic startle response at 
120dB minus pulse stimulus (F=2.357, p=0.069) in any group. As no gender differences 
were observed, further analyses were carried out grouping animals purely by genotype 
and drug treatment. 
 
3.2.2 Effect of Genotype on PrePulse Inhibition and  Startle Response in 
Mice 
I found no difference in total prepulse inhibition (F=1.788, p=0.185) or acoustic startle 
response at 120dB minus pulse stimulus (F=2.091, p=0.142) by genotype in non-drug 
treated animals (Figure 3.2). It should be noted at this point, however, that comparison 
with previously published data showed that the mutant mice were displaying comparable 
levels of PPI and startle response as previously described, but that the wild type controls 
were displaying lower levels than previously reported. When the total prepulse inhibition 
for the C57BL6/J mice used in my study was compared to that of the wild type littermate 
controls in the previously published study they were significantly different (t=4.07, 
p=0.0003, df=31). This is also true for the acoustic artle response (t=2.63, p=0.014, 
df=26). If I substitute the previously reported wild type littermate data for my C57BL6/J 
controls in my comparisons, I find no significant differences except in one comparison, 
total PPI in the Q31L mutant (t=2.17, p=0.029, df=27). 
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Figure 3.2: Total PrePulse Inhibition and Acoustic Startle Response in non-drug treated adult mice 
from each line. No difference is observed between groups in either comparison. Error bars depict standard 
error. 
Clapcote et al had previously reported that the level of prepulse may be significant in the 
manifestation of PPI in the mutant mouse lines. Analysis of variance was carried out on 
the data from the individual prepulse conditions (69dB, 73dB and 81dB) to determine if 
this was the case with my mice. While the both the L100P and Q31L mouse lines 
displayed a trend with reduced PPI at 69dB which increased through 73dB and 81dB 
there was again no significant differences between groups (F=1.478, p=0.844).  
 
Table 3.2: Mean results on PPI at all 3 levels tested, plus total. Pre-pulse inhibition was tested at 3 
decibel levels, and averaged across all levels to produce a mean PPI total. Values shown are startle 
response and standard error.  
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3.2.3 Effect of Drug treatment on PrePulse Inhibiti on and Acoustic Startle 
Response in Mice 
Prior to testing, 12 mice selected at random (8 Q31L) within each group had been treated 
with clozapine, bupropion or rolipram to determine th effects of these compounds on 
PPI and startle response within and between lines. Mice not receiving drug treatment 
received a saline injection.  
 
Table 3.3: Mean acoustic startle response and average PPI over all ranges tested. Table shows the 
total mean startle response and PPI by genotype and drug treatment. Values displayed are mean and 
standard error. 
 
The effects of the drug treatment by genotype were analysed using a one-way ANOVA 
and post-hoc Tukey test. Total PPI was found to be significantly different in L100P drug 
treated mutants (F = 4.67, p = 0.019) and post-hoc analysis revealed clozapine treatment 
significantly decreased PPI, while bupropion treatment increased PPI in these mice. 
Acoustic startle response was not altered significantly in these comparisons. In the Q31L 
mutant no significant drug effect on PPI was found (F=0.118, p=0.889), however 
treatment with clozapine was found to significantly lower the acoustic startle response in 
these mice (p=0.02).  
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3.3 Whole Genome Gene Expression Study Experimental  Design 
3.3.1 Sample size and power 
The RNA used in the microarray study was extracted from hippocampal brain tissues 
taken from the ENU mouse mutants immediately post behavioural testing. The result was 
57 samples across six adult groups, as outlined in table 3.4. 
 
Table 3.4 Summary of Adult Mouse Groups used in the genome-wide expression analysis. The groups 
are based on both genotype and presence or absence of drug treatment prior to behavioural testing. Group 
symbol is the annotation used throughout the rest of this thesis and the number of samples per group is 
shown in the final column.  
 
Additionally, to test the effect of the Disc1 ENU mutations on genome-wide expression 
levels during development, 29 samples from three further groups were added from mouse 
Embryonic day 13.5 as outlined in table 3.5. Previously published data by Shurov et al 
(2004) [134] had shown Disc1 to have a peak in exprssion at this developmental time 
point, which coincides with neural determination and differentiation after a peak in 
neuronal migration at timepoint E12.5[223].  
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Table 3.5 Summary of developmental mouse groups used in the genome wide expression analysis. 
Groups are based on genotype alone, no drug treatments were used in developmental samples. Group 
symbol is the annotation used throughout the rest of this thesis and the number of samples per group is 
shown in the final column. 
 
The aim of this study was to determine which genes are dysregulated on the basis of 
genotype and drug treatment by comparing each of the ENU groups to their appropriate 
control groups. The C57BL/6J wildtype group was used as the control for testing the 
effect of genotype while the effect of drug treatment compared the drug treated group to 
their respective saline treated counterparts.  
Power calculations were performed using the R/BioConductor (www.bioconductor.org) 
freeware with the power.multi function within the sizepower package[224]. As the true 
variability among individuals and actual effect size were unknown, a range of effect sizes 
and variance parameters were used to determine the ability of this experimental design to 
detect genes with differential expression. Natural variation among mice in inbred strains 
is thought to be very low (around 0.1-0.2 SD) so shuld result in low noise in the 
experiment and reasonable power to detect significat differential expression. As the 
mice used in this study had been backcrossed on to C57BL/6J (Jackson Laboratories) for 
10 generations they could be considered an inbred strain and thus should have similar 
genetic variation. Standard deviations tested ranged from 0.1-0.5. It was, however, 
considered highly likely the natural variation betwen mice would be below the 0.2 SD 
range. No adjustments were made for multiple testing a d five percent Type 1 error rate 
was assumed for each gene.  
The power curves for the full range of SDs tested ar  shown in Figure 3.3. A sample size 
of 7 (as graphed) gives 80% power to detect a 1.3 fold change, the lower limit of the 
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illumina array platform, given an SD of 0.15. This sample size also provides 80% power 
to detect a two-fold change in more variable genes with SD of up to 0.4. This was the 
smallest group used, with most groups having sample sizes of 10-12 animals. 
 
Figure 3.3: Power Curves. Power calculations were performed in the R/BioConductor 
(www.bioconductor.org) package sizepower using the multi.power function. Power curves were generated 
using the GraphPad software Prism 4.0 on license to the University of Edinburgh. The power (y-axis) was 
determined for the minimum number of samples and plotted against a range of standard deviation values 
(x-axis, range 0.1-0.5) using pairwise comparisons (NumTrt=2) with 7 samples per group (N=7, the 
smallest group size used) assuming a Type 1 error rate (α) of 0.05. Each coloured line represents the effect 
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3.3.2 Sample Layout and Technical Replication 
In total there were 86 samples to be hybridized to Illumina Mouse Ref-6 Beadchips. Due 
to the large number of samples available, and potential costs involved in running each 
sample individually, it was decided to pool samples ba ed on genotype, drug treatment 
and gender to reduce the number of bead array chips required for the study. Pooling of 
samples resulted in 33 groups to be hybridized to the bead chip (figure 3.4) plus 9 
replicate samples to be used for quality control. Pols from each biological group were 
evenly dispersed throughout the 7 BeadChips used to ensure that systematic bias or 
failure of one BeadChip did not sacrifice a whole biological group.  
The nine replicate samples previously mentioned were used to assess the reliability 
between-BeadChip and within-BeadChip with different amplification and labelling 
preparations. This was an essential quality control method as comparisons would be 
made of data both between and within BeadChips. Firtly the non-drug treated C57BL/6J 
adult mouse female pool 2 (C57BL/6J-Sal F2) was hybridized to each BeadChip in the 
array in position A (figure 3.4) to allow assessment of the reproducibility between 
BeadChips. Secondly the same mouse RNA was amplified and labeled in three separate 
reactions (C57BL/6J-Sal F2 (1-3)) and hybridized to the same BeadChip in three 
different positions to assess the within-BeadChip experimental reproducibility. 
According to the BeadChip specifications (www.illumina.com), the expected array-to-
array coefficient of variation (the ratio of the standard deviation of the mean expressed as 
a percentage and an indicator of within-BeadChip reliability) is <10%. This has been 
further corroborated by the Microarray Quality Contr l Consortium[225] through an 
intra-platform reproducibility study. As this has shown that within BeadChip 
reproducibility is reliable the main function of the technical triplicate was to determine 
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Figure 3.4: Layout of the seven Illumina mouse ref-6 version 2 BeadChips. Each column (1-7) 
represents a BeadChip and each row (A-F) represents an array on the BeadChip. Samples are named by 
their genotype, drug treatment, gender and pool number (as indicated in the key above). Samples in bold
italics are the same sample on each BeadChip acting as between-BeadChip replicate controls. Samples in 
italics are from the same source RNA, amplified in three separate batches and hybridized to the array s 
within-BeadChip experimental reproducibility controls. 
 
 
3.4 Sample Preparation and Quality 
Mice from the previously described behavioural study were sacrificed immediately post 
PrePulse inhibition testing by cervical dislocation. The brain was removed and stored in 
RNAlater for one week at 4°C to stabilize the tissues. Hippocampi were removed and 
RNA extracted. The time and date of tissue and RNA extraction was logged to allow 
identification of any batch effects. Total RNA was isolated and treated with DNase while 
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3.4.1 Integrity of total RNA 
Previous studies have shown that the integrity of total RNA is critical for successful 
microarray analysis. The Agilent 2100 Bioanalyser (Nano-LabChip) with 2100 expert 
software provides a standardized measure of RNA quality, the RNA Integrity Number 
(RIN) [226] which is based on the curve of the electrograph produced by the analyzer 
software package. RIN numbers range from 1 (totally degraded RNA) to 10 (totally intact 
RNA). A high RNA RIN number is obviously desirable however previous publications 
have advised that consistency of RIN values across samples is more important than high 
values[227]. A comparison between RNA integrity and success of GeneChip 
(Affymetrix) microarray analysis [228] suggests that RIN>5.5 gives sufficient quality of 
expression data. With both these points in mind, samples with RIN numbers below 5.5 
were not discarded immediately but were retained to be used if the other samples within 
that group were of consistently low value. Table 3.6 lists the identification numbers of 
mice used in this study alongside the date of RNA preparation and the RIN number 
returned from the Agilent Bioanalyser. RIN values ranged from 5.2 to 10.0, with an 
overall median RIN of 9.2 and a Mode RIN of 10.0. Median RINs from the three 
embryonic groups were comparable (C57BL6 E13, 9.85; L100P E13 9.80; Q31L E13 
9.55), within the L100P mutant group the rolipram trea ed pools stood out, with a lower 
RIN than the others (L100P Sal 9.05; L100P Cloz 9.55; L100P Roli 7.65) and within the 
Q31L mutant group the bupropion treated pools stood ut, with a lower RIN than the 
others (A31L Sal 9.30; Q31L Bupro 6.50). The C57BL6 Sal pools had a comparable 
median RIN to the two mutant untreated groups (C57BL6 Sal 9.30). Representative 
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                        (A)     (B) 
     
Figure 3.5: Examples of Agilent 2100 Bioanalyser output Electropherographs. (A) Total RNA with 
RIN 10 – intact with no contamination. (B) Total RNA with RIN 2.1 – low quality, high contamination and 
little intact RNA. Samples with RIN’s this low would not be used. 
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Table 3.6: Mouse samples used in the microarray analysis. Column 1 gives the animal ID, column2 the 
genotype and drug treatment, plus pool the animal was assigned to (F1 = female pool 1 etc), column 3 the 
mutation, column 4 the drug treatment, column 5 the gender and column 6 the RNA RIN number of the 
sample as an assessment of quality. 
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3.4.2 Integrity of cRNA 
The RNA from the mouse samples in table 3.6 was used to produce biotinylated 
amplified cRNA (antisense mRNA). Labelled samples were produced within the two 
weeks prior to the microarray being run so no samples were stored over long periods. 
Quality and concentration of the samples were obtained using the Agilent Bioanalyser 
(Nano-LabChip). The Agilent Bioanalyser software does not provide a metric measure of 
quality for mRNA but rather reports on contamination levels by ribosomal RNA (rRNA) 
and provides an electropherograph of peaks in RNA size distribution that must be 
examined manually (figure 3.6). Evidence of a shift on RNA size distribution towards 
lower sized fragments would indicate degradation of RNA, which was not seen in any of 
the electropherographs analysed (figure 3.6). There were, however, some cases where 
contamination with rRNA was reported by the Agilent Bioanalyser which was not 
evident on manual examination of the traces. After communication with Agilent technical 
support, it was agreed the contamination reported was an artifact of the Agilent 2100 
Expert software caused by high concentration levels clo e to the limits of detection for 
the Agilent Bioanalyser (Agilent RNA 6000 Nano chip = 25-250ng/µl mRNA). 
Dilution of highly concentrated samples and re-quantification gave concentration 
measurements with a CV of less than 10% compared to the original undiluted 
measurement (Christoforou, personal communication). The Agilent Bioanalyser product 
specifications expect a CV of less than 10% for any reproduced quantification 
measurement making this well within the expected reproducibility of sample 
quantification. For this reason it was decided not to re-quantify these samples and to use 
the original quantification results provided the electropherograph traces showed no 
evidence on contamination peaks at 18S and 28S (the fragments which make up total 
RNA). This allowed me to be confident that the samples submitted to the Wellcome Trust 
Clinical Research Facility, Western General Hospital, Edinburgh, for hybridization to the 
array chips were of sufficient quality and accurately quantified.  
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Figure 3.6: Agilent Bioanalyser output of cRNA Integrity . Figure shows examples of two samples that 
were analysed using the Agilent Bioanalyser 2100 Expert software. Fluorescent units (FU) are plotted 
against size of RNA fragment (nucleotides). The RNA marker is indicated in the trace and on the gel image 
on the right hand side of each trace. RNA concentration and contamination are indicated under each graph. 
Trace A shows a sample with good concentration and no estimated contamination while trace B shows 
good concentration but predicted 18.2% contaminatio. As seen on the trace there is no evidence of a peak
at 18S or 28S suggesting this is an artifact rather than true contamination. 
 
 
3.5 Data Generation using the Illumina BeadArray Pl atform 
Hybridisation of the cRNA samples was carried out at the Wellcome Trust Clinical 
Research Facility (WTCRF) at the Western General Hospital in Edinburgh. Samples were 
hybridized to seven Illumina Mouse-6 version 2 BeadChips on the Illumina BeadArray 
Platform. The chips were scanned using the Illumina Be dArray reader software, and 
image processing steps to determine the bead signal dat  from the raw images was 
automatically performed [229]. The Illumina BeadArray platform uses multiple bead 
copies for each probe allowing each probe signal intensity to be estimated from a number 
of beads reducing the likelihood of complete probe failure. Each bead copy is randomly 
positioned within the Beadchip to negate regional bi s, and on average each probe signal 
intensity is estimated from readings from 30-40 bead copies with a low probability of 
being calculated from less than five beads [229]. Outlying beads (those with a median 
deviation more than 3) were removed and the average intensity of the remaining beads 
used to calculate the probe signal. Across the seven chips used in this experiment the 
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average number of beads per probe was 37.8 with one probe intensity being calculated 
from less than 5 beads (table 3.7). Illumina BeadStu io software was used to generate the 
probe signal intensity from multiple bead readings, along with the standard deviation of 
bead intensities. The detection p-value (which determines whether a probe is present in 
the given sample) was also calculated using this software.  
 
Of the 48,000 probes on the BeadChip, 46,644 probes were successful (corresponding to 
34,492 individual genes). For the purposes of quality control, preprocessing and 
differential expression analysis, each probe was ident fied not only by probe ID but by 
gene name, meaning some genes appear more than once in the initial stages or analysis. 
This is purely because some genes had multiple probes and as such could not be 
identified by gene name alone. 
 
Table 3.6 shows the estimated average intensity and intensity range for each array as well 
as the average number of beads and minimum number of beads used to calculate the 
probe intensities. Across the whole experiment the mean probe intensity was 551.7 with a 
range of intensities from 10.1 to 48574. Interquartile ange analysis was used to confirm 
no BeadChip probe intensity was considered an outlier and a one-way ANOVA (with 41 
degrees-of-freedom) was performed on the raw, log2-transformed data to account for 
variability in the data. As expected the ANOVA showed statistically significant variation 
among the 42 arrays (F=5.23, p=0.0006), due to the effect of non-biological factors such 
as RNA integrity, hybridization and scanning, validt ng the need to normalize the data 
prior to further analysis. 
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Table 3.7: Summary of raw expression data. Table includes pool ID and beadchip number (as in figure 
3.4); average number of beads on each probe plus the minimum number of beads used to calculate probe 
intensity; the average probe intensity for each array plus the range of intensities recorded; and the 
background and noise recorded for each array. Replicate samples are shown in italics. 
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3.6 Quality Control 
Multiple methods were employed to determine the quality of the microarray experiment, 
including both platform specific and sample specific controls as outlined below. 
 
3.6.1 Illumina BeadChip Built in Controls 
The Illumina BeadChip system has six in built contrl categories designed to monitor 
multiple aspects of the array experiment including sample labeling, hybridization to the 
array chip, quality of biological specimen and generation of probe signals. Quality 
control results from the Illumina built in controls in this experiment are shown in figure 
3.7.  
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The negative controls (figure 3.7:A) consisted of 1,602 probe sequences which were 
thermodynamically comparable to the gene specific probe sequences but were made up of 
random sequence without specificity in the genome. Signal obtained from these probes 
was therefore an artifact of the imaging system background, non-specific binding or 
cross-hybridisation. The mean signal produced from these negative probes defined the 
system background (~ 69) while the standard deviation of the probes determines the noise 
in the array (~19) as outlined previously in table 3.7. This is significant to p<0.01. This 
value is then used in further analysis to establish the limits of detection within the array to 
allow genes with expression values lower than the negative to be discarded as they are 
not expressed above background. 
The housekeeping gene controls (gene intensity), as shown in figure 3.7 (B), consist of 24 
probes targeting seven housekeeping genes designed to monitor the integrity of the 
samples on the array. As these genes are expressed well in all intact samples it is 
expected that in a high quality sample the bead intensi y of the housekeeping genes will 
be considerably higher than the average of all genes. The bead intensity of the 
housekeeping genes in this experiment was ~18,900 compared to an average targeted 
gene intensity of ~555, indicating that the samples used were of high quality (p<0.001).  
The high stringency control and biotin-labelled contr l are both shown in figure 3.7:C. 
The high stringency control consists of two probes with high G+C content which define 
the upper bounds of stringency and are expected to hybridise regardless of the level of 
stringency observed. Signal from these probes in the absence of signal from the other 
hybridization controls would indicate that the stringency was too high. This was not the 
case in this experiment and it was determined that overall stringency was acceptable. 
The low stringency control consists of sixteen probes which determined the lower bounds 
of stringency (figure 3.7: D). The probes each contain wo mismatch bases (mm2) which 
is compared to their perfect-match counterparts (pm2). If the mm2 approaches the pm2 
the hybridization stringency is considered to be too low. In this case there is a significant 
difference between the mm2 and the pm2 values (p<0.001) indicating sufficient 
stringency of hybridization. 
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The hybridization controls (figure 3.7: E) consist of twelve Cy3-labelled oligonucleotide 
probes complimentary to those present in the hybridization buffer. This control is 
independent of sample quality and determines whether  hybridization step was 
successful during array preparation. The signal produced should be proportional to the 
concentration of the probe to indicate successful hybridization. As this was the case with 
the samples tested it was concluded that hybridization was successful. 
The biotin-labelled control determines the success of secondary staining and signal 
generation due to the presence of biotin labeled oligonucleotides in the hybridization 
buffer. The three probes gave a positive hybridisation signal indicating successful 
secondary staining.  
These primary quality control measures indicated that the RNA samples were of 
sufficient quality and hybridization to the BeadChips was successful in this experiment. 
However, I also analysed the control data from each array separately to compare quality 
between chips (figure 3.9), and found one chip appered to be significantly different to 
the others tested. 
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Figure 3.8: Signal Intensities for Illumina built-in Quality control measures by BeadChip. The figure 
depicts the signal intensities for (A) the negative control probes; (B) the housekeeping control probes; (C) 
the high stringency control probes; (D) the low stringency control probes; (E) the CY3 hybridisation 
control probes and (F) the biotin-labelled control probes for each individual BeadChip. BeadChip 5 has 
much lower probe signal intensities for low stringecy hybridization, CY3 hybridisation and Biotin-
labelled probes.  
 
While BeadChip 5 passed the previous quality control measures when all chips were 
analysed together, further analysis revealed the CY3, low-stringency hybridization and 
biotin labeled control measures were considerably lower than those of the other 
BeadChips. After discussions with the Illumina support staff it was determined that part 
of the hybridization process for chip 5 was unsuccessful, probably due to the chip drying 
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out slightly during this step. As a result, samples that had been run on chip 5 were re-
submitted to the WTCRF and hybridization of chip5 was repeated. The chip-by-chip 
control profiles with the new chip 5 data are shown in figure 3.9. 
 
Figure 3.9: Signal Intensities for Illumina built-in Quality control measures by BeadChip post chip5 
repeat. After the repeat run of BeadChip 5 the low stringency hybridization, CY3 hybridisation and biotin-
labelled control probes produce comparable signal itensities to the other BeadChips, allowing more 
confident comparisons between chips to be made. 
 
The repeat run of BeadChip5 gave results comparable to the control values previously 
observed for the other six BeadChips. From this point forward all analysis was carried 
out on the data from the repeated BeadChip5 run.  
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In summary, the initial analysis of the system contr ls did not indicate a problem with 
any BeadChip. Interquartile range analysis had not highlighted BeadChip5 as an outlier 
and primary quality control analysis was as expected in a successful array. Only the 
secondary analysis looking at each chip’s controls individually showed a potential 
problem with one chip. I would therefore conclude that this step is vital in ensuring all 
system quality control measures are accurate. 
 
3.6.2 Technical Replicates 
To assess the reproducibility of the BeadChip platform and RNA preparation in this 
experiment technical and experimental replicates were included in this study. The 
reproducibility of the BeadArray platform was determined by the inclusion of the 
C57BL6 F1 pool on all BeadChips while the joint within-BeadChip and RNA preparation 
reproducibility was determined by the inclusion of three RNA preparations of the same 
sample (C57BL6 F2) on BeadChip 7. 
Pairwise comparisons of the raw, untransformed C57BL6 F1 pool data (figure 3.10) 
revealed high correlation between the replicate samples across chips (Pearson’s r2 
≥0.972). Similarly high pairwise comparisons were observed between the RNA 
preparations of C57BL6 F2 (figure 3.11) on BeadChip7 (Pearson’s r2 ≥ 0.995) indicating 
that variability due to batch and experimental effect were within acceptable ranges. 
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Figure 3.10: Pairwise Comparisons of raw data for C57BL6 F1 pool samples. Figure shows pairwise 
scatter plots of the log2-transformed intensities of the C57BL/6J chip replicates produced using the 
Bioconductor lumi package. Correlation estimates (Pearson’s correlation coefficient r2) were calculated 
using the cor function in R. 
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Figure 3.11: Pairwise comparisons of raw data for C57BL6 F2 pool samples. Figure shows pairwise 
scatter plots of the log2-transformed intensities of the C57BL/6J technical replicates produced using the 
Bioconductor lumi package. Correlation estimates (Pearson’s correlation coefficient r2) were calculated 
using the cor function in R. 
 
 
 3.6.3 Quality Control using Cluster Analysis 
Cluster analysis is a basic statistical approach which assigns samples into groups based 
on similarity. Hierarchical cluster analysis starts with single-member groups which are 
merged based on how similar their expression profiles are resulting in a hierarchical tree 
known as a dendrogram. Multiple methods of calculating hierarchical clusters exist which 
differ in the way they calculate similarity, and give different clusters [230] highlighting 
Chapter 3 104 
different aspects of the data. The data was analysed by ‘average correlation’ using the 
freeware R with the pvclust application, that assesses robustness of the clusters using 
multiscale bootstrapping (1000 bootstraps). The cluster analysis was carried out on raw 
expression data to determine if technical or experim ntal artifacts affected clustering. It 
was expected that samples would not cluster into their respective biological group prior 
to data pre-processing and would show random spread across the dendrogram. 
 
Figure 3.12 shows the average correlation dendrogram for the raw expression data. The 
pairwise distance (or similarity) was measured using the correlation method (1 pearsons 
correlation) and clusters joined using ‘average linkage’ which measures correlation 
distances across clusters. The bootstrapping results are represented by the approximate 
unbiased (AU) probability values, which indicate th frequency at which that particular 
cluster was observed over the 1000 bootstraps. An AU value of 100 indicates the cluster 
was produced on every occasion during bootstrapping.  
 
At this stage the embryonic and adult samples are clearly separated into two distinct 
branches with a Pearsons correlation of around 0.75. This would be expected as the 
expression profiles of the embryonic samples would be markedly different to the adult 
samples. Within the two main branches there was a maxi um distance between two 
samples of ~0.025, indicating a Pearsons correlation of ≥0.975 which suggests low 
overall variability even before pre-processing and data stabilization. The technical 
replicates (C57BL6 F1) cluster together within the adult branch with an AU value of 100, 
and the chip replicates (C57BL6 F2 hybridised to each chip) also cluster together with the 
exception of the sample on chip 6 which falls closer to the technical replicate clusters. All 
other groups appear evenly spaced throughout the dendrograph with no observable 
clustering due to chip number or gender (figure 3.12). 
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3.7 Data Pre-processing 
The Illumina microarray platform is unique in having a high redundancy of randomly 
positioned beads, which reduces positional bias, increases robustness of hybridization 
intensity and measurement error estimates across each probe. As multiple samples are 
hybridized to each chip, hybridization batch effects are also reduced. These features mean 
pre-processing of the data prior to differential expr ssion analysis should be carefully 
considered to take advantage of this redundancy.  
Three levels of pre-processing were carried out on he raw data in this study. Firstly the 
variance within the data was stabilized, secondly the stabilized data was normalized, and 
finally the stabilized and normalized data was filtered to first remove any probes not 
expressed above background and then to remove any probes that were not expressed at a 
level considered biologically significant.  
 
3.7.1 Variance Stabilisation 
Microarray data has a tendency to be highly variable, with high intensity data displaying 
larger variance. Inconsistency in variance (heteroskadacity) is a violation of many 
parametric statistic tests, such as analysis of variance (ANOVA), which assumes constant 
equal variance. To stabilize the variance in this dataset the variance stabilizing function 
(lumi-vst) within the Illumina specific Bioconductor lumi  package 
(www.basic.northwestern.edu/projects/lumi) was used. Again, previous studies within the 
laboratory had shown this to be more reliable than st dard log2-transformation, as the 
lumi-vst function directly models the mean-variance relationship in the array by taking 
account of the within-array bead redundancy to generate an optimal transformation 
parameter. After stabilization of the data using the lumi-vst function, a generalized log 
transformation was then performed to give appropriate complete stabilization of the data 
and more manageable data values for further analysis. 
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3.7.2 Normalisation 
The second step in pre-processing is to normalize the data to remove the systematic 
variation caused by non-biological sources such as RNA quality, hybridization and 
scanning. Again the Bioconductor package lumi was utilized in this step using the lumi-
rsn function which was originally created to be used in conjunction with the lumi-vst 
function from the previous step 
(www.bioconductor.org/packages/2.1/bioc/vignettes/lumi/inst/doc/Bioc2007_lumi_prese
ntation.pdf). Due to the size of the dataset it was necessary to process each chip 
individually. This was possible as each array was normalized against a target array which 
was most similar to the mean of all samples. The mean r ported signal intensity across 
the whole array was ~555. With a mean signal intensity of ~551, the technical replicate 
C57BL6 F1 (1) was the closest to the overall mean and was used as the target array for 
normalization. All samples on the array were normalized to this array using the entire 
probe-set. 
Heirarchical cluster analysis was carried out on the stabilized and normalized data (figure 
3.13) showing a reduction in overall variability across the array. At this stage the 
embryonic and adult samples are still clearly separated into two distinct branches with a 
Pearsons correlation of around 0.85. This would be expected as the expression profiles of 
the embryonic samples would be markedly different to the adult samples. Within the two 
main branches there was a maximum distance between t o samples of ~0.015, indicating 
a Pearsons correlation of ≥0.985. The technical replicates (C57BL6 F1) cluster together 
within the adult branch with an AU value of 100, and the chip replicates (C57BL6 F2 
hybridised to each chip) also now all cluster together. All other groups still appear evenly 
spaced throughout the dendrograph although with greate  correlation than seen 
previously, with no observed clustering due to chip number or gender. Pairwise 
correlation of the technical replicates increased to r2 ~0.996 and chip replicates to ~0.991. 
Formal testing of the data using analysis of variance (ANOVA) with 41 degrees-of-
freedom showed no overall significant variability of the data indicating normalization 
was successful (F=5.23, p=0.0006). 
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As global background correction would have resulted in negative signals which would 
have affected the pre-processing steps this was not performed on the datasets. Instead the 
data was filtered to include only the probes that were expressed above background in 
each sample as described in section 3.7.3 below. 
 
3.7.3 Data Filtering 
Data filtering was used to reduce the multiple testing burden and increase sensitivity of 
the microarray analysis. The data was filtered in two steps; the first removed probes that 
were not expressed above background, and the second selected only the probes with 
biologically relevant differential expression levels. 
The detection limits of the array experiment are automatically generated from the 
background and noise measurements which are estimated from the signal intensities 
produced by the built-in negative controls. The detection P-value for each probe is 
calculated for individual and multiple samples using non-parametric methods that rank 
the probe signal relative to the negative control. This can be interpreted as the probability 
that the probe signal is no greater than background, relative to the noise in the data. The 
higher the intensity signal, the lower the probability that it is generated by non-specific 
sources. The detection P-value was calculated for each probe in each of the nine 
biological groups (C57BL6Sal, L100PSal, Q31LSal, L100PCloz, L100PRoli, 
Q31LBupro, C57BL6E13, L100PE13 and Q31LE13) and only those probes with a 
detection P-value of less than 0.05 in at least one of the nine groups were retained for 
further analysis. This allowed probes to be expressed in one group but not in another. Of 
the 46,644 successful probes (corresponding to 34,492 genes) on the Mouse Ref-6 
BeadChip, 21,869 (~47%) probes met this threshold. Estimates by others state that most 
tissues only express 30-40% of genes [231] so this is lightly higher than would be 
expected. Figure 3.14 illustrates the final cluster d ndrogram after the data had been 
filtered. There is very little difference between this and the previous dendrogram for the 
stabilized and normalized data. This was unexpected as filtering of probes not 
significantly expressed above background should increase the bootstrapping AU values 
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indicating stronger support for the observed clusters. However, the previous cluster 
dendrogram gave AU values all close to or equal to the maximum of 100 which is likely 
to be the reason that no difference is seen in this new filtered dataset. 
In the second filtering step only probes which showed potentially significant differential 
expression when compared to the relevant control grup were retained. This has 
previously been shown that the most reproducible and reliable method of determining 
differential expression in microarray analysis is based on a rank of fold-change and non-
stringent statistical significance (P-value) cut-offs [225]. As the Illumina platform offers 
the sensitivity to detect down to a 1.3 fold change 
(www.illumina.com/downloads/Mouse6-8v2Datasheet.pdf) this was used as the cut-off  
for this second filtering step.  
Fold change was calculated by taking the anti-log2 of the difference between the average 
normalized values of the two groups being compared at each probe. This fold-change 
filter reduced the number of probes to be tested from 21,869 to 1266 in the L100PSal vs 
C57BL6Sal comparison, 26 in the Q31LSal vs C57BL6Sal comparison, 996 in the 
L100PCloz vs L100P Sal comparison, 1313 in the L100PRoli vs L100PSal comparison, 
251 in the Q31LBupro vs Q31LSal comparison, 2005 in the L100PE13 vs C57BL6E13 


















This chapter has described the experimental preparation nd pre-processing analysis of a 
genome wide expression study carried out on two ENU mutant mouse lines which 
display distinct endophenotypes categorised as ‘schizop renic-like’ and ‘depressive-like’ 
using the Illumina BeadArray platform. 
The behavioural study carried out prior to the collection of samples for the microarray 
was designed to replicate the results obtained by Clapcote et al (2007) [197] to ensure the 
mutation continued to carry the behavioural phenotype previously described. As 
described, the animals used for this experiment were backcrossed for a further 3 
generations than those used in the previously published study and the pool of mice 
available was substantially affected by a spontaneous mutation within the breeding 
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programme which required a mass cull of animals prior to the breeding of those to be 
used in this experiment. This resulted in a much reduc d gene pool available, and the 
requirement to cross homozygous animals to generate the number of animals required, 
which further compounded the bottleneck effect. This also made it impossible to use 
wild-type littermates as a control as no heterozygous animals were used in the crosses. As 
the ENU mutant lines were established on a C57BL/6J genetic background it was 
determined that these animals would be the closest genetically to wild-type littermates.  
The PrePulse inhibition analysis carried out by myself did not replicate the study 
previously published by Clapcote et al using the ENU mutant mouse lines. There are a 
number of reasons which may explain this. It is possible that the further backcrossing 
reduced the effect of the mutation on the behaviour phenotype previously observed. This 
is unlikely however, as additional, more recent, studies (Tatiana Lipina, personal 
communication) have replicated the results previously published, and personal 
observations of the animals brain physiology and general behaviour concur with those 
reported previously. Subsequent literature searches ombined with results obtained in this 
experiment show the C57BL/6J mice may not have been th  ideal control for this 
experiment. Studies of PPI in rodents have been goig n for many years as researchers 
attempt to find the genetic basis for such behaviours. Paylor and Crawley (1997) [232] 
studied the differences in PPI in commercially available inbred mouse strains. One strain 
used in their study was the C57BL/6J strain from Jackson Laboratories as used in this 
study. They looked at mice between the ages and 9 and 14 weeks over 5 auditory 
prepulse stimuli. Interestingly, the C57BL/6J mice gave the lowest PPI of all the mice 
they tested[232]. Two of the decibel levels used by Paylor and Crawley [232] can be 
compared to those used in the current study and give an average of 20% PPI compared to 
the 23% PPI observed in the current study. It is also important to note that the original 
Clapcote [197] experiment grouped the wild-type littermates from both mutants in one 
‘control’ group so any differences which may appear between wild-types littermates will 
be hidden within the one group. While the C57BL6 mice were specifically sourced from 
the Jax substrain for the behavioural study, to be as close as possible to the original 
backcross strain used when establishing the ENU mutant colonies, the results obtained 
would suggest that they were not an adequate control, and there may be non-target 
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mutations in the wild-type littermates which may beresponsible for the differences 
observed. These could either be secondary ENU mutations hat co-segregated with the 
Disc1 mutation, or sections of DBA genome that remained, despite backcrossing, around 
the Disc1 gene. This is discussed further in Chapter 8 and any future work should review 
the validity of non-littermate controls. It should also be noted that while comparison 
between PPI deficits in rodents and humans are, for the most part consistent, some drug 
effects have been shown to give differing results across species[220]. Prepulse inhibition 
is regarded as a reliable endophenotype of major mental illness (and schizophrenia in 
particular) but care must be taken over the conclusions drawn from our results if we wish 
to relate our mouse model to human disease.  
Despite the limitations described above, it was determined that the full microarray 
experiment should continue as any genes which were ‘flagged’ as being differentially 
expressed in the comparisons with the C57BL/6J mice would be subsequently tested 
against wild-type littermates after the array as it would be possible to re-establish a 
complete ENU mutant mouse colony within this time. 
The aim of the microarray experiment was to determine which genes were differentially 
expressed on the basis of genotype, drug treatment and developmental stage (embryonic 
and adult). A total of seven comparisons were made across nine biological groups. The 
tissues used for the array analysis were taken fromthe animals used in the behavioural 
study immediately after completion of the PrePulse inhibition cycle. All animals that 
underwent behavioural testing were sacrificed and RNA extracted from hippocampal 
tissues, however only the groups outlined previously were included in the array. 
Abnormalities in hippocampal structure, activation, rganization of neurons and synapse 
function have been well documented in human schizoprenia patients and other mouse 
models [207, 214, 233, 234]. As there are working memory deficits often associated with 
schizophrenia [208], it is clear there is substantial hippocampal involvement in the 
disorder. The use of a single brain region also removed any confounding effects of 
compensation in other brain regions, which may have diluted the result. Financial 
constraints meant that only the drug treated groups which had shown a marked 
behavioural response in the previously published study were included, as these were 
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more likely to give a distinct genetic profile for comparison. The RNA from the other 
groups was retained to be used for future experiments a d to determine the importance of 
some of the results obtained (as described in Chapter 5). The sample preparation, quality 
control and pre-processing methods used had been prviously tested by other researchers 
within the laboratory and were considered of good standard with reliable output for 
differential expression analysis. Biotin labeling and hybridization controls indicated the 
RNA used was of good quality, increasing the likelihood of a reliable output from the 
array. 
The main limitation of this study was the requirement to use the C57BL/6J mouse as a 
wild-type control, particularly with the resulting PrePulse inhibition result, and if the 
experiment were to be repeated it would be advisable to use wild-type littermates as 
controls. The use of these animals was however justified by the fact the ENU mutants had 
been backcrossed for 10 generations and would be considered as close to the C57BL/6J 
genotype as possible, and further analysis would include wild-type littermates to validate 
any results. As RNA was available for other biological groups not included on the array it 
would also have been interesting to compare the drug treated C57BL/6J animals with the 
drug treated ENU mutant samples to potentially determine whether the drug treatments 
affected the ENU mutants in a different manner to their ‘wild-type’ controls. 
The next stage of analysis will describe differential expression profiles and potential 
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Analysis of differential expression between mutant li es provides insight into potential 
genes and pathways involved in the phenotypes expressed in these animals. By 
comparing these genes to those previously published in human studies we can identify 
genes and pathways involved in major mental illness and potentially determine targets for 
further study or new drug treatments. This chapter describes the process of differential 
expression analysis in the ENU mouse mutants including pathway analysis and overlaps 
with previously published human studies. 
 
 
4.2 Differentially Expressed Genes 
The array probes that survived the fold-change filtr described in chapter 3 were tested 
for differential expression using the Analysis of Variance model (ANOVA) written in the 
R package (MAANOVA) which is specifically designed to be used with microarray data 
[235]. The two main effects tested were genotype and drug treatment. Tests of 
differential expression were carried out using the MAANOVA matest function using the 
Fs test statistic, which makes no assumption about the distribution of variance but 
estimates it based on the information across all probes in the dataset. This has previously 
been shown to be more powerful than other F statistics available in the package for 
detecting differential expression [236] because of the employment of the James-Stein 
shrinkage concept. This concept uses the information across all probes, rather than probe 
specific estimators, to gain a better estimate of variance within the dataset. This increases 
the power of the test thus giving a higher reward in small sample sizes than standard F 
statistics. Table 4.1 shows the number of genes found to be differentially expressed in 
each group comparison (Fs p-value ≤0.05) based on genotype or drug treatment where 
appropriate. 
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For each probe tested I also calculated the false discovery rate (FDR), using the adj p-
value function in MAANOVA, to determine the stringency of the 0.05 cut-off. The FDR 
value determines the expected proportion of false positives when determining 
significance of each probe. Table 4.1 shows the mean FDR for each comparison based on 
the adj p-value for each probe called as significant within that comparison. The 
maximum FDR for any comparison was 0.35 suggesting a moderate probability of any 
probe being a false positive. As genes were to be su jected to further rounds of validation 
this was deemed to be acceptable. 
 
 
Table 4.1 Summary of probes differentially expressed by genotype of drug treatment. Column 1 
shows the pair-wise comparison made while column 2 gives the number of probes that passed the 1.3 fold-
change filter. Column 3 shows the number and percentag  of probes that were significantly differentially 
expressed (Fs p-value ≤0.05). The final column gives the mean and maximum false discovery rate (FDR) 
observed in the list of significantly differentially expressed probes.   
 
Some genes showed differential expression in more than one pair-wise comparison 
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Figure 4.1 Venn diagram of significant probes in the genotype comparisons. Pane A shows significant 
probes in both adult comparisons while pane B shows significant probes in both embryonic comparisons. 
The total number of differentially expressed genes are shown in parenthesis. Within the circles of the Venn 
diagram are the number of genes unique to each comparison and, where the circles overlap, the number 
common to the comparisons. 
 
In addition, eight genes that were found to be differentially expressed in the mutant vs 
wild-type comparisons were also differentially expressed when the mutant, non-drug 
treated (saline) animals were compared to their drug treated counterparts. When the drug 
treated animals were compared to the C57BL/6J non drug treated adults for expression at 
these genes no significant difference was observed, suggesting the drug treatment has 
corrected the expression level back to that of the control animal. Seven of these genes 
were in the L100Padult (saline) vs L100PRoli (rolipram) comparison while one gene was 
in the Q31Ladult (saline) vs Q31LBupro (bupropion) comparison. No correction of 
differential expression was observed in the L100PCloz (clozapine) group. 
 
 
4.2.2 Differentially expressed genes: primary annot ation and gene ontology 
Genes that were shown to be differentially expressed w re annotated using data provided 
by Illumina. Each probe sequence was also run through NGBI Gene to determine its 
location on the mouse genome and to check whether this corresponded to the gene name 
provided by Illumina. The official gene name, symbol, accession number, GI number and 
gene ontology were noted for each gene within this search.  
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Gene ontology (GO) analysis was performed to determine if the lists of significantly 
differentially expressed genes showed enrichment for any particular GO category relating 
to molecular function, biological processes or cell components. This was carried out 
using the web based GOTree machine (GOTM) (http://bioinfo.vanderbilt.edu/gotm) by 
comparing the list of differentially expressed genes to those expressed above background 
in the relevant groups. GO categories are arranged in a hierarchical structure of common, 
controlled vocabulary used to describe the roles of genes and gene products of different 
species. Only GO enrichments that are statistically significant (P<0.01, as determined by 
the hypergeometric test) are reported by GOTM. 
 
The list of statistically significantly differentially expressed genes was then compared to 
gene lists from recently published studies. Three of the studies used for comparison [83, 
84, 217]  described copy number variants in cases and controls of schizophrenia and 
other major mental illness. A further two, unpublished, microarray studies identified 
genes dysregulated in two large families with a history of mental illness. The first used 
lymphoblastoid cell lines from a large Scottish family with a balanced translocation 
(t1:11) that formed the original sample set used to identify the DISC1 mutation and the 
motivation for characterising the two Disc1 mutants used in this study [8, 56]. This 
family has a history of schizophrenia and schizoaffective disorders spanning multiple 
generations. The second used lymphoblastoid cell lin s from the F22 family which has a 
history of major depressive disorder and provides a dataset of both affected and 
unaffected individuals with married in controls[237]. Lastly, the DISC1 interactome 
[132] was used to identify dysregulated genes in this dataset that are known to interact 
with Disc1. 
 
Finally, pathway analysis was carried out on the lists of differentially expressed genes 
using the web-based software Ingenuity Pathway Analysis (IPA). All probes expressed 
above background in each comparison were loaded into the system regardless of fold-
change or p-value. These were then set as the main observations for determining cut-offs 
(ie, only include genes with FC>1.3 and p-val<0.05) so any pathways which were created 
by the system would highlight those genes with significant differential expression and 
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would also show (by shading) those genes expressed above background in the sample 
group. Any genes in the pathway which were not exprssed above background in the 
sample group would be left unshaded. IPA then assign  a significance score to each 
network (as described in section 2.7.2) which indicates the likelihood that the assembly 
of focus genes within a network could be explained by random chance.  
 
After these stages had been carried out all genes identified by the array analysis were 
scored on the basis of gene ontology, overlaps withprevious studies and presence or 
absence in high scoring networks, to determine which genes would be carried forward for 
further analysis. The following sections describe th  results of this process for each pair-
wise comparison from the array analysis. 
 
 
4.2.3 Differential Expression between the L100P adu lt ENU mutant and the 
C57BL/6J adult controls 
 
Of the 1266 probes that passed the pre-processing filters in the L100Padult group, 531 
showed differential expression compared to the C57BL/6J control group (table 4.3). 261 
of these genes were over-expressed and 270 under-expressed in the L100P adult group. 
Four of these genes (Akap9, Gnb1, Ppm1e and Smarce1) are known interactors of Disc1 
(Camargo et al 2006 [132]). With 127 genes in the Disc1 interactome, hypergeometric 
probability suggests this is a significant result (p=0.003).  Akap9, Gnb1 and Smarce1  
were over-expressed and Ppm1e under-expressed in the L100Padult sample group 
relative to the C57BL/6J controls.  
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Table 4.3: Complete list of dysregulated genes in the L100P adult group. Cont next page… 
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Table 4.3: Complete list of dysregulated genes in the L100P adult group. Cont next page…… 
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Table 4.3: Complete list of dysregulated genes in the L100P adult group. Columns show Target (gene) 
ID, full gene name, accession number and probe ID, log transformed expression values for both 
comparable groups, difference between groups, fold-change, p-value and GeneOntology terms for each 
gene. 
Chapter 4 131 
Nine genes showed overlap with the previously published schizophrenia CNV study by 
Walsh et al [83] and six of these findings have the same presumed directionality as the 
CNV study (ie over/under-expression corresponding to ain/loss of copy number). Two 
genes were found to overlap with a second CNV study [84] and again followed the same 
directionality (Table 4.2). Comparison with a microa ray study of the F22 family 
described above (Christoforou et al, unpublished) also showed two genes of overlap with
the current study following the same directionality. 
 
 
Table 4.2: Overlap with previous studies. This table shows the overlaps between genes from the current 
microarray study and large genome wide studies previously published from individuals with schizophrenia 
and other major mental illness. All genes with overlap were found within the L100P non-drug treated 
(saline) group. Column 1 shows the gene name, column 2 the comparative previously published evidence, 
column 3 the direction of change (with this study first and comparative study second) and column 4 the 
gene function/location. 
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GOTree analysis of the differentially expressed gene list did not find any categories to be 
overenriched in the sample dataset (table 4.2, figure 4.2). 
 
 
Figure 4.2: Bar graph of GOTree categories for L100Padult vs C57BL6adult. For each biological 
process GOTM calculates the expected number of genes within a dataset and graphs this against the 
observed genes within each category. A p-value is then calculated to determine the significance of 
over/under-enrichment for each category. For this dataset none of the categories were significantly 
overenriched. 
 
Pathway analysis of the L100P dysregulated genes using IPA gave three statistically 
significant high scoring networks. The top network for the L100P mutant adults was 
“neurological disorder” (IPA score 45. Scores greater than three have at least 99.9% 
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confidence that the genes are not grouped by random chance alone. For full score 
definition see Chapter 2 section 7.2) It contained 32 of the L100P dysregulated genes and 
had a high network score, with low probability these genes clustered by chance (fig 4.3). 
Calcium signalling was cited as the top canonical pathway. A canonical pathway is a core 
pathway established for a given molecule in the cell, in which molecular interactions 
occur in a linear and stepwise manner. Network 2 (IPA score 43) “cell cycle” contained 
28 L100P dysregulated genes while network 3 (IPA score 41) “developmental disorder”, 
also contained 28 L100P dysregulated genes, including one gene, Bex2, whose expression 
level was corrected toward the wild-type level by rolipram treatment (Figure 4.3).  
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4.2.4 Differential Expression between the Q31L adul t ENU mutant and the 
C57BL/6J adult controls 
The differentially expressed genes in the Q31L non-drug treated (saline) adult mice are 
shown in table 4.4. For this comparison, the top network contained only two genes from 
the array study. This was, however, expected as fewer genes were differentially 
expressed in this group. The small number of genes was insufficient to create canonical 
pathways. 
 
Table 4.4: Dysregulated genes in the Q31L adult group compared to C57BL/6J controls. Table shows 
the probe target (gene) ID, full name, accession and probe number, log transformed expression data for 
both Q31L and C57BL/6J, difference in expression, fld-change and p-value, and Gene Ontology terms for 





4.2.5 Differential Expression between the Embryonic  ENU mutant and the 
C57BL/6J embryonic controls 
In total 33 genes were found to be differentially expressed in the L100P embryo, and 15 
in the Q31L embryo (table 4.5).  
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Table 4.5: Dysregulated genes in the Embryonic sample groups. Panel A shows the genes dysregulated 
in the L100P embryo compared to C57BL/6J controls while Panel B shows the genes dysregulated in the 
Q31L embryo compared to the C57BL/6J control. Each table shows probe target ID (gene symbol), full 
gene name, accession number, Illumina probe ID, GI number, log transformed expression data, expression 
difference, anti-log of expression difference (to crrect for negative values), fold-change, p-value and 
GeneOntology terms where available. 
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For the L100P E13.5 embryos, there were nine genes in the top network (IPA score 22) 
and Notch signaling was the top canonical pathway. The Q31L E13.5 embryos had a 
lower but still significant top network (IPA score 10), with only four genes 
interconnecting. Three of these genes were also present in the L100P E13.5 embryo top 
network which added weight to taking them forward for further analysis. Consistent with 




Figure 4.5: Ingenuity Pathway Analysis of Embryonic dysregulated gene lists. Panels A and B show 
the top seven cananocal pathways for L100P E13 and Q31L E13 respectively. In both cases Notch 
signaling is the top canonical pathway, and in the case of the L100P, the only one to meet the significance 
threshold. Threshold bar shows cut-off point of significance P < 0.05. The yellow ‘ratio’ line shows the 
ratio of genes in network to total number of genes in ca onical pathway.  
 
 
4.2.6 The effect of Drug Treatment on gene expressi on in adult ENU mutant 
mice 
In total there were 150 genes dysregulated in the drug treatment groups compared to their 
drug naïve (saline) counterparts (table 4.6). While many of these genes were unique to 
the drug treatment groups, some had previously beens  to be differentially expressed 
in the non-drug treated (saline) groups compared to C57BL/6J animals. Treatment of the 
L100P adult with rolipram showed the most extensive gene expression rescue, with seven 
genes returning to levels not significantly different to wild-type (fold change +/-1.3, 
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p<0.05). Clozapine showed no correction of expression and the bupropion treated Q31L 
animals only had one gene show corrected expression. 
 
 
Table 4.6.1: Dysregulated genes in Clozapine treated L100P adults. Table shows the genes that are 
dysregulated in L100P adult mice treated with anti-psychotic Clozapine, compared to L100P drug naïve 
adult mice. Table shows probe target ID (gene symbol), full gene name, accession number, Illumina probe 
ID, GI number, log transformed expression data, expr ssion difference, anti-log of expression differenc  (to 
correct for negative values), fold-change, p-value and GeneOntology terms where available. 
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Table 4.6.2: Dysregulated genes in Rolipram treated L100P adults. Table shows the genes that are 
dysregulated in L100P adult mice treated with the PDE4 inhibitor and anti-depressant rolipram, compared 
to L100P drug naïve adult mice. Each table shows probe target ID (gene symbol), full gene name, 
accession number, Illumina probe ID, GI number, log transformed expression data, expression difference, 
anti-log of expression difference (to correct for negative values), fold-change, p-value and GeneOntology 
terms where available.  
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Table 4.6.3: Dysregulated genes in Bupropion treated Q31L adults. Continued on next page… 
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Table 4.6.3: Dysregulated genes in Bupropion treated Q31L adults. Table shows the genes that are 
dysregulated in Q31L adult mice treated with the anti-depressant Bupropion, compared to Q31L drug naïve 
adult mice. Each table shows probe target ID (gene symbol), full gene name, accession number, Illumina 
probe ID, GI number, log transformed expression data, expression difference, anti-log of expression 
difference (to correct for negative values), fold-change, p-value and GeneOntology terms where available.  
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The potential importance of genes corrected by drug t eatment was assessed by where 
they fell in the non-drug treated groups. For the L100P rolipram treated mice, Bex2 was 
sited in the 3rd network produced with a good network score and high probability that the 
grouping was not by chance. It also, interestingly, made indirect connections with NFKβ 
which has been implicated in major mental illness and forms a central connection in this 
network for many other genes. Pcbp1, Hnrpk and Wbp4 all appear in network 4 alongside 
Egr2, Egr3 and Egr4 which have been previously linked to major mental illness[238]. 
Egr2 and Wbp4 have a direct connection while Pcbp1 and Hnrpk connect to each other 
and an Actin complex (Figure 4.6) 
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4.3 Selection of Genes of Interest for Validation b y QT RT PCR 
The analysis outlined above resulted in a list of genes that were dysregulated in the Disc1 
mutant mice compared to C57BL/6J wild-type controls, and genes which showed 
correction of expression in drug treated mutants. This list totalled 835 genes with some 
overlap between groups. Obviously it was not going to be possible to validate all of the 
genes highlighted so it was necessary to determine which genes most warranted follow 
up. This was done by scoring genes based on fold change, p-value, IPA analysis, over-
enrichment of GO terms, presence in other groups from the array and overlaps with 
previously published studies on major mental illness. Genes were ranked within each 
pairwise comparison using a simple tally system, where each of the above selection 
criteria would add one tally to the gene ‘score’, and then the top 10% of genes were 
carried forward for validation. The list of genes taken forward for validation are shown in 
table 4.7. 
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Table 4.7: Genes for validation by qRT PCR. Columns 1 and 2 show the gene symbol and full name, 
column 3 shows the comparison in which it is dysregulated, columns 4 and 5 show probe ID and GI 
numbers for the gene, column 7 and 8 show fold-change and p-value, column 9 gives GOterms and column 





Chapter 4 147 
4.4 Identification of L100P outlier 
During the Taqman qRT-PCR, a conversation with a more experienced microarray 
statistician lead me to take a closer look at the normalised raw data for the L100P mutant 
mouse. As the number of genes classified as differentially expressed were very high it 
was thought that there may be an anomaly in the data skewing the result (Dr Freeman, 
personal communication).  
 
I picked twenty genes at random through the microarray dataset and ran interquartile-
range outlier analysis on the four L100P adult (saline) pools (3-4 mice per pool) which 
confirmed one pool, L100P Sal F2, as an outlier in 15 out of the 20 genes analysed. As 
there were 46,644 genes in the total dataset, it was not possible to test every gene to see 
whether this pool was an outlier therefore this pool was removed and the entire dataset 
reanalysed.  
 
The qRT PCR validation that had been run so far (22 genes on each mouse sample) 
suggested that only one mouse in the pool was an outlier by inter-quartile range analysis. 
Of the outliers removed during analysis of the Taqmn qRT-PCR data, 40% were mice 
from the L100P Sal F2 pool. Given that there were four L100P adult (saline) pools this is 
higher by ~15% than expected than random chance of 25%. 87.5% of the time the 
L100PSalF2 pool sample removed was B100-1-32 (14 times in 22 analyses). As the array 
data was run on the complete pool, all mice in the pool had to be removed from further 
analysis. The genes already validated by Taqman qRT-PCR would be reanalysed and will 
be described in chapter 5. 
 
After identifying this pool I went back and looked at the behavioural data from the 
PrePulse Inhibition trial to determine if the mice in this pool had displayed behaviours 
which would be suggestive of different genetic exprssion (figure 4.7).  
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Figure 4.7: PrePulse Inhibition data for L100PSaline and C57BL/6J mice. Panel A shows the total PPI 
values with no outlier removal. Panel B shows the total startle response with no outlier removal. Sample 
B100-1-32 is the sample most removed as an outlier in the genetic validation stage, shown here as not 
being an outlier in the behavioural study. 
  
As can be seen from the graph in figure 4.7, the B100- -32 mouse did not behave 




4.4.1 Reanalysis of array dataset 
The identification of the outlier group necessitated complete re-analysis of the entire 
array dataset post the normalisation step (see chapter 3 section 7.2). Removal of the 
L100Psaline F2 pool left seven samples in the L100P saline group, which still gave 80% 
power to detect a 1.3 fold-change. Analysis was carried out as described initially in 
chapter 3, and chapter 4 section 2.  
 
Removal of the L100Psaline pool altered the detection p-values for each probe and this 
gave rise to a completely new dataset for analysis. Of the 46,644 successful probes, 
20,302 (43.5%) probes were expressed above background. This is slightly higher than 
expected [231]. As described in Chapter 3, the next filtering step was to remove all 
probes with less than 1.3 fold-change in the dataset. This reduced the number of probes in 
the L100Psaline set to 1272, in the Q31Lsaline group to 26, in the L100PEmbryo to 
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1344, in the Q31LEmbryo to 613, in the L100PRolipram to 456, in the L100PClozapine 
to 321 and in the Q31LBupropion to 262 (Table 4.8) 
 
Finally, using the same methods as described in section 4.2, the probes that survived the 
fold-change filter were tested for differential expression using the Analysis of Variance 
model (ANOVA) (table 4.8).  
 
 
Table 4.8 Summary of probes differentially expressed by genotype of drug treatment. Column 1 
shows the group of interest and column 2 the control g up for the comparison. Column 3 shows the 
number of genes expressed above background, column 4 shows the number of probes surviving the fold-
change filter, and column 5 shows the number of probes, and percentage of those probes that were 
significantly differentially expressed (Fs p-value ≤0.05).  
 
In total 368 genes were found to be differentially expressed in this dataset (table 4.9). 66 
of these genes were also present in the previous data et, and overlap of only 18%. 
Chapter 4 150 
 
Table 4.9: New list of dysregulated genes post outlier removal. Continued next page……. 
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Table 4.9: New list of dysregulated genes post outlier removal. Continued next page……. 
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Table 4.9: New list of dysregulated genes post outlier removal. Continued next page……. 
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Table 4.9: New list of dysregulated genes post outlier removal. Continued next page……. 
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Table 4.9: New list of dysregulated genes post outlier removal. Continued next page……. 
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Table 4.9: New list of dysregulated genes post outlier removal. Column 1 and 2 show the gene symbol 
(Gene_ID) and probe ID, column 3 shows the comparison n which it is dysregulated, columns 4 and 5 
show fold-change and p-value, column 6 gives functio  GOterms and possible alias’, column 7 gives 
localisation where possible, column 8 further evidence to support validation from previously published 
studies, column 9 and 10 state whether the gene was overexpressed in GOTree analysis and/or IPA 
analysis. 
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Some probes were found to be differentially expressed in more than one comparison 
(figure 4.8) 
 
Figure 4.8: Venn diagram of significant probes in the genotype comparisons. Pane A shows significant 
probes in both adult comparisons while pane B shows significant probes in both embryonic comparisons. 
The total number of differentially expressed genes are shown. Within the circles of the Venn diagram are 
the number of genes unique to each comparison and, where the circles overlap, the number common to the 
comparisons. 
 
In addition, there were eight genes that showed corre tion with drug treatment, and a 
further four genes that had borderline fold-change and p-value for correction with drug 
treatment. Bupropion treatment of the Q31L saline mouse corrected three genes back to 
the expression level of the wild type, clozapine trea ment of the L100P mouse corrected 
one gene back to the expression level of the wild type, and rolipram treatment of the 
L100P mouse corrected five genes, and was close to correction of four genes back to a 
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4.4.2 New Gene Ontology, Pathway analysis and Compa risons with 
previous study 
Of the 88 genes shown to be differentially expressed in the L100PSaline group, 62 were 
upregulated and 26 were downregulated. GOTree analysis highlighted 11 biological 
processes over-enriched in the sample-set (table 4.10)
 
 
Table 4.10: Table of biological processes over-enriched in the L100PSaline group. Column 1 shows the 
biological process, column 2 the number of genes in the dataset involved in the process, column 3 the 
number of genes expected in a dataset, column 4 the p-value of the finding, and column 5 the genes found. 
 
 
None of the other groups showed overenrichment of GO categories. IPA analysis 
revealed a top network score of 48 “cellular development” for the L100P adult 
comparison, with 21 dysregulated genes appearing in the network (figure 4.9). The top 
canonical pathway for L100P was synaptic long-term depression (p= 0.005). There was 
now a significant canonical pathway for the Q31L analysis (p=0.01, figure 4.10 panel B), 
but no significant network of genes was identified. The L100P embryo pathway analysis 
changed very little, but the Q31L embryonic network analysis was greatly changed. For 
the L100P embryo the top network identified, “gene xpression”, gave a score of 25, and 
for the Q31L embryo the top network “cell signalling” gave a score of 35. A score of 25 
represents a 1.0E-24 probability of the genes within e network grouping by chance. 
While for the L100P embryo notch signalling remained the top canonical pathway 
(p=0.006), for the Q31L embryo this was replaced by caveolar-mediated endocystosis 
(p=0.001), pushing notch signalling into second spot (figure 4.10).  
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Figure 4.9: Ingenuity Pathway Analysis. Panel A shows top L100P adult network “cellular 
development”. Panel B shows the top L100P embryo network “gene expression” and Panel C the top Q31L 
embryo network “cell cignalling”. Those in green are downregulated, and those in red upregulated. Genes 
shaded grey do not appear in the dysregulated gene,but are expressed above background in the dataset. 
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Figure 4.10: Canonical pathways for IPA analysis on new dysregulated gene list. Panel A shows the 
top six pathways in the L100P adult group, panel B the top six pathways in the Q31L adult group, panel C 
the top six pathways in the L100P embryonic group, and panel D the top six pathways in the Q31L 
embryonic group. Threshold bar shows cut-off point of significance P < 0.05. The yellow ‘ratio’ line shows 
the ratio of genes in network to total number of genes in ca onical pathway. 
 
 
There were also eight genes found to overlap with previous studies of major mental 
illness, with one gene being present in two of the studies included in the analysis (table 
4.11). Probability distributions consider this a significant value (p<0.001). Studies used 
for comparison are described in section  4.2.3.  
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Table 4.11: Overlap with previous studies. This table shows the overlaps between genes from the current 
microarray study and large genome wide studies previously published from individuals with schizophrenia 
and other major mental illness. All genes with overlap were found within the L100P non-drug treated 
(saline) group. Column 1 shows the gene name, column 2 the comparative previously published evidence, 




4.5 New list of genes for qRT PCR 
Genes were selected for validation by qRT PCR based on fold-change, p-value, GOTree 
analysis, previous implications in mental illness research and overlaps with current 
studies of the human (t1:11) translocation carriers (Table 4.12). Initially, genes were 
sorted based on p-value and then fold change, and scored by where they fell within the 
list (ie those in the top 10% based on p-value were giv n a score of 10, top 11-20% 
scored 9 etc). Genes were then scored on whether they appeared in the ‘over-enriched’ 
functions based on GOTree analysis and/or Ingenuity pa hway analysis. Finally, genes 
were scored based on whether they had previous implications in major mental illness or 
overlapped with the human translocation carrier data. Scores were totalled and the top 
10% of genes from each comparison (now based on the to al combined score from p-
value, fold change, GOTree analysis, IPA and overlaps with other studies) were carried 
forward for further validation. 
Chapter 4 161 
 
Table 4.12: List of genes to be analysed by QT RT PCR. Column1 gives the gene name, column 2 the 
comparison in which it is dysregulated, column 3 the fold change from the array, column 4 the p-value 
from the array, column 5 the GeneOntology terms for that gene, and column 6 extra evidence for further 
analysis.  
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In total 36 genes were selected for further analysis, 20 from the non-drug treated adult 
mice, ten that showed correction, or near to correction, with drug treatment, and six from 






This chapter describes the analysis and significance of the results obtained from a 
genome-wide expression study as described in chapter 3. Genes that were found to be 
differentially expressed were weighted on their functional significance (based on gene 
ontology and pathway analysis) and previous implications in major mental illness 
research. Genes which showed correction by drug treatment were also considered. 
 
The initial analysis revealed a total of 835 genes that were differentially expressed across 
the sample set. As the one outlier pool gave erratic and unpredictable expression values, 
being neither consistently higher nor lower than the other samples, this likely explains 
why the initial analysis did not identify this pool as an outlier, as the effect was muted by 
combining all genes together. Thus when the average expression for each pool was 
compared no pool was initially identified as an outlier. This shows the need to take 
comparable biological groups and analyse the raw data of a subset of genes to ensure 
outliers are not missed in future.  
 
Secondary analysis revealed a total of 368 genes differentially expressed across the 
sample set. In hindsight, secondary analysis could have been avoided by checking a 
random subset of genes from the outset, rather than after the analysis had been carried 
out.  
 
The comparison between the L100P adult and the C57BL/6J adult mice identified 88 
genes that were differentially expressed, 62 of which were over-expressed and 24 under-
expressed in the L100P adult samples. The Q31L bupropion treated mouse showed the 
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highest levels of differential expression in the drug treated groups with 91 genes over-
expressed and 95 genes under-expressed compared to non-drug treated adults. Only three 
of these genes were also found to be dysregulated in the Q31L non-drug treated mouse 
and it is likely the high numbers are a factor of the drug treatment and not the Q31L 
genotype. The L100P rolipram treated mouse gave the most genes which showed 
correction under pharmacological influence. Of the 32 genes identified, seven showed 
correction of the L100Pnon-drug treated disregulation. Correction of expression was 
defined as returning that gene to a level not significantly different (FC+/- 1.3, p<0.05) to 
that of C57BL/6J controls. 
 
In the embryonic groups, L100P identified 45 differentially expressed genes, while Q31L 
identified 25. Four genes were identified in both groups, PRM3, Coro1B, Numb and 
PDE4D.  
 
Selection of genes for further analysis was performed in multiple ways. Genes were first 
ranked in order of fold-change and p-value then GOTree analysis was performed to 
determine which biological processes, cellular compnents and molecular functions were 
or were not overrepresented in the differentially expr ssed gene lists generated from the 
microarray analysis. This not only facilitates direct comparison with other studies of 
major mental illness due to the simple and uniform characterizations, but also helped to 
“compartmentalize” the data and identify promising genes for further analysis. The 
GOTree analysis revealed over-enrichment of genes ivolved in cell-cell signaling, 
transmission of nerve impulses and neurotransmitter sec etion in the L100P non-drug 
treated (saline) adult dataset. Among these genes are the two Neurexins (Nrxn1 and 
Nrxn3), Gria1 and Gria2, Erg2, Egr3 and Egr4. Both neurexin genes and Gria1 and 
Gria2 were found to be over-expressed in the L100P adult samples, while the three Egr 
genes were found to be under-expressed in the sample set.  
 
Ingenuity pathway analysis was also used to identify dysregulated genes that grouped 
together to form established networks and pathways. Nine genes showed both 
overenrichment in GO categories and were present in the top statistically significant IPA 
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network for the relevant group. One of the potential p tfalls of Ingenuity analysis for this 
study is the relevance of known networks to major mental illness. Much of the data 
currently held refers to networks established by studies of cancer genetics and diseases 
with simple genetic components. While these networks currently provide good points of 
reference and identify potential genes for further analysis, many connections are indirect. 
With continuing genetic studies being added to the existing datasets this is constantly 
improving but for this study IPA was used purely for identifying potential genes for 
further analysis and not to make direct claims to gene networks involved in major mental 
illness at this stage. Because the Ingenuity database is constantly being updated with new 
datasets, it is a dynamic tool and justifies repeat analysis in the future to determine 
whether new networks are identified with the same experimental dataset. 
 
Comparing the dataset from this study to selected pr viously published studies allowed 
me to not only identify genes for further analysis, but to determine how this study sat in 
relation to previous work, and to gauge the relevance of these two ENU mouse models to 
major mental illness research. Recent work has investigated the role of copy number 
variants (CNVs) in neurodevelopmental disorders (reviewed in Kirov 2010) [82]. As the 
aetiology of schizophrenia and other major mental illness is so varied, with multiple 
genetic components identified, the general consensus is that multiple small components 
are likely to be responsible, and as CNVs account for a substantial proportion of human 
genetic variation, are likely to play an important role. With this in mind I compared my 
dataset with three recently published studies of CNVs in major mental illness to 
determine whether they were comparable. Only two genes were present in both the 
dysregulated gene list from this study and copy number variants in the previous studies. 
Mll5, a transcription regulator, was present as a duplication in schizophrenia cases from 
Walsh 2008 [83], and was upregulated in the L100P non-drug treated adult group. MLL5 
has not been reported to interact directly with DISC1 [132], but DISC1 is well 
established as interacting with other kinases and mo ulating signaling pathways. For 
example, DISC1 interacts with PDE4B to dynamically regulate cAMP signaling, and also 
interacts with the cAMP response element-dependent tra scription factor, ATF4, possibly 
binding to chromatin remodelling factors, such as SMARCE1 [132]. PDE4s are 
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orthologous to the Drosophila Dunce, which is involved in learning and memory and 
known to affect synaptic plasticity, which in turn equires alteration of gene expression 
profiles [170].  These interactions with transcription factors, together with the fact that 
DISC1 localises to the nucleus [172, 173] is consistent with a role for DISC1 in 
transcriptional regulation. Nrxn1 was also found to be up-regulated in the L100P non-
drug treated adult group, with a CNV deletion present in a schizophrenia case and 
affected sibling [217]. The deletion spans the promoter and first exon of the gene and 
partially overlaps with previous deletions identified in autism [76] and mental retardation 
[239].   
 
I also had access to data from recently completed microarray studies on the DISC1 
translocation (t1:11) family that allowed an almost direct comparison to be made between 
the mouse and human model. Five genes (Dusp6, F5, Hook3, Nrxn1 and Nrxn3) were 
present in both studies, with Hook3, Nrxn1 and Nrxn3 dysregulated in the same direction 
in both arrays. These overlapping results between th  mouse and human sample subjects 
is promising as it provides further evidence of thevalidity of the animal model to this 
system. One major flaw of this comparison is the two arrays used different tissues as the 
primary RNA source. While it was possible to use brain tissues from the ENU mutant 
mouse, the human samples were from a blood-derived c ll line. Blood-derived 
(lymphoblastoid) cell lines do not express all genes and only a sub-set of those expressed 
in the brain[240]. This could obviously result in some genes not being present in the 
human dataset by virtue of the original tissues used, and not because they are not 
expressed, or potentially dysregulated in the human condition. 
 
This study had obvious limitations and weaknesses, not least of all the presence of an 
outlier group in the initial analysis. As described previously, the Illumina built in controls 
did not identify this one pool as an outlier, highlting the need to assess a subset of 
genes raw data across a group for complete confidence. A number of the genes identified 
as differentially expressed on the array were from a cDNA bank, with little or no 
functional information available. This made it difficult to determine the relevance of 
these predicted sequences to major mental illness and as such most were not chosen for 
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further analysis. It is possible that the lack of in ormation available for many genes 
biased the selection of the subset for further analysis. While the methods used for 
microarray analysis described in this section have be n widely used, it is important to 
note that other methods of data analysis are equally popular and different statistic 
procedures will give different lists of genes. The outcome of the analysis is obviously 
dependent on the starting data-set, thus testing for differential expression and then 
filtering on fold-change (rather than filtering by fold-change then potential differential 
expression as described here) would potentially lead to a different varience distribution 
(as more probes would be used to estimate the varience) and a different test statistic. This 
would potentially generate a different gene list from the same data. This has previously 
been addressed [241] with the conclusion that care should be taken when interpreting any 
results that rely on the structure of the starting dataset. It may be suggested that the 
dataset be reanalyzed in the future using the various methods available and only the genes 
which are consistant through all analyses be retaind for further follow-up work. Non-
parametric tests, Baysian models and t-tests (as used in this study) are all used to generate 
lists of differentially expressed genes from normalized microarray datasets [242]. 
Furthermore, once a list of genes is generated, there are multiple methods of describing 
changes in expression and identifying functional significance. Heirarchical clustering 
methods group genes by expression levels, but are of little use in determining functional 
significance [243]. Pathway analysis (as used here) is useful as it groups genes by 
GOTree classifications and so can be useful in ident fyi g common functions that may be 
affected by gene expression changes [243]. Neither of these methods, however, address 
the issue of false-positives and erroneous artifacts, which may lead to genes being studied 
further with no viable results. Bertsch et al (2005) propose to narrow the list of genes 
using Convergent Functional Genomics (CFG), which uses Baysian methods to cross-
validate datasets between arrays and linkage data, with the aim of reducing uncertainty 
and removing false positives [244]. 
 
The multiple stage selection process was employed to select the potentially most 
interesting and viable genes for further analysis, based on current knowledge of gene 
ontology, gene pathways and previous genetic work on schizophrenia and major 
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depression. However, there are multiple genes identified in the initial analysis which will 
not be investigated further at this stage. Ideally  genes identified would be validated 
using qRT-PCR but constraints on finances and time meant it was necessary to prioritise 
the most interesting and potentially viable genes for further study.  
 
In summary, this study has identified several putative candidate genes in both embryonic 
and adult stages. Correction of gene expression thrug  drug administration has also been 
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5. Quantitative real-time PCR analysis of candidate  differentially expressed 
genes in the L100P and Q31L mutant mice 
 
5.1 Introduction 
For the past decade researchers have been using qRT-PC  as a robust and reliable 
measure of gene expression through levels of RNA species [245]. It has widely become 
the standard technique for validating results obtained by microarray analysis [246] and 
the recent commercial availability of standard fluorescent tagged probes negates the need 
for researchers to design multiple probes. This makes confirmation of microarray results 
quicker and easier. qRT-PCR does have its limitations. One of the biggest limitations of 
qRT-PCR for gene expression studies is the necessity to use RNA which is then reverse 
transcribed to cDNA. RNA isolation must be performed with the utmost care to minimise 
the risk of contaminants (such as genomic DNA) and maintain the integrity of the RNA 
itself (reviewed in [247]). Design and testing of primers must also be stringent to 
minimise the likelihood of non-specific binding. Compounds found within tissues may 
also inhibit PCR. A number of measures were used in this study to minimise error in the 
PCR reactions. All RNA samples were tested prior to reverse transcription to identify any 
loss of integrity or possible contamination (chapter 2). RNA was treated to remove 
genomic contamination and primers chosen which spanned exon boundaries, so should 
not bind to genomic DNA in the sample. Primers used w re all commercially available 
and were assumed to have been stringently tested, however standard curves were 
obtained for all primers to ensure compatibility with the samples. While these measures 
were used to minimise error it is important to note that these limitations do exist and data 
should be viewed accordingly. 
 
In this chapter I will present the results from qRT-PCR analysis of 36 genes that were 
identified as differentially expressed in the microarray study of the ENU mutant mice. It 
should be noted that this is only a subset (~10%) of the genes identified as being 
differentially expressed. These genes were chosen for further study based on the criteria 
outlines in chapter 4. I will also describe the reanalysis of 20 genes that were tested prior 
to outlier removal described in chapter 4, and analysis of 3 drug treatment genes which 
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failed to validate in the drug naïve (saline) L100P mice, but which showed persistent 




5.2 Validating the Disc1 microarray result 
As described in Chapter 4, prior to the discovery of the outlier group qRT-PCR had been 
carried out with some genes showing differential expr ssion in the same direction seen in 
the microarray experiment. When the array data was re-analysed these genes would not 
have been selected for validation analysis (selection criteria outlined in chapter 4 section 
6), and in most cases did not make the criteria for differential expression (FC +/- 1.3, 
p<0.05). None-the-less, as these genes had already been tested the data was re-analysed 
with the outlier pool removed, and any genes which continued to show differential 
expression on qRT-PCR were tested on a second batchof mouse samples, alongside the 
new gene list. Two batches of mouse RNA were used for qRT-PCR validation. Batch 1 
was the RNA that went on the array, and batch 2 an independent sample set from a 
colony derived from the original animals. 
 
 
5.2.1 Initial Validations and Outlier removal of th e L100P drug naïve adult 
microarray 
Twenty genes identified as differentially expressed in the comparison between the L100P 
drug naïve (saline) animals and C57BL/6J animals had been tested by qRT-PCR prior to 
the identification of the outlier pool (described in Chapter 4 section 4). When the 20 qRT-
PCR data-sets were reanalysed following outlier removal, five of the 20 genes remained 
significant by qRT-PCR (FC +/- 1.3, p<0.05) (Table 5.1). Sort1 did not exceed the fold-
change cut-off imposed after the microarray, however, as this gene had previously been 
implicated in major mental illness it was tested in a second batch of mouse RNA 
alongside the five genes where the qRT-PCR result remained valid after outlier removal. 
Of these genes Bex2 was also still differentially expressed at the array level. All genes 
tested from the initial analysis are shown in table 5.1. 
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Nrgn1, Litaf, Id1 and Syn1 had significant fold-change and p-values after outlier removal, 
however in the opposite direction to the microarray. It is already known that between 
platform consistency decreases significantly with dfferent primers or increased sequence 
distance [246]. These genes have multiple transcript  which arise through alternate 
splicing which may account for the discrepancy in the results between platforms 
(www.ensembl.org).  
 
Twenty one genes that showed differential gene array expression in the L100P drug naïve 
saline-condition, adult mouse, post outlier removal were tested by qRT-PCR in both the 
RNA that was hybridised to the array, and a second batch of RNA samples. The six genes 
previously tested in the initial validation effort were also tested in a second batch of RNA 
and are displayed in table 5.1. 
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Table 5.1: Table of genes differentially expressed in the L100P drug naïve adult that were tested by 
qRT-PCR. Column 1 gives gene name, column 2 and 3 the array fold-change and p-value to be validated, 
columns 4 and 5 the first round qRT-PCR fold-change, and p-value for Mann-Whitney U test. Columns 6 
and 7 give these values for the second round of qRT-PCR on independent RNA samples. Significant p-
values are denoted in red text for both qRT-PCR rounds. Genes in the bottom half of the table below the 
thick dividing line were carried over from the original analysis. Genes not tested in the second round are 
denoted with ‘-‘ in those columns. 
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Four genes (wdfy1, Nrxn1, Nrxn3 and Egr4) from the post outlier removal data set 
validated robustly through both rounds of analysis. Rapgef5 failed to meet the fold-
change cut-off in the second round of qRT-PCR, even though it gave a significant p-
value in statistical testing. Of the genes carried forward from the pre-outlier removal list, 




5.2.2 Validation of the Q31L drug naïve adult micro array 
Only two genes were selected from the Q31L drug naïve rray for validation by qRT-
PCR. Wdfy1 and Ndn were both up-regulated in the Q31L adult compared to C57BL/6J 
wild-type controls. Differential expression of both genes was validated in the first qRT-
PCR analysis, however both failed to replicate when t sted in a second batch of 
independent RNAs using wild-type littermates as controls (table 5.2). 
 
 
Table 5.2: Table of genes differentially expressed in the Q31L drug naïve adult that were tested by 
qRT-PCR. Column 1 gives gene name, column 2 and 3 the array fold-change and p-value to be validated, 
columns 4 and 5 the first round qRT-PCR fold-change, and p-value for Mann-Whitney U test. Columns 6 
and 7 give these values for the second round of qRT-PCR on independent RNA samples. Significant p-
values are denoted in red text for both qRT-PCR rounds.  
 
A further three genes that showed correction with drug treatment were also tested in the 
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5.2.3 Validation of the L100P and Q31L embryonic mi croarray 
Seven genes were analysed using qRT-PCR for the embryonic array samples. Three of 
these genes, Pde4d, Coro1b and Numb were differentially expressed in both the L100P 
and Q31L embryonic samples in the array analysis (table 5.3).  
 
 
Table 5.3: Table of genes differentially expressed in the L100P and Q31L embryo that were tested by 
qRT-PCR. Column 1 gives gene name, column 2 comparison, column 3 and 4 the array fold-change and p-
value to be validated, columns 5 and 6 the first round qRT-PCR fold-change and p-value for Mann-
Whitney U test. Columns 7 and 8give these values for the second round of qRT-PCR on independent RNA 
samples. Significant p-values are denoted in red text for both RT-qPCR rounds. Genes not tested in the 
second round are denoted with ‘-‘ in the appropriate columns. 
 
Of the seven genes tested, four met the criteria fo significant differential expression in 
qRT-PCR analysis of the RNA that was hybridised to the array. Prm3 and Cdh11 also 
validated in the second round of analysis in the L100P embryonic samples. Pde4d 
validated in the first batch in the L100P embryo but failed to replicate in the independent 
sample, and did not validate in the Q31L embryonic samples at either stage of analysis. 
Coro1b and Numb unfortunately gave significant results in the opposite direction to those 
previously reported in the microarray analysis in both the L100P and Q31L embryonic 
samples. This negated them from further analysis at this stage. 
 
 
5.2.4 Validation of the L100P and Q31L drug treatme nt microarray 
As previously mentioned, there were a number of genes that were differentially expressed 
in the adult samples that showed correction of exprssion under drug treatment 
conditions. Correction of expression was defined as ifferential gene expression (FC +/- 
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1.3, p<0.05) in the drug treated group when compared to the homozygous mutant, but not 
when compared to the wild-type control. Of these, eight genes were corrected in the 
L100P Rolipram treated group and three in the Q31L Bupropion treated group. One gene 
corrected by Rolipram treatment was also corrected by Clozapine treatment according to 
the microarray result, although this did not validate by qRT-PCR. These genes were not 
tested as part of the L100P adult analysis as in some cases they were slightly below the 
fold-change cut-off, although became interesting for analysis when compared to the drug 
treated individuals. These eleven genes were analysed by qRT-PCR (Table 5.4) in both 
treatment groups (drug naïve vs wild-type control, and drug naïve vs drug treated) 
through two rounds where the first batch were consistent with the microarray data. 
 
 
Table 5.4: Table of genes differentially expressed in the L100P and Q31L drug treated adults that 
were tested by qRT-PCR. Column 1 gives gene name, column 2 comparison, column 3 and 4 the array 
fold-change and p-value to be validated, columns 5 and 6 the first round RT-qPCR fold-change, and p-
value for Mann-Whitney U test. Columns 7 and 8 give th se values for the second round of qRT-PCR on 
independent RNA samples. Significant p-values are denoted in red text for both qRT-PCR rounds. Genes 
not tested in the second round are denoted with ‘-‘ in the appropriate columns. 
 
Ranbp9, Pop4, 1500015O10RIK and Syn1 gave results in the opposite direction to the 
array negating them from further study. More concering was the result from Bex2 and 
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Gpr88, which replicated in the first round analysis but gave significant fold-changes in 
the opposite direction in the second round. As this was the same platform, probe 
incompatibility can be ruled out in these cases suggesting there was another factor 
involved. qRT-PCR was repeated for both these genes in the second batch of samples to 
check for experimental error and the result was found to be the same in both cases. 
 
Pak3 gave a consistent result, with higher p-values and lower fold change in the L100P 
drug naïve comparison across both rounds of testing. Mast3, Atp5b, Ndfip and Dusp1 
only replicated in the L100P drug naïve vs L100P Rolipram treated in the batch 2 
analysis. To determine if this change in expression was due to genotype or drug treatment 
I drug treated eight C57BL/6J adult mice and ran the qRT-PCR analysis of these four 




Table 5.5: Table of genes differentially expressed in the C57BL/6J drug treated adults that were 
tested by qRT-PCR. Column 1 gives gene name, column 2 comparison, columns 3 and 4 the second round 
qRT-PCR fold-change, and p-value for Mann-Whitney U test from the L100P drug naïve vs L100P 
Rolipram treatment. Columns 5 and 6 give these values for the second round of qRT-PCR on independent 
RNA samples from C57BL/6J mice treated with the same rolipram dose compared to drug naïve C57BL/6J 
mice. Significant p-values are denoted in red text for both qRT-PCR rounds.  
 
Mast3 did not show significant differential expression in the C57BL/6J drug treated mice 
suggesting a possible effect of genotype on drug action. Atp5b, Ndfip and Dusp1 all gave 
significant results in the C57BL/6J Rolipram treated group which would suggest that the 
results seen in the L100P Rolipram treated mice were more a factor of drug treatment 
than genotype. However, the Atp5b differential expression in the C57BL/6J comparison 
is in the opposite direction to the L100P comparison, which may suggest some effect of 
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Of the 40 genes tested by qRT-PCR only seven gave robust and reliable results through 
both rounds of validation. Of these, four were from the L100P drug naïve adult group 
(Wdfy1, Nrxn1, Nrxn3 and Egr4), two from the L100P embryonic group (Cdh11, Prm3) 
and one from the L100P Rolipram treated group which showed correction (Pak3). One 
(Rapgef5) gave p-value<0.05 but did not reach the 1.3 fold-change cut-off implemented 
in earlier analysis. Of the five genes carried over from the pre-outlier removal gene list, 
two validated through both rounds of RT-qPCR with sgnificant fold-change and p-value 
to meet the criteria imposed. While microarrays are powerful molecular biological tools, 
they have technical aspects which can produce results that erroneously under or over-
represent specific genes. False negativity can result from low expression levels, 
inefficient priming of specific mRNAs resulting in transcript drop out, poor adhesion of 
DNA to the slide, and splice variants with sequences not included on the array. 
Conversely, sources of false positivity include repetitive nucleotide elements, sequence 
homology between functionally different transcripts and high background levels due to 
nonspecific binding of nucleotides [248]. This not only justifies the need to validate 
results through other platforms, but may help to explain why two genes that were not 
seen to be differentially expressed on the array pltform post outlier removal, may be 
seen to be differentially expressed on the qRT-PCR platform.  
 
The neurexin family of proteins function as cell adhesion molecules and receptors. 
Neurexins 1-3 utilize two alternate promoters and include numerous alternatively spliced 
exons to generate thousands of distinct mRNA transcript  and protein isoforms. The 
majority of transcripts are produced from the upstream promoter and encode alpha-
neurexin isoforms; a much smaller number of transcripts are produced from the 
downstream promoter and encode beta-neurexin isoforms. The numerous isoforms of 
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Neurexin 1 (NRXN1) i sinvolved in maintenance of synaptic junctions and mediate 
intracellular signalling[249]. By making heterophillic connections with neuroligands it 
leads to maturation and differentiation of GABAergic and glutamatergic synapses 
through bi-directional signalling [250]. NRXN1 was implicated by Walsh et al (2008) 
[217] in an analysis of copy number variants in schizophrenia. Other studies on copy 
number variants have also implicated NRXN1 in schizophrenia pathology. Need t al 
(2009) [251] found deletions in the 3’ end of NRXN1 in patients with schizophrenia, but 
not in control groups.  Data from Vrijenhoek t al (2008) [252] suggest that CNVs that 
affect the first few exons of NRXN1 confer greater risk of major mental illness, while that 
from Rujescu et al (2009) [253] implies that deletions that affect exons directly increase 
susceptibility. In addition, a missense mutation in exon 1 of human NRXN1 has also been 
linked to autism [254]. Neurexin 3 (NRXN3) is a membrane protein involved in cell 
adhesion, synaptic transmission and neurotransmitter secretion [249]. SNPs in NRXN3 
have been associated with alcohol and nicotine dependence and linked with opiate 
dependence [255, 256].  
 
The Early Growth Response Factors (EGRs) 2, 3 and 4 are synaptic activity inducible 
immediate early genes and all show nominal associati n with schizophrenia in a Japanese 
population. They activate transcription of genes required for mitogenesis and 
differentiation. EGR1, 2 and 3 are downregulated in the prefrontal cortex of brains from 
patients with schizophrenia [238] , EGR4 expression was too low to measure 
disregulation. Treatment with the atypical antipsychotic and antidepressant Aripiprazole 
increases expression of Egr4 in rat frontal cortex[257].  
 
Little is known about the function of WD repeat and FYVE domain-containing protein 1 
(WDFY1 or FENS1) but it is known to be ribosomal and has been associated with alcohol 
consumption and preference [258]. Primary functional a alysis identifies Wdfy1 as being 
involved in endosome trafficking [259]. 
 
Eight genes from the initial analysis showed correction of the L100P non-drug treated 
disregulation. Only one of these validated through qRT-PCR. Serine/threonine-protein 
Chapter 5 179 
kinase 3 (PAK3), is involved in the Erb signalling pathway, axon guidance and focal 
adhesion. PAK proteins form an activated complex with GTP-bound RAS-like (P21), 
CDC2 and RAC1 proteins which then catalyzes a variety of targets. It is thought this 
protein may be necessary for dendritic development and for the rapid cytoskeletal 
reorganization in dendritic spines associated with synaptic plasticity. Mutations in PAK3 
have been associated with X-linked nonsyndromic mental retardation [260-262] and 
suppression of PAK3 results in formation of abnormally elongated dendritic spines and a 
reduction of mature synapses [263]. These elongated spines fail to express post-synaptic 
densities or contact presynaptic terminals resulting in reduced spontaneous activity and 
defective LTP. Pak3 knockout mice have deficiencies in learning and memory and 
abnormalities in synaptic plasticity along with a reduction of transcription factor cAMP-
responsive element-binding protein (CREB) suggesting a novel signalling mechanism 
with PAK3 and Rho signalling regulating synaptic function and cognition [264]. PAK 
genes also interact with the known Disc1 interactor Kalirin-7 which is thought to control 
multiple aspects of spinal plasticity [265]. 
 
Cadherin 11 (Cdh11) is a type 2 classical cadherin involved in mediation of calcium 
dependant cell adhesion. Type II (atypical) cadherins are defined based on their lack of a 
HAV cell adhesion recognition sequence, that is specific to type I cadherins. It comprises 
of a large N-terminal domain (extracellular), a single membrane spanning domain, and a 
small intracellular C-terminal domain. It was first discovered in rodent brain samples 
[266] with high expression in the developing olfactory system at E13-E17 [267] and has 
since been linked to multiple cancer types [268, 269]. 
 
The remaining three genes that have validated in the rolipram treated L100P adults but 
have not validated in the L100P adult are Atp5b, Ndfip and Dusp1. Two of these genes 
(Atp5b and Dusp1) are involved in phosphate metabolism and were classed as over-
enriched in the sample set by GOtree analysis. Thiscould be interesting on two counts; 
the action of Rolipram may target phosphate metabolism genes, which may or may not be 
significant in schizophrenia. Or phosphate metabolism is a key pathway in schizophrenia. 
When the list of genes differentially expressed in only the L100P adult group was run 
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through Gotree analysis the only over enriched genes w re involved in synaptic 
plasticity, not phosphate metabolism, suggesting this is more a function of the drug 
treatment than the mouse phenotype. To confirm this I te ted these genes in a C57BL6 
drug naïve group vs C57BL6 rolipram treated group as this would allow me to determine 
if the effect was due to the drug treatment or the mutation. Dusp1 was significantly up 
regulated in the C57BL6 rolipram treated group compared to the drug naïve group, as it 
had been in the L100P rolipram treated group compared to the L100P drug naïve group. 
Ndfip also behaved in the same way in the C57BL6 rolipram treated group as it had in the 
L100P drug treated group, being significantly down regulated compared to the drug naïve 
control. Atp5b was significantly down regulated in the C57BL6 rolipram treated group 
where it had been up regulated in the L100P rolipram treated group, but a significant 
difference in expression was observed suggesting it is an effect of the drug treatment as 
opposed to the mutation. As the changes in expression in these three genes appear to be 
an effect of the rolipram treatment rather than the mutation I feel they do not fit the 
criteria for further analysis within this project. 
 
Finally Sortilin (Sort1) and Shank3 which were carried over from the original gene list, 
validated in the second sample set. Sortilin (alias neurotensin receptor 3) has been 
implicated in the modulation of dopamine signals [270] and was found to be 
downregulated in a Scottish family with a history of bipolar disorder (Christoforou et al, 
manuscript in preparation). Shank3 is a structural post-synaptic density protein which has 
previously been implicated in mental retardation [271]. Mutation of a single Shank3 
allele has also been found in Autism spectrum disorers [272]. 
 
As described previously, some genes tested had fold-changes in opposite directions 
across the two platforms. This has been documented previously [246] and is thought to be 
due to the platform probes amplifying different isoforms of the gene in question. While 
every effort was made to ensure overlap of the two probes, a perfect match could not be 
ascertained. In all cases both probes were mapped to the same exon but as the sequences 
of the qRT-PCR probes are not made available identical sequence alignment could not be 
achieved. A more concerning observation was that Bex2 and Gpr88, both genes that 
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displayed correction through drug treatment, gave opposite fold-change directions 
between sample batches. As both batches were run on the same platform, this cannot be 
attributed to probe amplification discrepancy. Differences in the wild-type expression 
could be due to minor genetic differences between th  C57BL/6J and the L100P wild-
type. Although the L100P animals had been backcrossed for over 10 generations it is 
unlikely, but not impossible, that there were still some genetic differences.  
 
The difference in the drug treated groups is more difficult to explain. It could be 
speculated that differences in environmental conditions (such as feed, housing etc) can 
affect the effect of pharmacologicals. As the batches of RNA were collected from 
animals bred in different facilities (though of the same background strain) this may 
account for the differences seen here. Also, the anim ls used in the first batch underwent 
behavioural testing just prior to being culled. It may be that this would have an effect on 
gene expression and thus drug efficacy. 
 
Additional research would ideally focus on testing the other dysregulated genes present 
from the microarray study, which was outwith the scope of this project. As Disc1 has 
been shown to be developmentally regulated [134], establishing a developmental profile 
for both the Disc1 mutant, and the genes dysregulated by the mutation, w uld be an 
advantageous addition to the current data and is describ d in chapter 6. Protein analysis 
of those genes that showed robust disregulation is a logical next step for this project and 
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6. Establishing a developmental profile for the gen es of interest in L100P 
mutant mice and wild type controls 
Since the 1940’s and 50’s scientists have considered th  possibility that schizophrenia 
could be a developmental disease. In 1986 Weinberger proposed the developmental 
hypothesis of schizophrenia which suggested that smll neurodevelopmental deficits in 
key circuits could lie dormant until puberty, when normal molecular changes could 
facilitate the onset of disease in affected individuals [189]. With this in mind I decided to 
establish a developmental profile of each of the validated genes of interest in the L100P 
mouse model. As Disc1 has been shown to be developmntally regulated [134] the aim 
was to determine if a mutation to Disc1 would alter the developmental profile and/or the 
genes found to be dysregulated in the mutants by the microarray analysis. 
 
 
6.1 The Disc1 developmental profile  
While collecting samples for the Disc1 microarray I had also collected a developmental 
profile panel from both the L100P and Q31L mice, to determine whether Disc1 
expression was altered during development. A Disc1 developmental profile was 
previously published by Shurov et al (2004) [134] describing peaks in Disc1 protein 
expression at E13 and P35, corresponding to periods of neurogenesis in the developing 
whole brain and puberty in the adult mouse . The study used cortex from the adult mouse 
and whole brain from mouse embryos to determine protein expression through western 
blotting. However, Shurov et al did not specify the mouse strain used in their study. As 
each inbred strain is genetically different, I decid to establish a developmental profile 
for both ENU lines and wild-type counterparts to be used in this study, to determine 
whether the mutations affected the expression of Disc1 through development. 
 
Mice were taken at eight stages throughout development from both ENU mutant lines, 
their wild-type littermates and C57BL/6J animals which were used as controls in the 
microarray experiment. Whole brain was used for embryonic samples and hippocampus 
from mature mice matching the stages used in the array experiment. There were six mice 
at each stage, for each line, giving a total of 240samples to be run in triplicate. I used a 
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“pan” Disc1 probe, designed to hybridise at exons 4 and 5, thus covering all Disc1 
isoforms bar one (the extreme short isoform Es: contains an alternatively spliced DISC1 
exon 1a and terminates transcription two intronic codons after exon 3) to establish a 
developmental profile in these animals  (Figure 6.1). 
 
 
Figure 6.1 Developmental Profile of Disc1 in the mouse brain. Graph A shows the expression profile of 
Disc1 in the brain of L100P wild type littermates, L100P mutant and C57BL/6J mouse lines through 8 
stages of development. Graph B show the expression pr file of Disc1 in the brain of Q31L wild type 
littermates, Q31L mutant and C57BL/6J mouse lines through 8 stages of development.  
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I performed a one-way analysis of variance with a post-hoc Tuckey test to determine 
where the strains differed significantly in Disc1 expression across the panel tested. There 
was a significant difference across the whole dataset (F=41.65, df=34, p<0.0001) with 
within stage significant differences arising at E15, E18 and P1.  
 
With regard to Disc1 expression, the homozygous L100P mutant is significantly different 
from the L100P wild type littermate and the C57BL/6J (p<0.001) at E13. At E18, the 
L100P mutant and the L100P wild-type are not signifcantly different than each other, but 
are significantly different (p<0.001) to the C57BL/6J. At P1, the L100P mutant has 
significantly higher expression than both the C57BL/6J and the L100P wild-type 
controls. As reported previously (Clapcote et al 2007) [197], there was no difference in 
Disc1 expression levels in the adult mouse.  
 
The homozygous Q31L mutant has significantly higher Disc1 expression (p<0.001) than 
the C57BL/6J animals. At E18, the Q31L wild-type differs significantly from the Q31L 
homozygous mutant and the C57BL/6J (p<0.05). Perhaps the greatest difference was 
observed at P1, where the C57BL6 mouse is significatly different to all other groups 
(p<0.001) and the Q31L animals have significantly higher expression than their wild-type 
controls. 
 
It can be speculated that the different developmental expression patterns of the Q31L and 
L100P mutant may contribute to the different phenotypes observed in behavioural testing. 
This result gives rise to two important questions; what neurobiological processes are 
occurring at these stages where Disc1 expression is altered and was the C57BL6 a 
suitable control animal for the microarray experiment given the results? 
 
A review of the literature on mouse developmental st ges gave very few results but one 
review article can shed some light on the processes involved at stages E15-P1 where the 
Disc1 expression differences have been observed. Matsuki et al (2005) [223] carried out a 
microarray experiment to determine which clusters of genes were most highly expressed 
at stages E12, E15, E18 and P1. Their data suggests that, based on genes with known 
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neural functions, the functional gene clusters most highly expressed at E15 are involved 
in neural determination and differentiation, and at E18 and P1 are involved in synapse 
formation and function, and  survival and growth. Based on all genes differentially 
expressed at E18 and P1 the top functions are intra/inter cellular molecular transport, and 
signal transduction.  
 
From the results obtained from the developmental panel I would suggest that the 
C57BL/6J mouse was an adequate control at the stages (E13 and adult) used in this study 
as their expression of Disc1 did not differ significantly from the wild-type littermates at 
these stages. However, the results suggest that either the ENU lines were not suitably 
backcrossed for the C57BL/6J to be an ideal control, or there was another mutation 
present in the ENU mice which was retained throughot the backcrosses in the ‘wild-
type’ control animals. For this reason the remainder of the developmental panels were run 
with both ‘control’ groups for reference, although only the L100P wild-type animals 




6.2 Establishing developmental profiles for the gen es of interest 
As all genes that were successfully validated came from the L100P comparisons, the 
genes were only tested in the L100P developmental panel. Due to constraints on time and 
finances I pooled the samples at each developmental stage resulting in a total of 24 
samples to be run in triplicate, compared to 144 if left unpooled.  
 
 
6.2.1 The Disc1 developmental profile on pooled sam ples 
As I had pooled the samples for subsequent gene panls I decided to run the Disc1 panel 
on pooled samples to check it was comparable to the previous result. Figure 6.2 shows 
the pooled samples compared to unpooled samples acro s all stages. 
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While absolute expression values in the pooled and unpooled samples were not identical, 
the trend of expression was the same and there was no statistically significant difference 
between the datasets (p>0.05) suggesting little effct of pooling. As a new dilution of 
calibrator DNA was used for the pooled samples, the absolute expression values are 
graphed as normalized to both calibrator samples. These data indicate that pooled 
samples should give comparable data to the individual samples for subsequent 
developmental panels. 
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Figure 6.3: Developmental profile of Disc1 in the L100P mutant mouse. Graph shows the comparable 
Disc1 developmental profiles in the brains of pools from the L100P wild type and L100P mutant mouse. 
There is a notable time shift in peak expression in the L100P mutant mouse. 
 
When comparing the L100P mutant and wild-type littermates over the developmental 
panel, what is perhaps most evident, is the appearance of a shift in the peak of Disc1 
expression during development. The L100P wild type expression values peak at E18 and 
the drop to level out after birth. The L100P mutant however does not show a peak in 
expression until P1, with a shallower decline to adulthood, with the two lines converging 
by P20. This delay in the L100P mutant mouse could have detrimental effects on 
neurodevelopment in the mutant animals. Personal observations and those of other 
researchers working with these animals show that the mutant individuals are physically 
smaller when born, which could signify a delayed development (Clapcote t al. personal 
communication). While the result of one gene expression profile is not enough to 
stipulate cause and affect it is worth noting that low birth weights have previously been 
associated with schizophrenia [273] and a latent shift in the expression of key 
developmental proteins could be a factor in this. Hikida et al [193] also note that there is 
a 3month delay in neuronal migration in a Disc1 mouse model, which could potentially 
be attributed to a change in Disc1 expression during development. While this chapter will 
only describe the developmental profile results of genes of interest from the microarray 
study I believe this altered Disc1 expression during development is worthy of further 
investigation in the future. 
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6.2.2 Developmental Profile for Egr4 
As mentioned in chapter 5,Egr4 was the gene with the largest fold change in the sample 
set and a good gene for further analysis due to its nominal association with schizophrenia 
in a Japanese association study [238].  
 
As with the pooled Disc1 panel, the Egr4 probe was run against a pooled DNA panel 
across seven developmental stages from E13 to adult(figure 6.4). The Disc1 panel is 
being shown for comparison. 
 
 
Figure 6.4: Developmental profile of EGR4 in cDNA pools from the L100P mutant mouse. Graph A 
shows the developmental expression patterns of Disc1 in the brain of both the L100P wild-type and L100P 
mutant mouse. Graph B.1 shows the developmental expression pattern of EGR4 in the brain of the L100P 
wild-type, L100P mutant and C57BL/6J mouse as a bar ch t and B.2 as a line graph. In all cases the X axis 
shows the developmental stage, and the Y axis the arbitrary expression value from Taqman RT-qPCR 
analysis. 
 
The Taqman RT-qPCR analysis could not detect Egr4 in stages E13-E18. Levels of 
expression in all lines peaked at P20 with significant differences in expression between 
the L100P wild-type and L100P mutant samples at P7 (p=0.029) and P20 (p=0.0007), as 
well as the adult stage which was reported in chapter 5 (p=0.0465).  
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6.2.3 Developmental Profile for Nrxn1 and  Nrxn3  
As mentioned previously, NRXN1 is involved in mainte ance of synaptic junctions and 
is a mediator of intracellular signalling. A missen mutation in exon 1 of human NRXN1 
has been linked to autism [254] and many studies have noted CNV’s in NRXN1 and 
NRXN3 linked to schizophrenia [83, 217, 251-253]. NRXN3 is a membrane protein 
involved in cell adhesion, synaptic transmission and neurotransmitter secretion. SNPs in 
NRXN3 have been associated with alcohol and nicotine dependence and linked with 
opiate dependence [255, 256]. The developmental panel for both Nrxn1 and Nrxn3 are 
shown in Figure 6.5. 
 
 
Figure 6.5: Developmental profile of Nrxn1 and Nrxn3 in cDNA pools from the L100P mutant 
mouse. Graph A shows the developmental expression patterns of Disc1 in the brain of both the L100P 
wild-type and L100P mutant mouse. Graph B.1 show the developmental expression pattern of Nrxn1 in the 
brain of the L100P wild-type, L100P mutant and C57BL/6J mouse as a bar chart and B.2 as a line graph. 
Graph C.1 shows the developmental expression pattern of Nrxn3 in the brain of the L100P wild-type, 
L100P mutant and C57BL/6J mouse as a bar graph and C.2 as a line graph. In all cases the X axis shows 
the developmental stage, and the Y axis the arbitray expression value from Taqman RT-qPCR analysis. 
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The most obvious observation from both panels is the inverted trend of expression from 
E15 to P1 in both lines. That is, the L100P wild-type and L100P mutant show almost 
exact opposites in trend of expression at these stage . For Nrxn1 there is a peak in 
expression at E18 in the wild-type lines, while this stage represents a dip in expression in 
the mutant lines (Nrxn1 p= 0.01). Nrxn1 expression in the L100P mutant peaks at P7 with 
significantly different expression to the wild-types (p=0.029) and shows significant over-
expression in adulthood (p=0.048), confirming the previously reported result from 
chapter 5. Nrxn3 is significantly overexpressed at E15 (p=0.026), P7 (p=0.0036) and 
adulthood (p=0.04) and is significantly lower in the L100P mutants at E18 (p=0.016). 
The mutant lines show two peaks, at E15 and P7. At E15 neurogenesis occurring in the 
developing mouse brain and at P7 neurite outgrowth, myelination, synaptic pruning and 
apoptosis occur [274]. Given the later peak of Disc1 expression reported in the L100P 
mutants, and lower birth weights observed, it is posible there is a developmental delay in 
synaptogenesis in these animals but this cannot be confirmed without further 
physiological examination. As the predicted developmental function at E18 is the 
formation of synapses, the dip in expression of genes i volved in synaptic maintenance 




6.2.4 Developmental Profile of Pak3 
 As mentioned in chapter 5, Pak3 is involved in theErb signalling pathway, axon 
guidance and focal adhesion. Mutations in PAK3 have been associated with X-linked 
nonsyndromic mental retardation [260, 263]. Pak3 knockout mice have deficiencies in 
learning and memory, and abnormalities in synaptic plasticity. They also show reduction 
of transcription factor cAMP-responsive element-binding protein suggesting a novel 
signalling mechanism with PAK3 and Rho, regulating synaptic function and cognition 
[264]. PAK genes also interact with the known DISC1 interactor Kalirin-7 which is 
thought to control multiple aspects of synaptic plasticity [265]. It is also the only drug 
corrected gene which gave robust and consistent results through all stages of validation. 
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Figure 6.6: Developmental profile of Pak3 in cDNA pools from the L100P mutant mouse. Graph A 
shows the developmental expression patterns of Disc1 in the brain of both the L100P wild-type and L100P 
mutant mouse. Graph B.1 show the developmental expression pattern of PAK3 in the brain of the L100P 
wild-type, L100P mutant and C57BL/6J mouse as a bar ch t and graph B.2 as a line graph. In all cases th  
X axis shows the developmental stage, and the Y axis the arbitrary expression value from Taqman RT-
qPCR analysis. 
 
Expression of Pak3 in the L100P wild type littermate rises from E13 to E18. At E18 there 
is a significant difference between the expression levels of the L100P wild type and the 
L100P mutant (p = 0.049) as expression in the L100P mutant line starts to decline after 
E15. There is also a significant difference in exprssion between the wild-type and the 
mutants at P1 (p=0.0093). The L100P mutant peaks at E15 and falls away steadily to 
level out at P20 to adulthood. This is the only profile where the peak in expression of the 
mutants precedes that of the wild-type, although the level of the peak in the mutants is 
considerably lower than that of the wild-type, and no difference in expression value is 
observed at the E15 developmental stage. The previously reported over-expression of 
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6.2.5 Developmental Profile of Cdh11 
Cdh11 is a type II classical cadherin that mediates calcium dependant cell-cell adhesion. 
It was originally found to be differentially expressed in the embryonic samples run on the 
microarray. Enrichment of Cdh11 in future subplate neurons [275] has been linked to 
neuron extension and guidance in the developing mouse brain. 
 
 
Figure 6.7: Developmental profile of Cdh11 in cDNA pools from the L100P mutant mouse. Graph A 
shows the developmental expression patterns of Disc1 in the brain of both the L100P wild-type and L100P 
mutant mouse. Graph B.1 show the developmental expression pattern of Cdh11 in the brain of the L100P 
wild-type, L100P mutant and C57BL/6J mouse as a bar ch t and B.2 as a line graph. In all cases the X axis 
shows the developmental stage, and the Y axis the arbitrary expression value from Taqman RT-qPCR 
analysis. 
 
Throughout the developmental panel there is no significa t difference in Cdh11 
expression between the mouse lines, except at E13 as reported in chapter 5. At E13 the 
expression of Cdh11 is significantly higher (p=0.044) in the L100P mutant than in the 
wild type littermate. An increase in expression levels of Cdh11 at E13 may suggest 
excessive neurite extension in the developing brain of the L100P mutant mouse which 
would affect the positioning and effectiveness of neural connections in the developed 
animal. While the expression profile indicates enrichment at P7 this was not statistically 
significant (p=0.08).  
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6.2.6 Developmental Profile of Sort1  
Sort1 is one of the genes which was discarded after the identification of the outlier mouse 
during the microarray analysis. It did, however, validate as being dysregulated during 
Taqman RT-qPCR analysis (both pre and post outlier removal). For this reason, and 
because it was a gene of interest because it is dysregulated in a Scottish family with a 
history of mental illness, the developmental panel was run for Sort1 also (figure 6.8). 
 
 
Figure 6.8: Developmental profile of Sort1 in cDNA pools from the L100P mutant mouse. Graph A 
shows the developmental expression patterns of Disc1 in the brain of both the L100P wild-type and L100P 
mutant mouse. Graph B.1 show the developmental expression pattern of Sort1 in the brain of the L100P 
wild-type, L100P mutant and C57BL/6J mouse as a bar ch t and B.2 as a line graph. In all cases the X axis 
shows the developmental stage, and the Y axis the arbitrary expression value from Taqman RT-qPCR 
analysis. 
 
The L100P wild type showed peaks in Sort1 expression at E18 and P20 with the L100P 
mutant showing peaks at E15 and P20. Statistical analysis of the expression levels at each 
time point gave significant results at E18 (p=0.046) and adulthood (p=0.048). In both 
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6.3 Conclusions from the developmental profiles 
The developmental profile of Disc1 highlighted some key stages of development where 
expression is altered in the mutant mouse line, and also confirmed the previous result that 
expression was not significantly different at either E13 or adulthood between the L100P 
mutant and wild type controls. The disparity between the developmental profile of Disc1 
described in this chapter and that previously published by Shurov [134] highlights the 
importance of strain differences during development, and had this experiment been 
carried out prior to the microarray study it is likely a different developmental stage would 
have been chosen for the whole genome gene expression experiment. 
 
The time shift observed in the peak of Disc1 expression could signify a delay in neural 
development of the L100P mutant, although this cannot be confirmed without further 
physiological analysis. Further weight is added to this suggestion by a similar time shift 
in the peak expression of both the n urexin genes and Pak3 (summary figure 6.9).  
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Figure 6.9: Composite of the developmental profiles compared to Disc1. A and A2 are both 
the Disc1 developmental panel with B:Egr4, C:Nrxn1, D:Nrxn3, E:Pak3, F:Cdh11 and G:Sort1. 
 
 
The lack of definable expression of Egr4 in the embryonic stages is of great interest and 
has not been previously reported. Its significantly different levels of expression at P20, 
just prior to when the animal is effectively going through puberty, is also of interest due 
to the significance of pubescent molecular changes in the brain in the developmental 
hypothesis of schizophrenia [189]. If this is the case then the altered expression of the 
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other genes studied during development could be responsible for deficits in key circuitry 
which are exposed at this stage facilitating the disease phenotype, as described in 
Weinbergers developmental hypothesis [189], in the L100P mutant model. It is my 
opinion that these findings warrant further investiga ion into the developmental process 
of the schizophrenia-like phenotype in this mouse model, which may shed light on the 
development of the human disease. 
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7. Preliminary protein analysis of validated genes in L100P drug naïve adult 
mouse samples 
In this chapter I will present the results from semi-quantitative western blotting and 
immunocytochemistry for five of the genes validated hrough qRT-PCR in the L100P 
adult mouse mutant. Wdfy1 and Cdh11 were not tested at the protein level as suitable 
antibodies were not available. 
 
Validation of the changes at the protein level allows the investigation of alterations in 
isoform production and assessment of possible alterations in expression patterns. The 
data described here is not a full analysis but rather a first step in protein analysis for the 
genes identified in the array. 
 
 
7.1 Protein analysis of Egr4 
Egr4 had previously validated in an independent RNA sample set with a fold-change of -
2.89 and a p-value of 0.013. Protein extracted from the same animals used to collect the 
independent RNA sample was used for western blotting. Hippocampal neurons cultured 
from a third batch of adult mice were used for immunocytochemistry after 21 days in 
culture (figure 7.1). Egr4 is expressed as a 50 kDaprotein. Three replicates of each 
western blot was carried out and the results quantified using the Image J programme, 
which takes a scanned image of the blot and measures the intensity of each band. Two 
replicates and the quantification analysis were carried out by myself, and one replicate by 
Susan Anderson. 
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Figure 6.1: Western blotting and ICC for EGR4 in L100P ENU mutant mice. Panel A shows a 
representative western blot for Egr4 with the Gapdh membrane used for correction of loading differences 
below. Panel B shows the semi-quantative analysis of the blot using image J and a standard student t-test 
(p<0.01). Panel C shows the confocal microscope image of wild-type primary cultured hippocampal 
neurons (day 21) stained for Egr4 (green) and co-stained for β-actin (red). Panel D shows the mutant 
primary cultured hippocampal neurons stained for Egr4 ( reen) and co-stained for β-actin (red). 
 
As can been seen from the figure, the disregulation of Egr4 previously described at the 
RNA level is maintained at the protein level. There appears to be no overall change in 
expression patterns of Egr4 in the cultured neuron between wild-type and mutant 
animals. In both cases there are few disperse puncta on he dendrites, with the majority of 
Egr4 expression contained within the soma. Disc1 has been shown to be expressed in 
similar puncta in the dendritic shaft with localisat on to the ribosomes and microtubule 
structures in the soma [276]. It can be speculated that Egr4 has a similar, although not 
identical, expression pattern to Disc1 in the neuron, although further staining of specific 
cell components would be required to confirm this. Quantitative analysis of the neuron 
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cultures was not carried out so small changes not obvious to the naked eye cannot be 
ruled out, but this would require further analysis, which will be discussed later. 
 
 
7.2 Protein analysis of Pak3 
The mental retardation gene Pak3 was found to be differentially expressed in the L100P 
drug naïve adults in the microarray analysis, and was corrected to a level not significantly 
different to wild type when the animals were treated with the PDE4 inhibitor rolipram. 
This differential expression was confirmed in two sample batches by qRT-PCR. Pak3 is 
expressed as a 75kDa protein (figure 7.2). Again, one f the western blot replicates was 
carried out by Susan Anderson. 
 
Figure 6.2: Western blotting and ICC for Pak3 in L100P ENU mutant mice. Panel A shows a 
representative western blot for Pak3 with Gapdh membrane used for correction below. Panel B shows the 
semi-quantative analysis of the blot using image J and a standard student t-test (p<0.05). Panel C shows the 
confocal microscope image of wild-type primary cultured neurons stained for Pak3 (green) and co-stained 
for β-actin (red). Panel D shows the mutant primary cultured neurons stained for Psk3 (green) and co-
stained for β-actin (red). 
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There is a small but significant upregulation of expression at the protein level in the 
L100P drug naïve adult mouse compared to wild-type litt rmates that is corrected by 
treatment with rolipram (p<0.05). This correlates well with the results obtained from the 
gene expression analysis. No global changes in protein localisation are observed from 
ICC of primary cultured hippocampal neurons, but as the protocol used is not quantitative 
this cannot be accurately defined without further analysis. Initial observations suggest 
there may be slightly more puncta in the dendrites of the mutant animal, but further 
analysis and staining would be required to confirm this. The overall expression pattern of 
Pak3 in the hippocampal neuron is similar to that of Egr4. Further work is again required 




7.3 Protein analysis of NRXN1 
Nrxn1 has previously been identified as a schizophrenia candidate gene [83, 251-253] 
and was found to be upregulated in the L100P drug naïve adult mouse, in both the array 
experiment and subsequent qRT-PCR analysis. Protein which had been extracted from 
the hippocampus of animals used for batch two of the qRT-PCR was used to determine 
differences in expression at the protein level (figure 7.3). Nrxn1 is expressed as multiple 
isoforms due to alternate exon splicing. The two classes of isoform are determined by 
splice site and size. Large, or alpha, isoforms are the most common of the two. The most 
widely expressed Nrxn1 isoform is around 150kDa andthe antibody used in this study 
was designed to primarily detect this isoform, although it would also detect other large 
isoforms of Nrxn1. One replicate was carried out by Rosie Walker and the rest by myself. 
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Figure 7.3: Western blotting and ICC for Nrxn1 in L100P ENU mutant mice. Panel A shows a 
representative western blot for Nrxn1 with Gapdh membrane used for correction below. Panel B shows the 
semi-quantative analysis of the blot using image J and a standard student t-test (p>0.05). Panel C shows the 
confocal microscope image of wild-type primary cultured hippocampal neurons stained for Nrxn1(red) and 
co-stained for β-actin (blue). Panel D shows the mutant primary cultured hippocampal neurons stained for 
Nrxn1(red) and co-stained for β-actin (blue). 
 
The trend of expression of Nrxn1 protein between the L100P drug naïve adult mouse and 
the wild-type littermate is in the opposite direction to that observed in both the array and 
qRT-PCR analysis, however no significant difference was observed (p>0.05). 
Additionally, the datasheet for the antibody used stated the band size as 150kDa and not 
the 75kDa observed. After consulting the technical te m at Abcam who supplied the 
antibody, they have stated the 75kDa band is a Nrxn1 isoform, but have removed the 
mouse from their ‘tested in’ species. In the future this experiment should be repeated with 
a better characterised antibody. This will be discus ed further in section 7.6. Again no 
global changes in protein localisation are observed from ICC of primary cultured 
neurones but as the protocol used is not quantitative this cannot be accurately defined 
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without further analysis. The pattern of expression suggests endoplasmic reticulum 





7.4 Protein analysis of Nrxn3 
Nrxn3 is involved in synaptic transmission and neurotransmitter secretion, and has 
previously been associated with alcohol and nicotine dependence [255]. It was found to 
be upregulated in the L100P drug naïve adult mouse, in both the array experiment and 
subsequent qRT-PCR analysis. Protein which had beenextracted from the hippocampus 
of animals used for batch two of the qRT-PCR was used to determine differences in 
expression at the protein level (figure 7.4). Like Nrxn1, Nrxn3 also has multiple isoforms 
due to alternate splicing. The antibody used was design d to detect alpha isoforms of 
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Figure 7.4: Western blotting and ICC for NRXN3 in L100P ENU mutant mice. Panel A shows a 
representative western blot for Nrxn3 with GAPDH membrane used for correction below. Panel B shows 
the semi-quantative analysis of the blot using image J and a standard student t-test (p>0.05). Panel C shows 
the confocal microscope image of wild-type primary cultured hippocampal neurons stained for Nrxn3 
(green) and co-stained for β-actin (red). Panel D shows the mutant primary cultured neurons hippocampal 
stained for Nrxn3 (green) and co-stained for β-actin (red). 
 
While the trend of expression is consistent with the array and qRT-PCR analysis, no 
significant difference was observed at the protein l vel between the L100P drug naïve 
adult mouse and the wild-type littermate (p>0.05). The blot was considered rather dirty 
and it was difficult to obtain a clear result from this antibody. Another Nrxn3 antibody 
was tested but the result was even more ambiguous and this was considered the better of 
the two for analysis, however, these results should be viewed as preliminary. Again no 
global changes in protein localisation are observed from ICC of primary cultured 
neurones but as the protocol used is not quantitative this cannot be accurately defined 
without further analysis. 
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7.5 Protein analysis of Sort1 
Sort1 (neurotensin receptor 3) has previously been found to be down-regulated in 
sufferers of bipolar disorder (Christoforou et al, manuscript in preparation) and has been 
implicated in the modulation of dopamine signalling [270]. It was found to be down-
regulated in the L100P drug naïve adult mouse pre outlier removal, and remained 
significant by qRT-PCR analysis post outlier removal. Sort 1 is expressed as a 95kDa 
protein (figure 7.5). One replicate was performed by Susan Anderson. 
 
 
Figure 7.5: Western blotting and ICC for Sort1 in L100P ENU mutant mice. Panel A shows a 
representative western blot for Sort1 with gapdh membrane used for correction below. Panel B shows the 
semi-quantative analysis of the blot using image J and a standard student t-test (p<0.01). Panel C shows the 
confocal microscope image of wild-type primary cultured hippocampal neurons stained for Sort1(green) 
and co-stained for β-actin (red). Panel D shows the mutant primary cultured hippocampal neurons stained 
for Sort1(green) and co-stained for β-actin (red). 
 
There is a significant difference at the protein leve  between the L100P drug naïve adult 
mouse and the wild-type littermate (p<0.01). Images obtained from the ICC of Sort1 
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appeared blurry with bleaching of the Sort1 signal and the Actin signal. This occurred in 
every image taken and was consistent between wild-type and mutant, suggestive of an 
incompatibility between the two antibodies. Again no global changes in protein 
localisation are observed from ICC of primary cultured neurones but as the protocol used 





While identification of dysregulated genes gives inight into the mechanisms of mental 
illness, correlation at the protein level signifies a lack of cellular correction mechanisms 
allowing consequential effects of the gene disregulation at the cellular level.  In a review 
by Chuaqui et al (2002) [277]they state that a correlation between changes at the mRNA 
level and the protein level are accurate less than 50% of the time. This is due to post-
translational modifications of the proteins, and cellular feedback mechanisms which 
maintain proteins at optimal levels for cellular function and development. 
 
This study has identified three genes that are significa tly differentially expressed at both 
the gene and protein level; Egr4, Pak3 and Sort1. These three genes have all been 
previously implicated in major mental illness. Both Nrxn1 and Nrxn3 failed to replicate 
their differential expression at the protein level. This could be due to the mechanisms 
mentioned previously, however there were also problems involved with the NRXN 
antibodies used which could account for the lack of change observed. NRXN1 is present 
in multiple isoforms and non-specific binding could account for the problems 
encountered with this antibody. As mentioned in section 7.3, the NRXN1 antibody did 
not give a band corresponding to that suggested on the manufacturers’ datasheet. 
Consultation with the Abcam technical team revealed th  antibody had not been tested in 
this species, and it could not be guaranteed that this was specific binding. A clear result 
could not be consistently obtained for the NRXN3 antibody. There are multiple isoforms 
of both NRXN1 and NRXN3 that could potentially bind the antibodies used and 
obtaining reliable results proved problematic. 
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Protein concentration was measured for all samples rior to loading using the Thermo 
Scientific NanoDrop 100 spectrophotometer. Despite loading what was believed to be the 
same amount of protein (after quantification and required dilutions) in each well, the 
GAPDH loading control did not give the same intensity band for each well. There was no 
consistency in the direction of difference (ie the mutant animals were not consistantly 
higher than the wild-type with regards to protein con entration) nor was the position on 
the gel a factor. It is likely that these inconsistencies were due to errors with the initial 
quantification or inaccurate pipetting when loading the gel. It would be advisable to test 
the calibration of the NanoDrop for protein quantification by running samples on both the 
NanoDrop platform and a Bradford or a Lowry assay to check for inconsistencies. Due to 
these loading inconsistencies there was a greater margin for error when correcting the 
band intensity for overall protein concentration by densitometry. The outcome of western 
blot densitometry relies highly on the equipment used at every stage. In 2009, Gassmann 
et al [278] discuss the pitfalls of current methods of densitometry and state that the same 
blots can give vastly different p-values (0.000013 to 0.76) depending on the method of 
digitization used. By comparing the densitometry results obtained from the same blot 
using a densitometry camera and a standard office scanner (as used in this experiment) 
they concluded that the office scanner was not a suit ble tool for digitizing the image due 
to the inability to switch off the gain control. This resulted in a short optical density range 
and saturation at the higher levels was more frequent than with the densitometry camera. 
Lack of homogeneity across the scan area also means th t the optical density of a band or 
spot on the gel is a function of its position, and shading correction that would correct this 
problem cannot be performed due to the gain control. In this experiment, the image J 
software used relied on the quality of scanner used when uploading the blot image to the 
PC, and on the blots being compared being of a similar exposure. Grassmann et al’s 
results would suggest that a different digitization technique would have resulted in very 
different results from the same blots. As such the western blots displayed here may only 
be taken as an indication of differential expression and not an absolute value. Further 
attention to quantification methods may or may not confirm the reported result and it is 
suggested this be carried out using other suggested methods. 
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A similar statement could be made for the immunocythemistry staining reported in this 
chapter. There were no observable differences between mutant and wild-type animals in 
relation to protein distribution in the neuron, however this was a very broad brush 
approach aiming to identify areas for further study. Further research should involve co-
staining the protein of interest with a synaptic marker, such as PSD-95, to determine 
effects on synapse localization. Of interest would also be co-staining with markers for 
other cellular components (such as mitochondria etc) to give a greater idea of the effect 
of the dysregulated proteins on cellular function as a whole, and their localization in 
relation to Disc1.  
 
The above results, however, provide a good grounding for further research into the 
expression of these candidate genes at the protein level, in particular the localization and 
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8.1 Summary of findings  
This thesis has described findings from genome wide expression analysis, qRT-PCR and 
protein analysis of an accepted animal model of major mental illness. I have reported the 
discovery of a number of potential candidate genes for further research. In this final 
chapter I will present a summary of the findings, how they relate to the field of mental 
illness research, and a possible direction for future work based on these findings. 
 
8.1.1 Chapter 3: Sample collection and processing o f a genome wide 
microarray analysis of the Disc1 ENU mouse mutants   
One of the primary driving forces behind this study was the identification of the L100P 
and Q31L mouse mutants, and subsequent behavioural dat classifying them as 
‘schizophrenia-like’ and ‘depressive-like’ [197]. Both of these models carry missense 
mutations in exon 2 of the Disc1 gene which disrupt Pde4 binding sites. Expression of 
Disc1 protein is not altered in either animal, however Disc1-Pde4b binding is reduced in 
both models, and activity of Pde4b is reduced by up to 50% in the Q31L model [197].  
I repeated the prepulse inhibition studies carried out by Clapcote et al (2007) [197] in an 
attempt to confirm the behavioural phenotype in the mouse model prior to genome wide 
expression analysis. The prepulse inhibition experim nts I carried out did not give 
statistically significant results, but did follow the trend previously published. However, as 
mentioned in section 3.8, there were a number of caveats associated with these 
experiments. The identification of a de novo mutation in the mutant mouse lines meant it 
was necessary to cross only homozygous animals, making the use of wild-type littermates 
as controls impossible. As the mutation was on a C57BL6 background, this strain was 
used as a wild-type control. Studies of PPI in rodents have been going on for many years 
as researchers attempt to find the genetic basis for uch behaviours. In 1997, Paylor and 
Crawley studied the differences in PPI in commercially vailable inbred mouse strains. 
Interestingly, the C57BL/6J mice gave the lowest PPI of all the mice they tested[232].  
The PPI of the C57BL6 mice used in this study was not statistically different to the 
Chapter 8 212 
results obtained by Paylor and Crawley, but was significantly lower than Clapcote t al’s 
wild-type controls. The result obtained for the mutant mouse lines are not significantly 
different to those obtained by Clapcote et al (2007) in the mutant lines, suggesting that, at 
least for the behavioural study, the C57BL6 mice are a less than ideal control animal. It 
was concluded that, due to the similarity between the levels of PPI I observed and those 
obtained by Clapcote et al (2007) [197], that the PPI deficit in the mutant lines was a true 
result and the behavioural phenotype was present in the mice. In addition to this, other 
researchers have confirmed the PPI deficit in the ENU mouse lines using wild-type 
controls (Steven Clapcote, personal communication). 
Despite the limitations, the genome wide gene expression analysis was carried with 
C57BL6 control animals out due to time pressure and because validation of differential 
expression would be carried out using wild-type littermate controls once a colony had 
been established. The microarray analysis, therefore, compared drug naive adult mutant 
mice or adult mutant mice treated with selected antipsychotic or antidepressant drugs, 
with C57BL6 or drug naïve controls. Samples were also taken from embryonic day 13, 
which had previously been shown to be a peak in Disc1 protein expression [134]. Quality 
of RNA extraction from hippocampal tissue (or whole brain from the embryonic stage) 
was tested using Agilent technology. This showed that t e RNA extracted was of 
sufficient quality and could therefore be used to lo k for differential gene expression. 
 
 
8.1.2 Chapter 4: Differential Expression Analysis o f the Disc1 ENU Mutant 
Mouse Microarray 
Analysis of the genome wide expression data initially revealed a total of 835 genes that 
were differentially expressed across the sample set. However, subsequent analysis of 
individual gene expression using statistical methods and qRT-PCR identified one outlier 
pool that gave erratic and unpredictable expression values. Re-analysis of the whole 
genome data without this pool as expected revealed  reduced set, with 368 genes 
differentially expressed across the sample set. Of these genes, 62 were over-expressed 
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and 24 under-expressed in the L100P adult samples and 19 were found in the Q31L adult 
sample set. Three genes (wdfy1, LOC674214 and 2900040C04RIK) were found to be 
differentially expressed in both the L100P and Q31L non-drug treated adult mice. 91 
genes were over-expressed and 95 genes under-expressed in the Q31L bupropion treated 
group compared to non-drug treated adults. The L100P rolipram treated mouse gave the 
most genes which showed correction under pharmacologi al influence. Of the 32 genes 
identified, seven showed correction of the L100P non-drug treated disregulation. 
Correction of expression was defined as returning that gene to a level not significantly 
different (FC+/- 1.3, p<0.05) to that of C57BL/6J controls. 45 genes were found to be 
differentially expressed in the L100P embryo and 25 genes differentially expressed in the 
Q31L embryo. Four genes were identified in both groups, Prm3, Coro1B, Numb and 
Pde4d. With the exception of bupropion treatment, the L100P comparisons all produced a 
higher yield of dysregulated genes than the Q31L comparisons. The ‘schizophrenia-like’ 
phenotype of the L100P mouse is considered the moresev re of the two, and so it could 
be expected that this would give a higher level of differential expression observed in this 
animal. Due to the high number of genes differentially expressed with bupropion 
treatment that were not correspondingly differentially expressed in the Q31L mutant 
without treatment, it was concluded that this was an effect of drug treatment and not 
related to the genotype. No differences were observed between male and female mice in 
gene expression. The small number of genes that were differentially expressed in the 
adult mutants and then corrected by drug treatment would suggest the drugs used were 
active primarily at the protein function level, and had minimal effect on gene expression.  
 
GOTree analysis revealed over-enrichment of genes involved in the following categories: 
cell-cell signaling, transmission of nerve impulses/ ynaptic transmission. No 
overenrichment of gene categories was observed in any other group tested, possibly due 
to the small number of differentially expressed genes. Previous studies have identified 
clusters of genes involved in neural function [199] synaptogenesis and sensory perception 
[128] in schizophrenia. From the GOTree analysis, Egr2 and Egr3, which have 
previously been associated with schizophrenia in a Japanese population, [238] were both 
significantly down-regulated in the L100P adult sample, and are involved in cell 
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signaling and transmission of nerve impulses. The excitatory glutamate receptor 2 
(Gria2) was overexpressed in the L100P adult and is involved in cell signaling, 
transmission of nerve impulse and neurotransmitter sec etion. It has also been identified 
as a potential candidate gene for schizophrenia in ts own right [279].  Synapsin 2 was 
overexpressed in the L100P adult and was identified as being involved in cell signaling, 
neurotransmitter secretion, and transmission of nerve impulses. Syn2 has previously been 
implicated in confering risk to schizophrenia in a Korean cohort [280]. Neurexin 1 
(Nrxn1) was overexpressed in the L100P adult mouse. It is involved in maintenance of 
synaptic junctions and is a mediator of intracellular signalling[249]. NRXN1 was 
implicated by Kirov et al (2008) [217] in an analysis of copy number variants in 
schizophrenia. Other studies on copy number variants have also implicated NRXN1 in 
schizophrenia pathology. Need t al (2009) [251] found deletions in the 3’ end of NRXN1 
in patients with schizophrenia, but not in control groups.  Vrijenhoek et al (2008) [252] 
suggest that CNVs that affect the first few exons of NRXN1 confer greater risk of major 
mental illness, while Rujescu et al (2009) [253] suggest that deletions that affect exons 
directly increase susceptibility. In addition, a missense mutation in exon 1 of human 
NRXN1 has also been linked to autism [254] and recent studies have linked deletions in 
NRXN1 to a range of phenotypes, including autism spectrum disorder, mental retardation, 
hypotonia and language delays [281].  
 
Lots of recent work has investigated the role of copy number variants (CNVs) in 
neurodevelopmental disorders (reviewed in Kirov 2010) [82]. Only two genes were 
present in both the dysregulated gene list from this study and copy number variants in the 
previous studies. MLL5, a transcription regulator, was present as a duplication in 
schizophrenia cases from Walsh et al 2008 [83], and was upregulated in the L100P non-
drug treated adult group. As previously mentioned, NRXN1 was also found to be up-
regulated in the L100P non-drug treated adult group. Walsh et al (2008) reported a 
NRXN1 deletion present in a schizophrenia case and affected sibling [83]. The deletion 
spans the promoter and first exon of the gene and partially overlaps with previous 
deletions co-segregating with autism [76] and mental retardation [239]. I also had access 
to data from recently completed microarray expression tudies on LCLs from individuals 
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from the DISC1 translocation (t1:11) family that allowed an almost direct comparison to 
be made between the mouse and human model. Five genes (Dusp6, F5, Hook3, Nrxn1 
and Nrxn3) were differentially expressed in both studies, with Hook3, Nrxn1 and Nrxn3 
dysregulated in the same direction in both arrays. These overlapping results between the 
mouse and human sample subjects is promising in terms of candidate gene identification 
and because it provides further evidence of the validity of the animal model to this 
system.  
 
One major flaw of this comparison is the two arrays used different tissues as the primary 
RNA source. While it was possible to use brain tissue  from the ENU mutant mouse, the 
human samples were from a blood-derived cell line. Blood-derived (lymphoblastoid) cell 
lines do not express all genes and in particular those expressed in the brain[240]. This 
could obviously result in some genes not being present in the human dataset by virtue of 
the original tissues used, and not because they are not expressed, or potentially 
dysregulated in the human condition.  
 
Using Ingenuity pathway analysis, nine genes were id nt fied that showed both 
overenrichment in GO categories and presence in the top statistically significant 
Ingenuity pathway analysis network in the L100P adult group. Ingenuity pathway 
analysis identified networks involved in cellular development, gene expression and cell 
signaling for the L100P adult, L100P embryo and Q31L embryo respectively. On the 
basis of fold-change, p-value, function (by GeneOntology classification) and overlap with 
previous studies, 40 genes from the microarray study were chosen for validation by qRT-
PCR. Genes chosen were mainly involved in synaptic transmission, neurotransmitter 
transport and secretion, and central nervous system d velopment. Genes whose 
differential expression was corrected by drug treatment were also carried forward for 
validation. 
 
This study had obvious limitations and weaknesses, not least of all the presence of an 
outlier group in the initial analysis. In addition, a number of the genes that showed 
differential expression on the array were anonymous sequences from a cDNA bank with 
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little or no functional information attached. This made it difficult to determine the 
relevance of these predicted sequences to major mental ill ess and therefore, most were 
not chosen for further analysis. It is possible that t e lack of information available for 
many genes biased the selection of the subset for further analysis.  
 
 
8.1.3 Chapter 5: Quantitative real-time PCR analysi s of candidate 
differentially expressed genes in the L100P and Q31 L mutant mice 
qRT-PCR was used for the validation of the microarray results. Two cDNA batches were 
used; one from the RNA that went on the array, and an independent batch extracted from 
mutant animals and wild-type littermate controls. Genes that failed to validate from the 
first batch of cDNA were not tested in the second batch. While every effort was made to 
ensure overlap of the microarray probes with the qRT-PCR probes, a perfect match could 
not be ascertained. In all cases both probes were derive  from the same exon but, as the 
sequences of the qRT-PCR probes are not made publicly available, identical sequence 
alignment could not be achieved. Slight misalignment of probes could result in 
amplification of different isoforms of the gene in question. Also, false positivity in array 
data can occur by binding of repetitive nucleotide elements, sequence homology between 
functionally different transcripts and high background levels due to nonspecific binding 
of nucleotides [248]. For these reasons it was decided that genes must show consistent 
results across platforms to be considered valid, thus ensuring as much as possible a true 
result. 
Of the 40 genes tested by qRT-PCR, 24 validated in the first round and only seven gave 
robust and reliable results through both rounds of validation. Correlation estimates 
predict a Spearman coefficient of 0.708 [282] betwen microarray data and qRT-PCR. 
The results obtained from this study are therefore slightly lower than would be expected, 
however lack of concordance between platforms at low f ld-change (<1.4) has been 
previously reported [283]. What is more concerning is the lack of concordance between 
the two batches of RNA, suggesting differences in the wild-type expression could be due 
to minor genetic differences between the C57BL/6J and the L100P wild-type. Although 
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the L100P animals had been backcrossed for over 10 generations it is unlikely, but not 
impossible, that there were still some genetic differences present.  
 
Of the seven genes validated, four were from the L100P drug naïve adult group (Nrxn1, 
Nrxn3, Egr4 and Wdfy1), two from the L100P embryonic group (Cdh11, Prm3) and one 
from the L100P Rolipram treated group which showed correction (Pak3). The neurexin 
genes (Nrxn1 and Nrxn3) are involved in synaptic transmissions and the maintenance of 
synaptic junctions. Nrxn1 has been shown to be involved in the maturation and
differentiation of GABAergic and glutamatergic synapses through bi-directional 
signalling [250] . DISC1 has previously been shown to interact with GSK3β, which 
suppress long-term potentiation and presynaptic releas  of excitatory glutamate in 
cortical neurons by inhibition [284]. As the glutamte hypothesis of schizophrenia 
predicts that decrease of NMDA receptor signaling during interneuron development 
could result in the behavioural phenotypes observed in schizophrenia [285], the potential 
interaction between DISC1 and another regulatory glutamate gene is of great interest. 
NRXN1 has also previously been identified as a candidate gene for schizophrenia [83, 
217, 251-253] and Autism [254] while SNPs in NRXN3 have been associated with 
alcohol and nicotine dependence and linked with opiate dependence [255, 256].  The 
Early Growth Response Factors (EGRs) 2, 3 and 4 are synaptic activity inducible 
immediate early genes and all show nominal associati n with schizophrenia in a Japanese 
population. EGR1, 2 and 3 are downregulated in the prefrontal cortex of schizophrenic 
brains [238] , EGR4 expression was too low to measure disregulation however, treatment 
with the atypical antipsychotic and antidepressant Aripiprazole increases expression of 
EGR4 in rat frontal cortex[257]. Little is known about the function of WD repeat and 
FYVE domain-containing protein 1 (WDFY1 or FENS1) but it is known to be ribosomal 
and has been associated with alcohol consumption and preference [258].  
 
Cadherin 11 (Cdh11) is a type 2 classical cadherin involved in mediation of calcium 
dependant cell adhesion. It was first discovered in rodent brain samples [266] with high 
expression in the developing olfactory system at E13- 7 [267] and has since been 
linked to multiple cancers [268, 269].  
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Pak3 was the only drug-corrected gene validated. Mutations in PAK3 have been 
associated with X-linked nonsyndromic mental retardation [260-262] and suppression of 
Pak3 results in formation of abnormally elongated dendritic spines and a reduction of 
mature synapses [263]. Pak3 knockout mice have deficiencies in learning and memory 
and abnormalities in synaptic plasticity along with a reduction of transcription factor 
cAMP-responsive element-binding protein (CREB) suggesting a novel signalling 
mechanism with PAK3 and Rho signalling regulating synaptic function and cognition 
[264]. PAK genes also interact with the known DISC1 interactor Kalirin-7 which is 
thought to control multiple aspects of spinal plasticity [265].  Kal-7 activates Rac-1 to 
control spine size. In the presence of DISC1, Kal-7 is anchored, regulating access to Rac-
1 and controlling duration and intensity of Rac-1 activation.  It is thought that constitutive 
activation of Rac-1 (due to Kal-7 not being anchored by DISC1) results in decreased 
spine size and may underlie the disturbances in glutamatergic neurotransmission 
observed in schizophrenia [286]. 
 
Five genes from the pre-outlier removal gene list (a  described in chapter 5) were tested 
by qRT-PCR and two validated through both rounds, with significant fold-change and p-
values that meet the criteria imposed. As previously mentioned, false positivity in array 
data can occur through multiple routes. In parallel, false negativity can occur through low 
expression levels, inefficient priming of specific mRNAs resulting in transcript drop out, 
poor adhesion of DNA to the slide, and splice variants with sequences not included on the 
array [248]. As the fold changes observed on the microarray for these genes were below 
the accepted sensitivity level of the array (http://www.switchtoi.com/pdf/GXHuman6-
8v2Datasheet.pdf) but were subsequently found to be diff rentially expressed through 
qRT-PCR they may be considered as false negatives. This does, however, raise 
speculation to the criteria imposed when selecting genes for validation and this will be 
discussed in section 8.2. 
Three additional genes (Dusp1, Ndfip and Atp5b) were found to be robustly dysregulated 
in the L100P rolipram treated group, but did not differ in the L100P adult vs wild-type 
controls. I, therefore, proposed that the disregulation of these genes was a function of 
drug treatment and not a result of the mutation. To confirm this I tested these genes in a 
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C57BL6 drug naïve group vs C57BL6 rolipram treated group. Dusp1 was significantly 
up regulated in the C57BL6 rolipram treated group compared to the drug naïve group, as 
it had been in the L100P rolipram treated group compared to the L100P drug naïve group. 
Ndfip also behaved in the same way in the C57BL6 rolipram treated group as it had in the 
L100P drug treated group, being significantly down regulated compared to the drug naïve 
control. Atp5b was significantly down regulated in the C57BL6 rolipram treated group 
where it had been up regulated in the L100P rolipram treated group, but a significant 
difference in expression was observed suggesting it is an effect of the drug treatment as 
opposed to the mutation. As the changes in expression in these three genes appear to be 
an effect of the rolipram treatment rather than the mutation I feel they do not fit the 
criteria for further analysis within this project. These data may, however, provide some 
information on the pathways through which these drugs act. 
 
 
8.1.4 Chapter 6: Establishing a developmental profi le for the genes of 
interest in L100P mutant mice and wild type control s 
The developmental profile of Disc1 highlighted key stages of development where 
expression is altered in the mutant mouse line, andlso confirmed my previous 
microarray result which showed that Disc1 expression was not significantly different at 
either E13 or adulthood between the L100P mutant and wild type controls. It was 
previously thought that the ENU mutations affected DISC1 protein function and not 
expression levels [197]. The data from these developmental profiles redefines our 
knowledge of this model and suggests that the behavioural phenotype observed is a 
combined effect of differences in DISC1 function and developmental expression.  
 
In the L100P mutant mouse there is an obvious peak in Disc1 expression at P1, with a 
peak at E18 observed in the wild-type controls. This is similar to the pattern observed in 
the Q31L mutant mouse. In addition, the Q31L mutant animals have significantly higher 
Disc1 expression than their wild-type counterparts at E15. It can be speculated that the 
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different developmental expression patterns of the Q31L and L100P mutants may 
contribute to the different phenotypes observed in behavioural testing. A review of the 
literature on mouse developmental stages suggests tha , based on genes with known 
neural functions, the functional gene clusters most highly expressed at E15 are involved 
in neural determination and differentiation, and at E18 and P1 are involved in synapse 
formation and function, and survival and growth [274]. Based on all genes differentially 
expressed at E18 and P1 the top functions are intra/inter cellular molecular transport, and 
signal transduction [274]. This delay in Disc1 expression in the L100P mutant mouse 
could have detrimental effects on neurodevelopment in the mutant animals. Personal 
observations and those of other researchers working w th these animals show that the 
mutant individuals are physically smaller when born, which could signify a delayed 
development (Steven Clapcote personal communication). Activity at the three 
developmental time points highlighted here roughly correspond to human 
neurodevelopment at weeks 9-12, 12-15.5 and 13.5-17.5 in utero [287]. 
 
While the result of one gene expression profile is not enough to stipulate cause and effect 
it is worth noting that low birth weights have previously been associated with 
schizophrenia [273] and a latent shift in the expression of key developmental proteins 
could be a factor in this. Hikida et al [193] also note that there is a 3month delay in 
neuronal migration in a Disc1 mouse model, which could potentially be attributed o a 
change in Disc1 expression during development.  
 
Developmental expression analysis of five differentially expressed genes highlighted 
some interesting developmental changes. Both neurexin genes showed a marked shift of 
peak expression in the L100P mutant compared to wild-type littermates. Nrxn1 peaks at 
E18 in wild-type, and P1 in L100P mutant animals. Conversely, Nrxn3 plateaus from 
E15-P1 in wild-tpe and peaks at E15 in mutant animals, with significantly lower 
expression at E18 and P1 than wild-type. As the predict d developmental function at E18 
is the formation of synapses, the dip in expression of genes involved in synaptic 
maintenance and transmission in the mutant animals is considered of key importance. 
Pak3 developmental expression is identical in the wild-type and mutant animal until E15. 
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After this the wild-type expression continues to rise to peak at E18, while the mutant 
expression decreases, plateauing at P20. There is significant underexpression of Pak3 at 
E18 and P1 in the mutant mouse. As Pak3 was the only gene to show correction through 
drug treatment, it would be interesting to see if earli r intervention would facilitate 
complete rescue of the phenotype, or if treatment pos hoc is sufficient. Egr4 displayed a 
distinct lack of expression in both wild-type and mutant until P1, which has previously 
not been reported, and significantly higher expression in the L100P mutant at P20, just 
prior to puberty in the mouse. According to the developmental hypothesis of 
schizophrenia, the molecular changes in the brain at the time of puberty are partially 
responsible for disease development in predisposed individuals[189]. If this is the case 
then the altered expression of this and other genes studied during development could be 
responsible for deficits in key circuitry which are exposed at this stage, facilitating the 
disease phenotype, as described in Weinberger’s developmental hypothesis [189], in the 
L100P mutant model. 
 
8.1.5 Chapter 7: Preliminary protein analysis of va lidated genes in L100P 
drug naïve (saline) adult mouse samples 
Due to post-translational modifications of proteins, and cellular feedback mechanisms 
that maintain proteins at optimal levels for cellular function and development, it has been 
reported that a correlation between changes at the mRNA level and the protein level are 
accurate less than 50% of the time [277]. I identified three genes that are significantly 
differentially expressed at both the gene and protein level; Egr4, Pak3 and Sort1 in the 
L100P adult mouse model. Both Nrxn1 and Nrxn3 failed to replicate their differential 
expression at the protein level. This could be due post translational modifications of the 
proteins, however there were also problems involved with the neurexin antibodies used 
which could account for the lack of change observed. The Nrxn1 antibody did not give a 
band corresponding to that suggested on the manufacturers’ datasheet and clear result 
could not be consistently obtained for the Nrxn3 antibody. There are multiple isoforms of 
both Nrxn1 and Nrxn3 that could potentially bind the antibodies used and obtaining 
reliable results proved problematic. 
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Immunocytochemistry was used to visualise the proteins of interest in cultured 
hippocampal neurons from L100P mutant and wild-type animals. No obvious overall 
changes in expression pattern were observed in any of the cultures, however the analysis 
was not quantitative and small changes would not be observed by the naked eye. Egr4 
appears to be expressed in disperse puncta on the dendrites, with the majority of Egr4 
expression contained within the soma. Disc1 has been shown to be expressed in similar 
puncta in the dendritic shaft with localisation to the ribosomes and microtubule structures 
in the soma [276]. It can be speculated that Egr4 has a similar, although not identical, 
expression pattern to Disc1 in the neuron, although further staining of specific cell 
components would be required to confirm this. The ov rall expression pattern of Pak3 in 
the neuron appears similar to that of Egr4. Initial observations suggest there may be 
slightly more puncta in the dendrites of the mutant imals but further quantitative 
analysis would be required to confirm this. Nrxn3 again appears localised to the some, 
with few puncta in the dendrites. Staining of the hippocampal neurons for Nrxn1 gave a 
slightly different pattern of expression, suggestive of endoplasmic reticulum 
involvement. Disruption of the neurexin PDZ-binding domain motif in Nrxn1 knockout 
mice has been shown to result in diffuse distribution patterns with Nrxn retained in the 
endoplasmic reticulum and not packaged into vesicles for transport to the synapse [288]. 
It could be speculated that disruption of Nrxn1/PDZ binding by Disc1, or one of its 
interactors, prevents trafficking to the synapse. Further staining with synaptic markers 
would be required to determine if Nrxn1 is localising to the synapse or if it is being held 
in the ER. Images obtained from the ICC of Sort1 appe red blurry with bleaching of the 
Sort1 signal and the actin signal. This occurred in every image taken and was consistent 
between wild-type and mutant, suggestive of an incompatibility between the two 
antibodies.  
 
While there were a number of limitations to this study (as described in more detail in 
section 7.6), these results provide the basis for further research in this area. They are to be 
considered preliminary findings, and it would of course be advantageous to continue 
these experiments, and in some cases repeat with more reliable antibodies. Further neuron 
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staining using cellular markers to compare co-localisation of proteins between mutant 




This work has identified a number of genes dysregulated by missense mutations in Disc1 
that are proposed to be involved in the schizophrenia dophenotype displayed by the 
mouse model. Most notably, the striking disregulation of a number of known candidate 
genes for major mental illness in the L100P Disc1 mutant animals suggests a common 
network involved in the pathogenesis of schizophrenia and major mental illness. The 
altered expression of these genes during development in the mouse model also suggests a 
substantial neurodevelopmental component, supporting previous hypotheses from 




No experiment is perfect, and it is important to record and analyse the potential caveats to 
improve future work. In the whole genome expression study, potentially the biggest 
question was the use of C57BL6 as a wild type control, particularly given its reduced PPI 
compared to the mutant wild-type littermates. The justification for this was two fold; 
firstly, the results from the array would be validated using wild-type littermate controls so 
any change attributed to the use of C57BL6 over wild-types would be identified at a later 
date. Secondly, the mutant mouse line had been backcrossed for 10 generations and 
would be expected to be genetically identical to at le st 98.9%. C57BL6 mice were 
specifically sourced from the Charles River substrain to be as close as possible to the 
original backcross strain used when establishing the ENU mutant colonies, however, 
results obtained from both the behavioural study and comparison between the C57BL6 
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and wild-type littermate controls would suggest thepr sence of non-target mutations 
which may be responsible for the differences observed. These could either be secondary 
ENU mutations that co-segregated with the Disc1 mutation, or sections of DBA genome 
that remained, despite backcrossing, around the Disc1 gene. Comparative genotyping of 
the whole chromosome would allow this to be determined. In retrospect, the use of wild-
type littermates for the array, as was the initial pl n, would have reduced the number of 
false positives and false negatives, and provided a ‘cleaner’ result from the offset. 
However, due to circumstances outwith my control this was not possible, and it was 
necessary to continue with the closest viable control that was available at the time, the 
C57BL6 mouse. I would suggest that further experiments of this kind use wild-type 
littermate controls as standard, or that the C57BL6 be fully genotyped and compared to 
the mutant mouse line to fully establish and genetic differences that may be present. 
Hippocampal tissue was used in the array study for a number of reasons. Abnormalities 
in hippocampal structure, activation, organization of neurons and synapse function have 
been well documented in human schizophrenia patients a d other mouse models [207, 
214, 233, 234]. Added to the working memory deficits often associated with 
schizophrenia [208], it is clear there is substantial hippocampal involvement in the 
disorder. The use of a single brain region also removed any confounding effects of 
compensation in other brain regions, which may have diluted the result. As such, this 
study can make direct inferences as to the gene expression in the hippocampus of the 
adult mutant mouse. Due to researcher inexperience, it was not possible to remove only 
hippocampal tissue from the embryonic mouse samples, and in these cases whole brain 
was used. This was not ideal and it would be suggested that analysis of distinct brain 
regions should be carried out on the embryonic mutant mouse, particularly with reference 
to the developmental panel. It would be very interesting to discover if the changes of 
gene expression over development observed in this sudy are confined to one brain 
region, or if they are a global effect. 
Microarray technology has a number of inherent limitations that cannot be ignored. 
Genes with low expression levels, or genes with a sm ll change in expression level, can 
often be overlooked due to the background noise of a heterogenous sample. It is highly 
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probable that this could occur in the sample set usd for this experiment. The genetics of 
psychiatric disorders are known to be very complex, with multiple genes likely to be 
involved. Illumina state confidence in detecting a ene expression fold changes greater 
than 1.3, essentially meaning that any change in expression less than 30% from the norm 
cannot be reliably detected. Prior to filtering thedata based on fold-change, 78% of genes 
with a significant p-value gave a fold-change between 1.01 and 1.25. These were 
obviously discarded from further analysis due to the detection cut-offs imposed by 
Illumina. This cut-off should however be considered arbitrary. Prior to the identification 
of the outlier 20 genes had been tested by qRT-PCR that did not make the 1.3 fold-
change cut-off on reanalysis. Of these, two validate  independently by qRT-PCR, 
suggestive that in these cases there was differential expression that was not apparent from 
the array analysis. The problem of tissue heterogeneity was in part addressed by using 
inbred mouse strains, however even within a small region of the brain (in this case 
hippocampus) there are multiple cell types with different expression patterns adding to 
the background noise of the array. This could be ovrcome using microdissection of 
specific cell types and it would be suggested this is carried out for future experiments. 
The identification of an outlier group post analysis was indeed a blow to the study. Not 
least it meant the total reanalysis of the dataset nd questioned the validity of previous 
quality control measures. As the outlier did not consistently show over or under 
expression, its effects were diluted when analysing the data as a whole. While this may 
be an isolated case, it highlights how important it is to analyse each group individually, 
by checking a random set of genes, as well as the group as a whole. 
It was stated in chapter 4 that no corrections were made for multiple testing in this 
dataset. False discover rates (FDRs) were calculated for each pairwise comparison. As 
the maximum FDR was ~30% it could be predicted that 110 of the 368 genes found to be 
differentially expressed would be false positives. While this value is high it was decided 
that continuing without correction was viable as the data would be validated on an 
independent platform which should see any false positive  from the array removed at that 
stage. If this experiment were to be repeated I would s ggest either analyzing the dataset 
using ANOVA and posthoc tests, or, if carrying out multiple t-tests as was done here, that 
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some multiple testing corrections be carried out. This could potentially increase the 
number of false negatives from the data but would produce a dataset that was more likely 
to be reproducible on the independent platform. 
 
Validation of the microarray result was two fold. In the first instance, genes of interest 
were analysed by Taqman real-time PCR using RNA from the animals that were used on 
the array. Of the subset of genes analysed, 51.5% gave reproducible results across both 
platforms. While every effort was made to ensure ovrlap of the two probes, a perfect 
match could not be ascertained. In all cases both probes were mapped to the same exon 
but as the sequences of the qRT-PCR probes are not made available identical sequence 
alignment could not be achieved. This may account for he low levels of reproducibility. 
Also, as mentioned previously, the array false discovery rate was high, so it could be 
expected that some of the genes identified and subseq ently analysed on the Taqman 
platform were false positives. Wang et al (2006) [289]compared microarray platform and 
Taqman real-time PCR performance and found correlation ranges between 0.45 and 0.79 
between platforms. They also noted that correlations were higher in genes with greater 
expression levels and larger fold changes. As the majority of genes selected for validation 
in this study had low fold-changes (classed as <2) it appears consistant with a smaller 
correlation between platforms. The second round of validation used RNA from an 
independent set of animals derived from the original line, with wild-type littermate 
controls. Only those genes that had reproduced succe sfully in the first round were tested 
in this sample set. Seven of the 19 genes tested reproduced in this second round. This 
could not be due to between platform differences, or probe alignment issues. It is 
therefore assumed that the issues discussed previously regarding the use of the C57BL6 
as a control affected the result. Genotyping both ‘wild-type’ controls would be advised if 
this experiment was to be repeated, although the use of wild-type littermates from the 
offset would be likely to reduce this problem. 
As stated previously, the selection criteria for genes for further study was, with 
retrospect, less than ideal. Small fold changes cloe t  the detection sensitivity of the 
array could have resulted in a high number of false negatives, as demonstrated by the 
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validation of two genes by qRT-PCR that did not meet th  selection criteria on the array. 
If the data were to be reanalyzed it would perhaps be prudent to select more on the basis 
of functional significance and p-value with less weight being left to fold-change values. 
While it is accepted that there must be a cut-off leve , it is suggested that due to the 
complex nature of schizophrenia and other major mental illness, and the predicted 
multiple genes of small effect, that current array technology may not yet be sensitive 
enough to pick up the small changes in gene expression that may contribute to disease 
pathology.  
The inclusion of the drug treated groups, while of interest, also increased the spread of 
the data and the propensity for error. Increasing the number of groups increases the 
multiple testing burden and reduces the statistical power. It is also likely that the primary 
effects of the drug treatments are not at the level of gene expression, but in post-
translational protein modification and/or action on neurotransmitter systems [290, 291]. 
Previous studies have identified gene expression cha ges after clozapine treatment ([292, 
293] and others), however these studies used chronic treatments and whole brain tissues, 
increasing the heterogeneity of the sample. I would conclude that while the drug 
treatments were interesting they were not necessarily n essential part of this study. 
Further work to investigate the actions of psychiatric drugs would be of interest, and the 
use of this mouse model an advantage for this, but it would be of more interest to 
investigate at the level of the synapse for change in neurotransmitter binding and 
secretion, than at the gene expression level. 
 
 
8.3 Relevance of this study to the field 
Since the discovery of the DISC1 gene in 2000 [56], a number of studies have identifi d 
variants within this locus as susceptibility factors for major mental illness. Many DISC1 
binding partners have also been associated with major mental illness in their own right 
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[131, 144-146, 156, 294], suggesting a network of gene involvement in these 
synaptopathies.   
While microarray analysis has been previously used to i entify candidate genes for major 
mental illness, this is the first study to look at genome wide gene expression in a model 
system with mutations in Disc1, an already established candidate gene. The use of a well 
classified animal model, with mutations in Disc1 and behavioural characteristics 
consistent with a schizophrenic or depressive-like endophenotype, has allowed me to 
carry out this analysis on a uniform genetic background, with sufficient numbers for 
statistically relevant conclusions. Due to problems with tissue access and genetic 
heterogeneity, this would not have been possible using human samples.  
I have identified a number of genes that are dysregulated as a result of the Disc1 
mutation. Most of these genes have not previously been shown to interact with Disc1, 
suggesting either indirect interactions and/or the possibility of network involvement of 
these genes, which together contribute to the disease pathology. It may also suggest 
involvement of transcriptional control. As some of the genes identified and validated in 
this study have previously been associated with major mental illness in their own right, 
there is a convincing argument for network involvement in schizophrenia pathology, at 
least in this system. 
 
It has previously been reported that genes related to CNS development, neuron guidance 
and neurotransmitter secretion were down-regulated with age (birth-20 years) in normal 
individuals [200]. Torkamani et al (2010) [199] found that while this downregulation 
continued in control subjects, it did not in indiviuals with schizophrenia, suggesting a 
progressive neurodevelopmental deficit. This is not a new idea, as Weinberger (1986) 
[189] proposed the neurodevelopmental hypothesis of chizophrenia on the basis that 
altered gene expression during development could be responsible for deficits in key 
circuitry, which are exposed when molecular changes occur in the brain during puberty, 
facilitating the disease phenotype. As schizophrenia is not normally diagnosed until the 
late teens at the earliest, gene expression measurements of individuals with schizophrenia 
during their early post-natal development is not possible, however, using the L100P 
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Disc1 mutant I have shown that there are developmental gene expression differences 
between the L100P mutant and wild-type littermates round the time of birth, and at P20. 
This is an exciting development as it not only redefines what we thought we knew about 
the mouse model, but can be related to an already established hypothesis in a way which 
may help to broaden our understanding of disease dev lopment. While only a small 
number of genes were tested in the L100P developmental profiles, this evidence suggests 




8.4 Differential networking and other future work 
As schizophrenia and other major mental illnesses ar  considered complex trait disorders, 
the identification of individual candidate genes only gives us a small insight into the 
disease cause. A more general, and perhaps more useful, tool is the identification of 
networks of genes involved in the disease pathology. I presented data from Ingenuity 
Pathway Analysis, identifying predicted gene networks on the basis of fold-change and p-
value from the differential expression analysis of the microarray. Networks identified 
were cellular development, gene expression and cell signaling in the L100P adult, L100P 
embryo and Q31L embryo respectively. These proposed networks rely on the expression 
differences between affected and unaffected individuals (or in this case, mutant and wild-
type animals). Disregulation of cell-cell signaling has previously been implicated in 
schizophrenia [295] and Disc1 has been shown to be involved in cellular development 
and neurite outgrowth ([160, 296] and others) so these networks are comparable with that 
data. What is more interesting, is the failure of all but two of the genes contained in these 
networks to validate by qRT-PCR in the mouse model, suggesting the analysis used may 
not be an ideal method for selecting genes for further study.  
Differential networking proposes that co-expression of genes within disease groups is 
more important than differences in expression betwen groups. By performing pair-wise 
comparisons for co-expression it is possible to identify regulatory relationships between 
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genes and, eventually, extrapolate whole disease networks [297] and regulatory systems 
of disease. It would be interesting to carry out this analysis on the current L100P dataset 
to compare the two methods, and determine whether the networks generated could also 
be related to human disease.  
The evidence for developmental disregulation of candidate genes in the L100P mutant 
mouse is intriguing, and further work to determine a clear developmental course for the 
phenotype is highly recommended. Hikida et al (2007) [193] previously showed a three 
month developmental delay in neuronal migration in a dominant-negative Disc1 mouse 
model. Kamiya et al (2005) [133] have also shown that expression of dominant-negative 
mutant Disc1 in the mouse leads to a delay in neuronal migration at P2, with a reduction 
in correctly oriented pyramidal cells in the cerebral cortex at P14. Neither experiment 
looked at the whole developmental time course, but selected key points in postnatal 
development. Experiments of this type on the L100P ENU mutant mouse would allow a 
direct comparison between the rate and success of neuro al migration in the developing 
brain, and the expression levels of Disc1 and differentially expressed genes. This would 
allow conclusions to be made as to the effect of gene xpression levels on brain 
development and would provide insight into the development of the ‘schizophrenia-like’ 
phenotype in this model.  
Once the developmental neuroanatomy of the L100P Disc1 mouse is established, it 
would be interesting to see if any deficits can be rescued with the use of drug treatment, 
and if this also rescues the behavioural phenotype. For example, the Fmr1 knockout 
mouse, a model of Fragile-X syndrome – the most comm n genetic cause of childhood 
cognitive impairment- shows an increase in dendritic spine maturation and improved 
behavioural performance when treated with minocyline, a tetracycline analogue [298] 
from an early age. Minocyline has also been found to have antipsychotic effects, and has 
been used to help treatment resistance schizophrenia [299]. It would be interesting to test 
the effect of this, and the other drugs used in this study, in early postnatal animals and 
adults. This would help us to determine to effect of treatment on behaviour and 
neuroanatomy, and whether early intervention can rescu  both aspects of the phenotype. 
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8.4 Final comments 
It is very clear from this and previous work that the genetics of major mental illness are 
incredibly complex. The Disc1 mutant mouse lines have opened the door for further 
studies into genetic variations in the DISC1 locus culminating in susceptibility to major 
mental illness. By increasing our knowledge of the knock-on effects of Disc1 mutations 
on down-stream gene functions and affected pathways we could be a step closer to 
determining the biological mechanism conferring common risk to major mental 
disorders. A better understanding of the aetiology f schizophrenia, bipolar disorder and 
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